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Abstract 
 
 
 
The main challenge in transdermal drug delivery is to overcome the barrier of the stratum 
corneum (SC), the outermost layer of the skin. Many approaches have been used to enhance 
the penetration of drugs through this layer, covering passive and active methods or the 
combination of both. This work aimed at developing a transdermal delivery system for the 
simultaneous administration of olanzapine and simvastatin.  
In order to fulfill the main goal, the potential combination of lipid nanoparticles and 
chemical enhancers was addressed, in what concerns passive strategies. Additionally, the active 
microneedle-mediated delivery of nanoparticles into the skin was investigated as an alternative 
to potentiate drug transport. Lipid nanoparticles, comprising solid lipid nanoparticles (SLN) and 
nanostructured lipid carriers (NLC) were prepared by the solvent emulsification-evaporation 
(SE/E) and high pressure homogenization (HPH) methods. Full factorial designs, 2k, were 
conducted to rationalize and optimize formulation composition, production conditions and 
application. The combined effect of lipid nanoparticles and chemical enhancers was investigated 
by in vitro, in silico and cellular viability methodologies. The formulations were assessed in a 
joint in vitro/in vivo approach.  
As a result of the reduced solubility of olanzapine in the solid lipid, tripalmitin, NLC were 
selected for co-encapsulation. For NLC production, the HPH technique was chosen, since it 
allowed a higher drug loading, a more sustained release, better permeation rate, in conjunction 
with the ability to scale up, avoidance of organic solvents and shorter production times.  
The in vitro skin experiments showed that the external medium in the NLC dispersion 
strongly influenced permeation. Olanzapine exhibited a higher permeation than simvastatin. 
Moreover, it was also seen that the use of NLC determined a synergistic effect with the selected 
permeation enhancers, ethanol and limonene, thus promoting marked flux enhancement ratios, 
relative to the drugs in solution. The further gelation of the formulation led to a reduction roughly 
by half in the flow rate. A correlation between enhancer positioning in a lipid bilayer and 
enhancement effect was suggested from both molecular dynamics studies and experimental 
results.  
  x 
The study of the interaction of limonene, ethanol and Carbopol Ultrez® 10NF as gelling 
agent with the NLC dispersion covering rheological, mechanical and physicochemical properties, 
suggested that the developed formulation was suitable for transdermal administration. 
Additionally, the optimal formulation was not considered irritant. 
As a proof-of-concept of the above findings, in vivo transdermal administration to rats 
were conducted, which resulted in steady-state levels reached after 10 h and maintained for 48 
h. The NLC dispersions displayed a better in vivo performance than hydrogels, which was 
consistent with the in vitro results. These differences were, however, negligible in the flux values, 
supporting the use of hydrogel as final, more convenient, formulation. Skin perforation promoted 
by the microneedles device only slightly increased the permeation rate. This emphasized that 
the formulation itself determined the main driving force for skin permeation.  
Overall, these findings highlight the NLC-based formulations as promising for the 
development of a clinical transdermal system, covering an innovative therapeutic approach. 
 
 
Keywords Co-encapsulation, solid lipid nanoparticles, nanostructured lipid carriers, factorial 
design, permeation enhancement, molecular dynamics, pharmacokinetics, transdermal delivery 
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Resumo 
 
 
 
O principal desafio na administração transdérmica de fármacos consiste em transpor  a 
camada córnea, a mais externa da pele.  
Têm sido desenvolvidas diferentes estratégias para promover a penetração de fármacos 
através desta barreira, as quais incluem métodos passivos, activos ou uma combinação de 
ambos. O presente trabalho teve como objectivo o desenvolvimento de um sistema   
transdérmico para a administração simultânea de olanzapina e sinvastatina. 
De forma a atingir este objectivo, foi abordada como estratégia passiva a combinação de 
nanopartículas lipídicas com promotores químicos de penetração. Por seu lado, a administração 
de nanopartículas recorrendo a microagulhas enquanto método activo foi avaliada como 
estratégia alternativa para potenciar o transporte de fármacos através da pele. 
As nanopartículas lipídicas, compreendendo as nanopartículas lipídicas sólidas (SLN) e 
os transportadores lipídicos nanoestruturados (NLC), foram preparadas pelos métodos de 
emulsificação-evaporação do solvente (SE/E) e homogeneização a alta pressão (HPH). 
Recorreu-se a planeamentos factoriais, do tipo 2k, para racionalizar e optimizar a composição 
das formulações, condições de produção e respectiva aplicação. O efeito combinado das 
nanopartículas lipídicas e promotores químicos foi investigado recorrendo a metodologias in 
vitro, in silico e estudos de viabilidade celular.  As formulações foram adicionalmente  avaliadas 
numa abordagem combinada in vitro/in vivo. 
Como resultado da reduzida solubilidade da olanzapina no lípido sólido, tripalmitina, 
foram utilizadas NLC para a co-encapsulação. A técnica HPH a quente foi seleccionada para a 
produção das NLC,  uma vez que permitiu uma maior capacidade de carga de fármaco, uma 
libertação mais sustentada, uma melhor permeação, evitar o recurso a solventes orgânicos e 
tempos de produção mais curtos, apresentando também a possibilidade de transposição de 
escala. 
Os ensaios in vitro demonstraram que o meio externo da dispersão NLC influenciou  
marcadamente a permeação. Verificou-se também um efeito sinérgico entre as NLC e os 
promotores químicos seleccionados, etanol e limoneno, evidenciado pelas acentuadas razões 
  xii 
de permeação, em comparação com soluções de referência. A olanzapina apresentou uma 
permeação superior à sinvastatina, resultados que foram confirmados nos ensaios in vivo 
referidos mais adiante. A posterior gelificação do sistema levou a uma redução para cerca de 
metade nos fluxos de permeação. As simulações de dinâmica molecular e os resultados 
experimentais permitiram estabelecer uma correlação entre o posicionamento dos promotores 
químicos (terpenos) numa bicamada lipídica e o seu efeito de intensificação na permeação.  O 
estudo da interacção entre o limoneno, o etanol e o Carbopol Ultrez ® 10NF, como gelificante, 
com a dispersão de NLC, abrangendo as propriedades reológicas, mecânicas e físico-químicas, 
sugeriu que a formulação desenvolvida era adequada para administração transdérmica. 
Verificou-se, também, não ser irritante. 
Para a avaliação da eficácia do conceito acima desenvolvido, foram conduzidos ensaios 
in vivo em ratos, cuja administração transdérmica permitiu atingir o estado estacionário após 10 
horas, mantendo-o durante 48 h. As dispersões de NLC caracterizaram-se por um melhor 
desempenho, in vivo, comparativamente aos hidrogéis, em concordância com os resultados in 
vitro. Estas diferenças foram, no entanto, mitigadas nos valores de fluxo, justificando a 
utilização de hidrogel como formulação final. A perfuração da pele promovida pelo dispositivo de 
microagulhas apenas aumentou ligeiramente a velocidade de permeação. Estes resultados 
corroboraram  que a formulação, por si só, constitui a principal força motriz para a permeação 
de fármacos através da pele. 
Em geral, estes resultados indicam as formulações baseadas em NLC como 
promissoras para o desenvolvimento de um sistema transdérmico clínico, abrangendo uma 
abordagem terapêutica inovadora. 
 
 
Palavras-chave Coencapsulação, nanopartículas lipídicas sólidas, transportadores lipídicos 
nanoestruturados, planeamento factorial, promotores de permeação, dinâmica molecular, 
farmacocinética, administração transdérmica 
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Chapter 1 
 
General introduction 
 
 
 
1.1 Scope 
 
Over time, the skin has become an important route for drug delivery encompassing 
topical, regional or systemic effects. The present work focuses on the pharmaceutical 
development of a transdermal drug delivery system (TDDS), i.e., a product intended to 
deliver a drug through the skin in order to attain the bloodstream. The advantages of 
transdermal delivery include providing a noninvasive, painless and convenient means of 
drug administration, avoidance of possible infection and compliance issues related to 
injections, steadier and sustained drug levels over a prolonged period of time, reduced 
side effects associated with peaks and troughs in drug plasma concentration, avoidance 
of the liver first-pass metabolism and other variables associated with the GI tract (pH, 
gastric emptying), as such providing an alternative route when oral dosing is not possible 
(unconscious or nauseated patients), and the ease of dose termination when adverse 
effects occurs [1].  
Nevertheless, the skin constitutes an excellent natural barrier, which limits the 
number of drugs able to cross its external layer, the stratum corneum, in sufficient 
quantities to reach a therapeutic plasma concentration. This explains why ca. 30 years 
since the approval by FDA of the first transdermal patch, the Alza’s Transderm Scop® 
(scopolamine) to treat motion sickness, only approximately 20 drugs or drug 
combinations have been marketed in the United States and European Union [2]. 
In Portugal, there are currently 39 different presentations of TDDS approved, 
spanning 14 molecules [3], which represents an annual turnover of about 52.4 million 
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euros, or about 1% in unit and 2.7% in value of the total ambulatory market (Figure 1.1) 
[4].  
 
Figure 1.1 Transdermal market trends in Portugal, reporting IMS Health data in value 
and units, from MAT December, 2012 [4].  
 
Taking into account the TDDS market, for the period between May 2011 and May 
2012 the brand (original) medicines occupied a market share of 93,5% and the generics 
6,5% (in value). Considering the previous period, between May 2010 and May 2011, the 
market share values suffered no change, which may indicate that this TDDS market is 
relatively stable and protected from the entry of generics [5].  
Facing a declining output from innovative pharmaceutical research, before starting 
the development process of a new product, a careful analysis of the market is crucial in 
order to identify relevant needs. Thus, a problem must first be identified for which a 
solution with a discernible benefit can be found.  
The above market trends indicate that TDDS are limited to some drugs/therapeutic 
areas, such as nitroglycerin for cardiovascular disorders, rivastigmine for Alzheimer’s 
disease, fentanyl for pain management, estradiol and testosterone for hormone 
replacement, ethinylestradiol/norelgestromin for female contraception and nicotine for 
smoking cessation. 
We have explored a new therapeutic area, the antipsychotic market, where non-
compliance represents a crucial issue that affects most therapeutics, and selected 
olanzapine as a model drug, with the purpose of combining improvement over an 
existing therapy, and providing a solution to a problem with an existing drug [6].  
Olanzapine belongs to a class of second generation derivative antipsychotic agents, 
the so-called atypical antipsychotics. Atypical antipsychotics have greater affinity for 
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serotonin 5-HT2A receptors than for dopamine D2 receptors, causing fewer 
extrapyramidal symptoms and improving negative symptoms in contrast to classical 
antipsychotics, such as haloperidol [7]. Olanzapine is indicated for the treatment of 
schizophrenia and moderate to severe manic episodes. In patients whose manic 
episodes have responded to olanzapine treatment, it is indicated for the prevention of 
recurrence in patients with bipolar disorder [8]. It should be noted that schizophrenia 
affects about 24 million people worldwide, presenting a high prevalence due to chronicity 
[9].  Currently, olanzapine is administered orally or by injection, being commercially 
available in tablet and intramuscular form, administered once daily. Thus, a potential 
benefit of transdermal administration of olanzapine is the improvement of patient 
compliance, in particular for this population, which is known for having problems with 
adherence to medication. It should be stressed that poor compliance is the leading 
cause for relapse and re-hospitalization among schizophrenia patients [6]. Despite the 
effective benefits as a therapeutic antipsychotic, the long-term use of olanzapine has 
been limited by its substantial, un-wanted effects on metabolism that result in weight gain 
and increase in insulin resistance and lipid metabolism [10]. The alterations in the lipid 
profile can contribute to the increase in cardiovascular mortality that has been observed 
among patients with schizophrenia since the availability of the atypical antipsychotic 
medications [11-14]. Besides, metabolic syndrome and other cardiovascular risk factors 
are also highly prevalent in people with schizophrenia, which are attributable in part to 
the unhealthy lifestyle, including poor diet and sedentary behavior [15].  
All these aspects support the association with simvastatin, belonging to the class of 
statins, in order to prevent dyslipidemia and cardiovascular risk [16, 17]. Additionally, co-
administration of two drugs to treat chronic conditions further reinforces compliance 
problems, in particular if transdermally delivered. Naturally, to be addressed for 
transdermal administration, both drugs should also gather adequate physicochemical 
and pharmacokinetic properties, which will be discussed below in this chapter. 
The administration of both drugs was based on a nanoparticulate system that 
allowed co-encapsulation. The enhancement of drug transdermal absorption was further 
explored in an innovative combination of different passive and active methodologies. 
The system uses thus nanotechnology to address a therapeutic issue, increasing the 
value of the co-encapsulated drugs in a clearly differentiated approach. 
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1.2 Skin 
 
1.2.1 Function 
 
The skin is the largest organ of the human body, covering about 1.7 m2 and 
accounting for more than 10% of the total body mass of an average person [1, 18]. 
Numerous functions have been attributed to the skin. As the human integument, it 
establishes the interface between body and external environment, ensuring a protective 
barrier against chemical, mechanical, microbial, physical, and ultraviolet (UV) radiation 
injuries, and preventing the loss of moisture and body nutrients [18-20]. Besides limiting 
the entrance of xenobiotics, it constitutes a physical barrier for the penetration of 
microorganisms. The production of the “acid mantle” (pH~5) by the sebaceous and 
sweat glands, the presence of a thin film on the skin surface comprised of sebum, 
corneocyte debris and residual material from sweat, the low surface water content, the 
resident microflora, and surface-deposited antimicrobial lipids contribute additionally to 
the antimicrobial protection [21, 22].  
The skin also serves important metabolic, immunological and sensorial functions. It 
has an important role in the metabolism of melanin, vitamin D, lipids, collagen and 
keratin. Additionally, it presents immunological activity, as it contains Langerhans cells 
[23, 24]. The skin also provides sensory information, such as  pressure, pain and 
temperature, since it encloses nerve endings and receptors [18]. 
Furthermore, its role in assuring the homeostasis of the body should be stressed, not 
only in terms of the maintenance of the respective composition and excretory functions, 
but also in blood pressure control and thermoregulation [18, 24].  
 
1.2.2 Structure 
 
To properly assess and rationalize the ability of a drug to be delivered transdermally, 
an understanding of the fundamental aspects of skin anatomy and physiology is of 
crucial importance and will be firstly discussed in this chapter.  
Essentially, the skin consists of four layers: the stratum corneum (nonviable 
epidermis), the remaining layers of the epidermis (viable epidermis), dermis, and 
subcutaneous tissues (hypodermis). A number of appendages are also associated with 
the skin, comprising hair follicles, apocrine and eccrine sweat glands, and nails (Figure 
1.2) [24]. 
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Figure 1.2 Schematic representation of the skin layers and appendage. From 
reference [25].  
 
Although the large surface area would indicate that the skin is as a suitable pathway 
for drug delivery, from a permeation point of view skin represents a challenge due to its 
outermost layer, the SC, which determines the formidable barrier described above. The 
qualification for this is the unique physicochemical composition and architecture of the 
SC. Therefore, the structure of this layer will be discussed in more detail. The other 
layers and appendages present important functions, constituting target sites for drug 
delivery. 
 
Epidermis 
 
The epidermis is a dynamic multilayered region, with a thickness ranging from ca. 
0.06 mm on the eyelids to 0.8 mm on the soles of the feet and on the palms of the hands 
[18]. The epidermis is avascular, composed by keratinocytes (95% of cells) that 
undergoes constant proliferation, differentiation, and keratinization, being responsible for 
the constant physiological renewal of the skin. Each layer is known to represent a 
different level of cellular or epidermal differentiation [1]. Thus, the structure and 
composition of the keratinocytes change during their migration from the stratum basale, 
through the stratum spinosum, stratum granulosum, and the stratum lucidum up to the 
outermost SC. During their maturation process, keratinocytes synthesize and express 
numerous different protein and lipids [26]. On reaching the SC, cells become enucleated 
(corneocytes) and flattened, being usually referred as nonviable epidermis, in 
contradistinction to the lower epidermal layers (viable epidermis) [18, 27]. Interspersed 
among the keratinocytes in the viable epidermis, another population   exists (accounting 
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for the remaining 5% [28] of cells), but do not participate in the process of keratinization. 
These include the melanocytes, Merkel cells (tactile epithelioid cells), and Langerhans 
cells (intraepidermal macrophages) [29]. In addition to the structured cellular 
components of skin, various skin appendages, such as hair, sweat and sebaceous 
glands exist as specializations of the epidermis. The epidermis also possesses many 
enzymes capable of metabolizing topically applied compounds, which are also involved 
in the physiological keratinocyte maturation and desquamation process, formation of 
natural moisturizing factor (NMF) and general homeostasis [23, 30, 31]. 
The stratum basale (SB), also referred as the stratum germinativum or basal layer, is 
a single layer of columnar cells, presenting a high nucleo-cytoplasmic ratio, attached to 
the basement membrane via hemidesmosomes (proteinaceous anchors). Desmosomes 
interconnect the keratin of adjacent and overlying cells, thereby ensuring the structural 
integrity of the skin. It is the only layer of the epidermis composed of keratinocytes able 
to undergo cell division (stem cells) [32]. It also contains the melanocytes, Langerhans 
cells, and Merkel cells.  
Melanocytes are dendritic cells that synthesize melanin, a high molecular weight 
polymer that provide the pigmentation of the skin, hair, and eyes. Melanin is packaged in 
subcellular organelles, called melanosomes and transported to the neighboring basal 
keratinocytes [28]. The main function of melanin is to afford protection of the skin by 
absorbing potentially harmful UV radiation, thus minimizing the liberation of free-radicals 
in the basal layer [18].  
Langerhans are bone marrow-derived dendritic cells and the major antigen 
presenting cells in the skin [28]. They are activated by the binding of antigen to the cell 
surface, then migrating from the epidermis to the dermis and on to the regional lymph 
nodes, where they sensitize T cells to generate an immunological response [18]. 
Merkel cells are associated with the nerve endings and are concentrated in the 
touch-sensitive sites of the body, such as the fingertips and lips, being associated to 
sensorial perception [18, 22, 33]. 
The stratum spinosum (SS) is composed of two to six rows of keratinocytes 
immediately above the basal layer. Their morphology changes from columnar to 
polygonal, and possess an enlarged cytoplasm containing a higher number of keratin 
filaments (tonofilaments) and organelles when compared with the SB. Beyond the typical 
cell organelles observed in SB, the presence of Odland bodies, lipid-enriched lamellar 
bodies (LB) is also evident in this layer. The increase in protein and lipid synthesis 
denotes the dual aspect of epidermal differentiation [18, 32] 
The stratum granulosum (SG), also known as granular layer is composed by 
keratinocytes at a different level of differentiation. They contain intracellular keratohyalin 
Chapter 1 – General Introduction 
 
 7 
granules, composed by keratin, as well as profillagrin, loricrin and a cysteine-rich protein. 
The fillagrin subunits of profillagrin are important as matrix molecules to promote the 
aggregation and alignment of the keratin filaments [32]. The rise in the protein synthesis 
is accompanied by an increased lipogenesis, as evidenced by the large numbers of LB, 
which are believed to be the precursors of the intercellular lipid lamellae of the SC [34]. 
The LB also contain hydrolytic enzymes, such as the SC chymotryptic enzyme, a serine 
protease which has been associated with the desquamation process [35]. As the cells 
ascend in the SG, the LB are extruded to the intercellular domains (Figure 1.3) [18]. 
 
 
Figure 1.3 Schematic representation of epidermal differentiation. Major events 
include extrusion of lamellar bodies, loss of nucleus, and increasing amount of keratin in 
the stratum corneum. From reference [24].  
 
In the stratum lucidum (SL), a layer present in the palms and soles where the skin is 
particularly thick, the cell nucleus and other organelles disintegrate,  keratinization 
increases, and  cells become flattened and compact [18]. 
 
Stratum corneum: a key role  
 
The stratum corneum, also known as horny layer, is the outermost layer of the skin, 
consisting of 10-15 cells in depth, which corresponds to 10-20 μm cell layers of high 
density (1.4 g/cm3 in the dry state) with low hydration (10-20% in comparison to ca. 70% 
in viable epidermis). The SC has been described as a brick wall-like structure, in which 
the corneocytes represent the “bricks”, embedding in a “mortar” of the intercellular lipids, 
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interlinked by desmosomes (Figure 1.4a) [36]. The corneocytes are flat  and elongated 
cells, usually up to 50 μm in length and 1.5 μm thick, devoid of nucleus, and  composed 
of about 70-80% keratin and 20% lipid within a cornified cell envelope (~10 nm thick) 
[18]. The cornified cell envelope is a protein/lipid polymer structure formed just below the 
cytoplasmic membrane, surrounding the exterior of the corneocytes. It consists of two 
parts: a protein envelope and a lipid envelope (Figure 1.4b). The protein envelope is 
thought to contribute to the biomechanical properties (e.g., impact resistance) of the 
cornified envelope, as a result of the cross-linking of specialized structural proteins, 
mainly involucrin and loricrin, by both disulfide bonds and N-(γ-glutamyl) lysine 
isopeptide bonds formed by transaminases [37].  
 
 
 
 
 
 
 
 
 
 
Figure 1.4 Schematic representation of (A) the “bricks and mortar” model for human 
stratum corneum, with the corneocyte “bricks”, the intercellular lipid “mortar”, and the 
corneodesmosomes connecting the corneocytes, and (B) the corneocyte envelope. From 
reference [38].    
 
The lipid envelope comprises ω-hydroxyceramides covalently bound to the protein 
matrix of the cornified envelope [39, 40]. There are indications that it is essential in the 
assembly of the intercellular lipid lamellae, thus  providing the structure and barrier 
function of the SC [41]. 
The unique composition of the SC intercellular lipids and their particular organization 
as multiple stacked membrane layers within a continuous lipid domain is critical to the 
permeability barrier function of the SC. The major components of the lipid domains are 
ceramides, cholesterol, free fatty acids, cholesterol esters, and cholesterol sulfate, 
whose  contents vary between individuals and with the anatomical site [18, 42, 43]. 
Ceramides, the most abundant lipids in SC, consist of a sphingoid base (sphingosine, 
dihydrosphingosine, phytosphingosine, or 6-hydroxy-sphingosine), linked via an amide 
bond to a fatty acid (nonhydroxy, α-hydroxy, or ester-linked ω-hydroxy) [44]. Both 
Intercellular 
lipids 
Deslosomes: 
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variations in the fatty acid carbon chain and the sphingoid base architecture result in a 
large number of ceramide subclasses, with a wide variation in chain length distribution, 
as depicted in Figure 1.5. 
 
 
Figure 1.5 Ceramides structure. Four possible sphingosine related chains (S, 
sphingosine; dS, dihydrosphingosine; H, 6-hydroxysphingosine; P, phyto-sphingosine) 
are linked via an amide bond to either of three different fatty acid, R (N, nonhydroxy fatty 
acid; A, α-hydroxy fatty acid; EO, esterified ω-hydroxy fatty acid) resulting in 12 different 
ceramides subclasses [44]. 
 
Another important lipid class in stratum corneum is cholesterol, the second most 
abundant, which is crucial for promoting the intermixing of different lipid species [32]. On 
the other hand, cholesterol sulfate, in spite of being present in small amounts (typically 
2–5% w/w),  plays an important role in the SC desquamation process [26, 45]. 
Free fatty acids have also been identified among the intercellular lipid, and consist of 
long chain saturated free fatty acids, especially lignoceric acid (C24) and hexacosanoic 
acid (C26), and trace amounts of very long-chain (C32-C36) saturated and 
monounsaturated free fatty acids [46].   
Hitherto, several models for the structural organization of lipids have been 
suggested. These include the “sandwich model” proposed by Bouwstra et al, in which a 
long periodicity phase, consisting of three regions (a central liquid crystalline layer 
surrounded by two crystalline gel phases in an orthorhombic arrangement on both sides) 
was identified [47] or the ‘single gel phase’ model propounded by Norlén [48], which 
suggests a lipid arrangement in a single coherent gel phase with no boundaries. 
However, there is no consensus about the existence of a single, general, model for lipid 
packing. 
Chapter 1 – General Introduction 
 
 10 
Thus, the impermeable character of the cornified envelope, together with the highly 
structured lipid lamellae that are oriented parallel to the corneocyte cells, defines a very 
densely packed structure in the SC, important to consider as main barrier for drug 
penetration. 
 
Dermis 
 
Beneath the epidermis, separated by a thin basement membrane, is the dermis, a 
layer of about 2-5 mm in thickness, composed of dense irregular connective tissue. It 
consists of collagen fibrils that provide support, and elastic connective tissue that 
ensures elasticity and flexibility, embedded in an amorphous ground substance of 
mucopolysaccharides. Predominant cell types of the dermis are fibroblasts, responsible 
for the synthesis and renewal of the components of the connective tissue, mast cells, 
and macrophages involved in immune and inflammatory response. As a result of its 
structure, dermis affords low resistance to drug permeation. Nevertheless, the transport 
of very lipophilic drugs to the deeper tissues may be compromised, due to the increased 
hydration degree [18, 23]. 
It provides a highly vascularized network that ensures the removal of the permeant 
molecules from the dermo-epidermal junction to the bloodstream, thus allowing a 
concentration gradient between the applied formulation on the skin surface and the 
dermis. Lymph vessels within the dermis can also remove permeated molecules from the 
skin, which is particularly important in the case of large molecules. Moreover, it plays a 
crucial role in the physiological temperature maintenance and in tissue nutrition and 
metabolic changes. It also contains sensory nerves (free nerve endings and end 
corpuscles), including Pacinian corpuscles that sense vibration and Meissner corpuscles, 
responsible for tactile and pressure sensations  [28].  
Besides, a number of appendages are originated within the dermis, such as the hair 
follicles and associated sebaceous glands, eccrine and apocrine sweat glands.  
 
Hypodermis 
 
Beneath the dermis is a layer of loose connective tissue, commonly known as the 
hypodermis or subcutaneous tissue. It is composed of lipocytes, arranged into fat lobules 
with interconnecting collagen and elastin fibers [28]. Its primary functions are protection 
against physical shock, heat insulation, and energy storage. Blood vessels and nerves 
are supplied to the skin via the hypodermis. It also aids in binding the skin to the 
underlying fascia and skeletal muscle [24].  
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Appendages 
 
The hair follicles are distributed across the entire skin surface with the exception of 
the soles of the feet, the palms of the hands and the lips, representing a fractional area 
of about 1/1000 of the total skin surface. The sebaceous gland associated with each hair 
follicle secretes sebum, which is composed of free fatty acids, triglycerides, and waxes. 
Sebum ensures protection and lubricates the skin, also maintaining the skin surface at a 
pH value of about 5. A smooth muscle, the erector pilorum, attaches the follicle to the 
dermal tissue, enabling hair to respond to fear or cold. Eccrine glands, present a 
fractional area of about 1 in 10,000 of the total body surface, and secrete sweat in 
response to exercise, high environmental temperature, as well as emotional stress. The 
apocrine glands are limited to specific body regions (axillae, nipples, and anogenital 
area), being about ten times the size of the eccrine glands [18, 24]. 
 
1.3 Percutaneous absorption 
 
According to what was mentioned above, the process of drug absorption from a 
transdermal drug delivery system into the systemic circulation may be regarded as a 
passage through consecutive skin layers. Thus, it starts with the release of the permeant 
from the dosage form, followed by penetration into the SC. It diffuses through the 
lipophilic SC at a rate determined by its diffusivity within this layer, then partitioning to the 
more aqueous epidermal environment of viable epidermis (VE). Finally, it is absorbed by 
the capillaries in the dermis, also hydrophilic in nature.  
From what was exposed, the first limiting step is the drug partitioning into the SC, 
which may be, to a certain extent, modulated by the release from the vehicle. On the 
other hand, all these steps are highly dependent on the solubility and diffusivity of the 
permeant within each environment. Release of the permeant from the vehicle and 
uptake into the lipophilic SC is dependent on the relative solubility in each part, and 
hence the vehicle-SC partition coefficient. In turn, the diffusion coefficient or the speed at 
which the permeant moves within each environment is dependent on both the permeant 
properties and factors related to the environment, such as its viscosity and tortuosity, i.e.  
diffusional path length  [18, 49].  
Despite of the heterogeneity of the skin barrier, steady-state permeation or flux (J) of 
a drug through the SC can be simplistically described by Fick’s first law of diffusion 
  
  
  
  
    
 
                                                             (1.1) 
where   is the drug amount permeating a certain unit area of skin,   is the diffusion 
coefficient of the permeant in the skin,    is the partition coefficient between the stratum 
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corneum and the vehicle,    is the applied concentration of permeant, and   the 
diffusional path length. The mechanism of drug penetration can be primarily considered 
driven by passive diffusion and, thus, dependent on the concentration gradient. 
 
1.3.1 Routes of drug penetration 
 
The transport of drug through the skin may be carried out through three potential 
pathways: sweat ducts, hair follicles and associated sebaceous glands 
(transappendageal route), or across the continuous stratum corneum (transepidermal 
route) (Figure 1.6). In what regards the latter, two particular pathways through intact SC 
may exist: the intercellular lipid route between the corneocytes (intercellular) and the 
transcellular route through the corneocytes and interleaving lipids (transcellular) [50, 51].   
 
 
Figure 1.6 (A) Schematic representation of the possible penetration pathways 
through the SC (from reference [50]); (B) Partitioning and diffusion processes involved in 
drug penetration through the stratum corneum (from reference [49)]. 
Transcellular                  TransappendagealA 
B 
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It should be noted that these pathways are not mutually exclusive, that is, a drug may 
use more than one penetration route, which will be dependent on its physicochemical 
properties. 
The transcellular route has been regarded as a polar route through the SC, since the 
corneocytes contain an intracellular keratin matrix that is relatively hydrated and, thus, 
polar in nature. Therefore, permeation requires consecutive partitioning between this 
polar environment and the lipophilic domains involving the corneocytes [18, 49]. This a 
preferential route for hydrophilic compounds, despite the need of the permeant to cross 
the intercellular lipids, in order to jump from one corneocyte to another [52].  
Although this is the more direct route, the transport  is predominantly carried out by 
the intercellular route, which provides the only continuous route through the SC [50]. In 
this case, the diffusional path length is much longer than the simple thickness of the SC 
(10-15 μm), since the intercellular domains are highly tortuous, and may be in excess of 
150 μm. Within intercellular spaces, a diffusing molecule has to cross a variety of 
lipophilic (via lipid core) and hydrophilic (via polar head groups) domains of the 
structured lipids [49, 53]. 
Despite the appendages (glands and hair follicles) have been considered as low 
resistance shunts, their contribution was primarily estimated to be small, since they 
represent only 0.1-1% of the total skin surface area [54]. However, it is suggested that 
the appendageal route dominates during the lag phase of the diffusional process [18]. In 
recent years, there has been renewed interest in targeting follicular delivery through 
colloidal-based formulation approaches [29]. 
 
1.4 Factors affecting drug permeation  
 
Physiological factors 
 
Skin permeability may be affected by a large number of physiological factors. This 
includes age, anatomical site, ethnicity, gender and some skin disorders. 
Intrinsic aging leads the epidermis to become thinner and the corneocytes less 
adherent to one another, although the SC thickness has been shown not to significantly 
change [55]. It is also reported that the lipid composition suffers alterations with age, with 
decreased levels of all major lipid species, particularly for ceramides. Additionally, the 
dermis becomes atrophic and relatively acellular and avascular. The reduced hydration 
levels and lipid content of ageing skin may be responsible for a demonstrated reduction 
in skin permeability with hydrophilic compounds [49, 56]. Moreover, the skin barrier 
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function in young children is significantly reduced, which may lead to an increased 
permeability [57]. 
Skin permeability may also vary with anatomical site. Several studies have revealed 
that distinct anatomic skin sites possess different morphologic and functional 
characteristics. These regional variations induce skin barrier function alterations in the 
following order: genitals (more permeable)>head and neck>trunk>arm and leg (less 
permeable).  
Some differences have been reported across ethnic groups, although inconsistent, 
suggesting that ethnic differences are much less profound than interindividual 
differences within ethnic groups [43]. 
Concerning gender, only slight or no differences in the epidermal barrier have been 
reported as determined by basal transepidermal water loss (TEWL) between male and 
female skin [18, 58, 59]. 
The state of the skin (normal, abraded, or diseased) may also influence permeation. 
A number of common skin disorders, such as eczema (dermatitis), psoriasis, ichthyosis, 
and acne vulgaris may compromise barrier function. Skin infections that manifest 
eruptions at the skin surface, e.g. impetigo, Herpes simplex and fungal infections can 
also temporarily reduce the barrier [18, 25]. 
 
Properties of the drug 
 
The capacity of a drug to enter the skin depends on its ability to penetrate, 
consecutively, the hydrophobic and hydrophilic domains of the skin. From Equation (1.1), 
ideal physicochemical properties of a molecule to penetrate and permeate through the 
SC can be extracted. These include [51, 60]  a high, but balanced partition coefficient 
(K). Thus, a log P(o/w) comprised between 1 and 3 is pointed as optimal, since drugs 
that are too hydrophilic are unable to partition from the vehicle into the SC. On the other 
hand, very lipophilic drugs will be retained in intercellular SC lipids, and will not partition 
to the more aqueous viable epidermis, thus limiting their skin permeation rate. 
Additionally, ionized species of a drug has also a lower permeability coefficient than its 
respective unionized species, as the log P of ionized species is lower [53]. A low 
molecular weight is also desirable, since the size of the permeant will influence the 
diffusivity (D) within the SC. An inverse relationship between permeant size and skin 
permeation has been reported. As a general rule, permeants selected for transdermal 
delivery tend to be less than 500 Da, when D tends to be high.  It should also possess 
an adequate lipid solubility (high diffusion coefficient, D), but also reasonable aqueous 
solubility (> 1mg/mL) (high donor concentration, Cv, in order to ensure a high 
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concentration gradient, the driving force for diffusion) to maximize flux. Finally, a low 
melting point (<200 ºC) is also a good characteristic, since it correlates with good 
solubility of the drug in the intercellular SC lipid domain. 
In addition to these specific physicochemical properties, drug candidates should be 
characterized by a high therapeutic potency (deliverable dose ideally below 20 mg/day), 
poor oral bioavailability and short biological half-live, in order to take maximal advantage 
of a transdermal administration. The drug should also not be irritant to the skin nor 
stimulate an immune reaction in the skin [61, 62].  
 
Properties of the vehicle 
 
The successful development of a transdermal drug delivery system relies on the 
application of the skin permeation fundamentals to the design of an appropriate 
formulation. The latter assumes particular importance, since the vehicle may profoundly 
influence the drug release mechanism from a formulation (by modulating the vehicle/SC 
partition coefficient), alter the skin barrier properties (by SC modification/circumvention), 
or simply promoting an increase of the drug solubility in the SC. The effects upon the SC 
may range from the interaction with SC intrinsic elements, including the intercellular lipid 
lamellae and protein components, or promoting SC hydration by an occlusive effect [49, 
63]. Methods to enhance skin permeation are discussed in detail below. 
 
1.5 Permeation enhancement 
 
Under normal circumstances, due to barrier properties of the skin, transport from 
simple vehicles will often be insufficient to achieve therapeutic drug concentrations at the 
site of action [64]. In order to overcome this limitation, a number of techniques have 
been developed aiming at increase the range of penetrants and the rate of transdermal 
delivery. Strategies to achieve penetration enhancement can be categorized as passive 
and active, ranging from simple occlusion and formulation optimization, to the use of 
chemical and physical methods or combinations of both (Figure 1.7). These rely on two 
main approaches: increasing skin permeability and/or providing a driving force acting on 
drug [25].  
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Figure 1.7 Passive and active (indicated by the red solid line) methods to facilitate 
penetration of drugs through the skin. Adapted from reference [51].   Highlight (orange 
background) is given to the strategies considered in the present work. The mechanisms 
by which compounds permeate the skin through these approaches are discussed later in 
this chapter. 
 
1.5.1 Passive methods  
 
Passive penetration enhancement can be achieved by formulation manipulation, 
increasing the thermodynamic activity of the drug in formulations (e.g., supersaturated 
and nanocarrier systems), drug modification, and/or by using chemical penetration 
enhancers (CPE) that interact with skin constituents to promote drug flux [60].  
 
Supersaturated systems 
 
Supersaturation is a state reached when the amount of drug dissolved in a matrix 
exceeds its equilibrium solubility. Supersaturated formulations allow an increased driving 
force by increasing the concentration of the drug in the vehicle. However, since the 
thermodynamic activity of supersaturated systems is higher than that of saturated 
systems, they are inherently unstable, thus compromising long-term stability. The use of 
mixed cosolvent systems (e.g., mixtures of propylene glycol and water), with antinucleant 
polymers to inhibit or retard crystallization [65], or the induction of in situ changes in drug 
Lipid
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Chemical
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concentration with solvent evaporation [66] are some of the strategies employed to 
produce supersaturated systems and avoid stability problems [60, 61].  
 
Drug modification 
 
Other approaches to increase drug delivery through the skin rely on chemical 
modification of a poorly penetrating drug into a pharmacologically inactive prodrug, 
which readily penetrates the skin, as a result of the increase in  lipophilicity [67].   
The ion-pair formation and the use of eutectic mixtures are other examples of drug 
modification. Ion pairs are defined as neutral species formed only by electrostatic 
attraction between oppositely charged ions, which exhibit sufficient lipophilicity to 
dissolve in the SC [60]. The ion pair diffuses subsequently to the aqueous viable 
epidermis, where dissociation into the charged species occurs, before diffusing onwards 
[51]. 
Eutectic mixtures take advantage of a reduction in the melting point of a permeant, 
which will have a direct effect on its solubility in skin and thus should increase skin 
permeability [68].  
 
Chemical penetration enhancers  
 
Chemical penetration enhancers (CPE) are pharmacologically inactive compounds 
that may temporarily diminish the barrier of the skin, by affecting drug partition and 
diffusion into the skin, thus interacting with the SC constituents [67]. Several substances 
have been identified as drug penetration enhancers. However, safety issues constitute 
the major concern that limits their clinical use. Therefore, there is an attempt to identify 
new CPE that are classified as GRAS (generally recognized as safe). Ideal properties of 
a chemical enhancer are depicted in Table 1.1. 
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Table 1.1 Properties of an ideal chemical penetration enhancer [69]. 
Ideal chemical penetration enhancer 
 Pharmacologically inert. 
 Nonallergenic, nonirritating, and nontoxic. 
 Rapid onset of effect with a predictable duration of activity. 
 After removal of the enhancer, the SC should immediately and 
completely recover its normal barrier property. 
 The barrier function of the skin should decrease in one direction 
only; loss of endogenous materials should not occur. 
 Physically and chemically compatible with drugs and excipients in 
the dosage form; readily incorporated into the delivery system. 
 Cosmetically acceptable when applied to the skin. 
 Inexpensive, odorless, tasteless, colorless. 
 
CPE are believed to affect permeation via one or more of three main mechanisms, 
relying on the lipid-protein-partitioning theory of skin penetration enhancement [70]. This 
concept comprises lipid bilayer interaction (intercellular route), protein modification 
(intracellular route), and  partitioning promotion effects [51]. Therefore, enhancers can 
[71] modify the intercellular lipid domains, reducing the barrier resistance of the lipid 
bilayers, and thus, augmenting diffusivity in the SC. Multiple actions are described 
regarding interaction of the CPE within the intercellular lipid domain (Figure 1.8A).  
 
 
 
 
 
 
 
 
 
 
 
Figure 1.8 Modes of action of CPE with the intercellular lipids (A), desmosomes and 
protein structures (B), and with corneocytes. From reference  [72].  
 
Thus, they may interact with the lipid polar headgroups by establishing H-bonding 
and/or ionic forces and causing alteration in the hydration spheres of the lipid bilayers, or 
insert between the hydrophobic lipid tails (e.g. terpenes). As a result, they are able to 
disturb the lipid packing, thus increasing lipid fluidity and promoting drug permeation. On 
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the other hand, perturbation in the lipid order may arise when the enhancer forms pools 
in the skin, as a result of its structure (polar head and long saturated alkyl chain, e.g., 
oleic acid), allowing the permeant to diffuse faster either through them or through the 
defects between the pools and the structured lipids [60, 73]. Some CPE may also cause 
lipid extraction (e.g., ethanol).  
They can also act on SC proteins, such as intracellular keratin, causing its 
denaturation or modification of its conformation, which leads to swelling and increased 
hydration (Figure 1.8C); or, by interacting with desmosomes, responsible for the 
maintenance of cohesion between corneocytes (Figure 1.8B). 
In some cases, they alter the partitioning of the drug or of a co-solvent into the skin, 
by promoting modifications in the solvent nature (aqueous domain) of the stratum 
corneum. Solvents such as propyleneglycol, ethanol, and Transcutol® (diethylene glycol 
monoethyl ether) are believed to act in this way [74]. 
CPE may also indirectly increase the thermodynamic activity of the vehicle or 
promote the solubilization of the permeant in the formulation [71].  
 
Nanocarrier systems 
 
Nanocarrier systems including, liposomes and derivatives, microemulsions, 
nanoemulsions, polymer and lipid nanoparticles have deserved increasingly attention in 
the delivery of drugs to the skin. Particular emphasis will be given to lipid nanoparticles. 
 
Lipid nanoparticles 
 
Solid lipid nanoparticles (SLN), considered the first generation of lipid nanoparticles, 
were introduced in 1991 as an alternative carrier system to emulsions, liposomes and 
polymeric nanoparticles [75]. SLN are colloidal carriers, with sizes typically ranging from 
40 to 1000 nm, derived from o/w emulsions, in which the liquid lipid (oil) was replaced by 
biodegradable and biocompatible solid lipids (0.1-30% w/w), that is, lipids that are in the 
solid state at both room and body temperatures, and stabilized by aqueous emulsifiers 
(0.5-5%) solution. Solid lipids can vary from pure lipids or a mixture of lipid compounds, 
encompassing triglycerides, partial glycerides, fatty acids, and waxes.  On the other 
hand, the emulsifiers, including a large variety of non-ionic and ionic surfactants, are 
chosen depending on the administration route, being often used in association, in order 
to prevent particle agglomeration more efficiently [76].  
At the turn of the millennium, a second generation of lipid nanoparticles, consisting of 
a matrix composed of a blend of solid and liquid lipids (oils),  led to the creation of the 
Chapter 1 – General Introduction 
 
 20 
concept of nanostructured lipid carriers (NLC) [77]. NLC were introduced to overcome 
some potential limitations of the SLN, such as low drug loading and drug expulsion 
during storage [78]. These problems are a consequence of the SLN crystalline matrix 
(pure solid lipid or a mixture of solid lipids) and of the occurrence of polymorphic 
transitions, respectively [79-81]. Lipids molecules are known to exhibit polymorphism, 
that is, presenting different three-dimensional structures (polymorphic forms): unstable α, 
metastable β′, and as the most stable the β modification [82]. After preparation, at least a 
part of the lipid particle crystallizes in a higher energy modification (α and β’ polymorphic 
forms). During storage, rearrangement of the crystal lattice might occur evolving to a 
more thermodynamically stable configuration (β form), which corresponds to a lower free 
energy state and, consequently, to a highly ordered system, with less imperfections on 
the crystal lattice of the lipids [83]. This transformation leads to the expulsion of the drug 
and contributes also to the instability of the system. The drug expulsion as a 
consequence of the crystallisation process led to the development of NLC, in which the 
matrix remains solid, but not crystalline [84]. In the NLC, the incorporation of a liquid lipid   
in the solid matrix creates a less ordered structure. This characteristic makes them able 
to accommodate higher amounts of drug, which can be located not only between the 
fatty acid chains and the lipid layers, but also in imperfections of the lipid matrix (Figure 
1.9). Additionally, the solubility of the drug in oils is usually higher than in solid lipids [78, 
79, 85, 86]. 
 
Figure 1.9 Difference between an SLN and NLC lipid matrix structure. Adapted from 
[87]. 
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Several mechanisms of drug incorporation have been considered for these 
nanocarriers. For the SLN, three models can be applied: SLN type I or the homogenous 
matrix of solid solution, in which the drug is molecularly dispersed in the particle matrix, 
SLN type II or the drug enriched shell  and SLN type III or drug enriched core models, 
where the drug is concentrated in the particle shell and core, respectively. For NLC, also 
three types are described: NLC type I or the imperfect model, with many imperfections in 
the matrix which are able to accommodate the drug, being created when small amounts 
of the liquid lipids are employed, NLC type II or the structureless/amorphous model, 
which is created when mixing special lipids which avoid the occurrence of crystallization , 
and NLC type III or the multiple O/F/W model, which is characterized by small oil 
nanocompartments dispersed in the solid lipid matrix. This can be obtained when the 
liquid lipids are incorporated in the solid matrix, exceeding the respective solubility. 
These particles are able to accommodate higher amounts of drug, in particular drugs 
more soluble in the liquid than in the solid lipids.[82, 84] Thus, either the composition or 
the method of production contribute to obtain different types/structures of lipid 
nanocarriers, which therefore result in different performances in terms of drug loading 
and release. 
The nature of lipid nanoparticles confers them distinct advantages over conventional 
carriers (emulsions, liposomes, and polymer nanoparticles), such as an excellent 
tolerability, resulting from the generally recognized as safe (GRAS) status of the 
excipients employed. Thus, there is a reduced danger of acute and chronic toxicity, 
improved physical stability, protection of incorporated labile drugs from degradation, low 
cost, possibility to modulate drug release due to the solid nature of the lipid matrix, drug 
targeting, feasibility of scaling-up, cost-effective production method, and relatively low 
cost of excipients [80, 86, 88-92]. Moreover, their unique properties such as reduced 
size, combined with a large surface area and high drug loading are attractive for a 
potential improvement in the performance of pharmaceuticals, in particular for 
transdermal delivery [93, 94].  
 
1.6 Active strategies 
 
Active methods involve the use of external energy to act as driving force and/or to 
reduce the barrier function of the SC, which allows expanding the range of permeants to 
deliver through the skin. These manipulations include the application of various forms of 
energy (e.g., heat, electrical, magnetic), or breaching, reducing, or weakening the SC 
barrier by mechanical means [1]. Focus will be given to electrically assisted and 
mechanical methods. However, other technologies, such as magnetophoresis, which 
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involves the application of a magnetic field, to enhance the driving force on a penetrant 
[95], photomechanical waves  [96, 97], or thermal ablation [98] to increase the 
“permeabilization” of the SC have also been investigated.   
 
Electrical assisted methods 
 
Iontophoresis is a noninvasive method that involves the application of a small electric 
current to drive ionic molecules across the skin. It is particularly effective for ionic and 
polar drugs such as peptides, which are very poorly absorbed by the skin under normal 
conditions [99]. The technology employs the use of two electrodes immersed in a 
solution containing the drug compound. The application of a potential difference 
(voltage) across the electrodes results in the motion of drug molecules, in the form of 
charged ions, which travel from the electrodes into the skin [100]. Transdermal drug 
transport enhancement by iontophoresis is promoted by three main mechanisms: 
electrorepulsion of charged solutes by the electrode, electroosmotic effects on 
unionized, polar species, and permeabilization of the skin by the electric current [61, 99].  
Electroporation involves the application of high voltage (>50V) pulses to the skin, 
lasting for a period in the microsecond-millisecond range, and leading to the creation of 
aqueous pores or pathways through the SC. The pores formed are small (<10nm), 
transient (from microseconds to seconds), sparse (0.1% of surface area), and 
congregated in discrete local transport regions. This technique also expands the range 
of drugs (small to macromolecules, lipophilic or hydrophilic, charged or neutral 
molecules) which can be delivered transdermally [99, 101]. 
Sonophoresis is used to describe enhanced transdermal delivery following 
application of ultrasound energy to the skin. Low-frequency ultrasound (<100 kHz, 
usually 20 kHz) is reported to disrupt the lipid bilayer of SC through several phenomena: 
cavitation, which leads to generation and oscillation of gas bubbles form small 
hydrophilic channels through the SC, combined with thermal effects (temperature 
increase), induction of convective transport and mechanical effects (occurrence of 
stresses due to pressure variation induced by ultrasound) [102]. This technique has 
been employed in the enhancement of the delivery of drugs, macromolecules, 
oligonucleotides, DNA and vaccines [103].  
 
Mechanical methods 
 
The microneedles technique uses small micron-sized needles as a mechanical 
approach to breach the SC, creating microchannels through the skin, so as to deliver a 
drug at a predetermined depth [104]. Microfabrication techniques have been developed 
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for silicon, metal, biodegradable polymers, and sugar-based microneedle arrays, having 
solid and hollow bores with different geometries and sizes. There are four general 
approaches of transdermal delivery by microneedles: (a) hollow microneedles, whereby 
a drug in solution is active and passively delivered through the bore of the microneedle 
(“poke and flow” approach), (b) solid microneedles to pierce the skin, following by 
application of a patch to diffuse drug through the skin (“poke and patch” approach), (c) 
biodegradable polymeric microneedles, containing the drug encapsulated (dissolving or 
porous microneedles), allowing a controlled drug release by dissolution or diffusion from 
the pores into the skin (“poke and release” approach), and (d) drug coated microneedles, 
inserting them into the skin for subsequent release through hydration of the coating 
(“coat and poke” approach) [25, 105]. Microneedles have been used to deliver drugs, 
proteins, and particles across skin in a simple, painless and minimally invasive manner, 
since they do not penetrate up to the papillary dermis where nerve endings are located 
[104]. However, important issues concerning safety and difficulty in self-administration 
can be pointed as disadvantages, which may delaying the introduction of microneedles 
in the market [106].  
Needleless jet injectors arise as a painless technique, alternative to conventional 
needle injection, that enable to overcome the SC barrier, in this case by propel powders 
or liquids at high velocity into skin. It has been particularly employed in the transdermal 
delivery of proteins and peptides [107].   
Other mechanical techniques, such as microdermabrasion or tape stripping may 
enhance penetration by reducing the thickness of the SC barrier, whereas stretching or 
flexing can lead to a general weakening of the barrier [99, 108]. 
 
Recent combinational techniques 
 
In order to make the transport through the skin more effective, combinations among 
several strategies have been investigated. This has involved the association of passive 
with active methods, such as CPE-iontophoresis [109], SLN-iontophoresis [110], CPE-
electroporation [111], CPE-sonophoresis [112], and between active technologies, e.g., 
microneedles-iontophoresis [113], microneedles-sonophoresis [114], microneedles-
electroporation [115], or electroporation-iontophoresis [116]. 
 
1.7 Development of the transdermal formulation 
 
The development of a transdermal pharmaceutical formulation may range from an 
aerosol spray, a semisolid or self-adhesive patch (reservoir, matrix, drug-in-adhesive or 
microreservoir). Whatever the dosage form, important technological concerns must be 
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undertaken throughout the pharmaceutical development, including compatibility, stability, 
acceptability, as well the bioavailability in order to ensure the therapeutic outcome. That 
implies an optimization of the applied formulation focused on the improvement of release 
and permeation through the skin [74]. Accordingly, the composition of the vehicle and 
the active substances deserves special emphasis, especially because a close contact 
with the skin is often accompanied by possible risks of adverse reactions. Furthermore, 
the lack of precision related to the variability of the amount of drug delivered through the 
skin as a result of the epidermis thickness, as well as to a possible mechanical removal 
of the applied formulation must be equated [82]. In order to overcome the above-
mentioned issues, better solutions have still to be found.   
 
1.7.1 Drug and formulation strategies 
 
Drug characteristics 
 
Olanzapine (OL), chemically a thienobenzodiazepine described as 2-methyl-4-(4-
methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5] benzodiazepine [117] (Figure 1.11a) is a 
second-generation antipsychotic drug used for the treatment of schizophrenia, bipolar 
mania and associated agitation [7]. Although it is more effective than other first-line 
second-generation drugs, the long-term use of olanzapine has been limited by its 
substantial, un-wanted effects on metabolism that result, among others, in weight gain 
and development of dyslipidemia, as above referred (it increases the levels of 
triglycerides and low-density lipoprotein cholesterol, LDL-C, and decreases high-density 
lipoprotein cholesterol, HDL-C) [10, 118], which leads to an increased cardiovascular risk 
[11, 119]. This calls for the need of a close monitoring of patients on olanzapine 
treatment so that, if these adverse events arise, the maintenance of the therapy may be 
evaluated [120]. In order to mitigate some of these unwanted effects, the treatment with 
statins, such as simvastatin, might be required [121, 122].  
Simvastatin (SV), chemically butanoic acid, 2,2-dimethyl-,1,2,3,7,8,8a-hexahydro-
3,7-dimethyl-8-[2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl]-1-naphthalenyl ester, 
[1S-[1α,3α,7β,8β(2S*,4S*),8aβ]] [117] (Figure 1.10b), is the lactone prodrug that is 
hydrolyzed in vivo, in the liver and non-hepatic tissues, to the corresponding β-hydroxy 
acid (simvastatin acid, SVA, Figure 1.10b) [123, 124]. The latter is a potent inhibitor of 
the enzyme 3-hydroxy-3-methylglutaryl coenzyme A reductase, involved in the 
cholesterol synthesis. This inhibition is mainly responsible for reducing LDL-C levels, but 
simvastatin has also been shown to reduce the levels of triglycerides and increase the 
levels of HDL-C. SV is also reported as effective in the reduction of the morbidity and 
mortality associated to the coronary heart disease [16].  
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Figure 1.10 Chemical structures of (A) olanzapine and (B) simvastatin (left), the 
prodrug as inactive lactone form with simvastatin acid (right), the respective active β-
hydroxy acid form. Note that simvastatin is rapidly absorbed from the gastrointestinal 
tract after oral administration, but undergoes extensive first-pass metabolism in the liver, 
which is responsible for its low oral bioavailability [125]. 
 
Lipid nanoparticles for the coencapsulation of OL and SV arise as a promising 
approach in a transdermal drug delivery system (TDDS). Moreover, the complementarity 
between the therapeutics and the advantage that clearly results in the improvement of 
treatment compliance, a reduction in the time of production and the challenge stemming 
from the simultaneous incorporation of drugs with different lipophilicity into the same 
colloidal carrier, are also appealing factors from a nanotechnological point of view. 
In addition, both drugs gather properties that make them suitable as candidates for 
transdermal delivery (Table 1.2).  
 
Table 1.2 Physicochemical and pharmacokinetic properties of olanzapine and 
simvastatin. 
Drug Olanzapine Simvastatin 
Molecular weight 312.433 418.566 
Log P/Lipophilicity 2.8
a
 4.7
b
 
Aqueous solubility 3–5 µg/mL
c
 30 µg/mL
d
 
Melting point 195°C
d
 135-138°C
d
 
Daily oral dose 5-10 mg/day
e
 10-40 mg/day
f
 
Half-life 33 h
g
 2 h
h
 
Bioavailability 60%
g
 5%
h
 
a Ref. [126], b Ref.[127], c Ref. [128], d Ref. [129], e Ref. [130], f Ref. [131],  g Ref. 
[132], h Ref. [125]. 
 
 
A B 
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Lipid nanoparticles 
 
SLN and NLC as colloidal systems claim several advantages for improving 
penetration of drugs through the skin. These include their chemical similarity to skin 
lipids, stemming from the common hydrophobic character, the existence of a solid 
matrix, and the biocompatibility, which makes these carriers suitable for long-term 
controlled-release skin administration. Moreover, as a result of the small particle size, a 
high specific surface area for drug absorption through the skin is made available, thereby 
providing a larger efficacy as a delivery system [133]. Additionally, the adhesion of lipid 
nanoparticles to the skin leads to the formation of a film, and subsequently, to an 
occlusive effect with the reduction in transepidermal water loss [134, 135]. The resulting 
hydration of the SC could be also related to a reduction of corneocyte packing and a 
widening of the inter-corneocyte gaps, hence facilitating drug penetration into deeper 
skin strata (Figure 1.11) [135-137].  
 
 
 
Figure 1.12 Transdermal administration of lipid nanoparticles. (A) When in contact 
with the skin, lipid nanoparticles create a thin film with very narrow interspaces between 
the particles. Adapted from [87]. (B) This film hinders water evaporation, leading to an 
occlusive effect, and subsequently, to increased skin hydration, resulting in drug 
penetration-increasing effects. Adapted from [82]. 
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Ethanol and terpenes 
 
The use of chemical permeation enhancers has long been shown to increase the 
diffusivity and/or the solubility of the drugs by reversibly disordering or ‘fluidizing’ the lipid 
structure of the SC, thus reducing the barrier resistance of the skin [25, 71, 138]. Bearing 
this in mind, terpenes and ethanol as co-solvent were subsequently incorporated in a 
lipid nanoparticles formulation so as to maximize permeation, by combining the occlusive 
and adhesive properties of the latter with the skin permeability alterations promoted by 
the chemical enhancers. 
 
Skin perforation 
 
A further alternative that is probed in this work is the perforation of the SC by a 
microneedle roller device (Dermaroller®). Microneedles can transiently create 
micropathways that help lipid nanoparticles and drugs to bypass the SC, the major rate 
limiting barrier for transdermal delivery, thus facilitating their permeation into the viable 
epidermis.[25, 139] 
Different approaches are thus sequentially addressed, attempting to assess the 
respective influence in the simultaneous drugs permeation.  
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Chapter 2  
 
Methods for lipid nanoparticles production, 
characterization and optimization 
 
 
 
In this chapter, a brief introduction to most of the methods and techniques used in 
this study is presented. Further details, including practical considerations about the 
actual procedures are provided in the specific methods and results sections along the 
thesis.   
For convenience, the methods were divided into nine sections, encompassing the 
different stages of the work, and ranging from the experimental to the simulation part. 
The former comprises a comprehensive description of the preparation methods of lipid 
nanoparticles carried out, a technical description of the methods used for the lipid 
nanoparticles characterization, including particle size analysis, zeta potential, drug 
incorporation measurements, morphological and crystallinity characterization techniques, 
such as high-resolution microscopy (scanning electron microscopy, transmission 
electron microscopy and atomic force microscopy), differential scanning calorimetry and 
attenuated total reflectance infrared spectroscopy, respectively. Experimental design 
was a technique omnipresent throughout the study and is addressed in the perspective 
of its importance for the screening and optimization procedures. A short introduction to 
rheological and texture analysis, and to the methods for studying in vitro and in vivo 
percutaneous absorption, stability and cytotoxicity is provided. Some general aspects of 
molecular dynamics simulation are, finally described. 
 
2.1 Production  
 
Numerous methodologies for lipid nanoparticles production are described in the 
literature, including high pressure homogenization [1-3], via microemulsion [4, 5], solvent 
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emulsification-evaporation [6, 7] or diffusion [8-10], w/o/w double emulsion [11, 12], 
phase inversion [13-15] and high shear homogenization [16] and/or ultrasonication 
techniques [17]. Other approaches have been developed as described elsewhere [18].  
The lipid nanoparticles addressed in this work were produced by two different 
methods: a modified solvent emulsification-evaporation method, combined with high 
shear homogenization and ultrasonication, and hot HPH. For this reason, these 
techniques will be described in more detail in what follows. 
 
2.1.1 Solvent emulsification-evaporation  
 
The solvent emulsification-evaporation is a method similar to the production of 
polymeric nanoparticles by solvent evaporation in o/w emulsions. The lipid is previously 
dissolved in a water immiscible organic solvent (e.g. chloroform, or methylene chloride) 
and the organic solution is dispersed in aqueous surfactant phase, in order to obtain an 
o/w emulsion. The solvent is then removed by evaporation and a solid lipid nanoparticle 
dispersion is formed [6, 19, 20]. 
The emulsification step was supported by the ultrasonication technique, followed by 
high shear homogenization (Figure 2.1). Both are dispersing techniques also employed 
in the preparation of lipid nanoparticles.  
 
 
Figure 2.1 Schematic representation of the two main steps in the modified solvent 
emulsification-evaporation method for lipid nanoparticles production [21]. 
 
Ultrasonication is based on the mechanism of cavitation through which high 
frequency sound waves propagate into liquid media, resulting in cavitation bubbles which 
generate high shear forces to reduce droplet size (Figure 2.2). On the other hand, the 
implosion of the cavitation bubbles cause intensive shock waves in the surrounding 
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medium,  resulting in the formation of liquid jets of high velocity leading to the reduction 
of droplet size to nanoscale [18]. 
 
Figure 2.2 Mechanism of formation of lipid nanoparticles by the ultrasonication 
technique. Adapted from [18]. 
 
High shear homogenization takes advantage of high shear rates performed by high 
speed rotor homogenizers. Centrifugal force drives the dispersion to the periphery of the 
workhead and subjects it to mechanical shear in the precision gap between the rotor and 
stator. This is followed by an intense hydraulic shear, which allows to reduce droplet size 
[22].  
The main advantage of this procedure is that it avoids thermal stress. The use of 
organic solvents and some ultrasonication probe metal contamination  arises as potential 
drawbacks [19]. The low dispersion efficiency attributed to high shear homogenization 
and ultrasonication [23] can be overcome by combining the two different homogenization 
methods.  
 
2.1.2 Hot high pressure homogenization 
 
HPH is a technique broadly used in several research areas, including the 
pharmaceutical, for example, in the production of parenteral emulsions [24]. The already 
established HPH large-scale production lines allows to overcome the lack of scaling up 
associated to some nanoparticle production methods, being also a simple and very cost-
effective  technique  [20, 25]. 
Additionally, HPH leads to a product  relatively homogeneous in size, that is, 
possessing a higher physical stability of the aqueous dispersion [20]. 
High pressure homogenizers functions as follows: a pump pushes a liquid (the hot 
pre-emulsion, as referred below) with high pressure (100–2000 bar) through a 
constricted passageway called the gap region (in the range of a few microns). The fluid 
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accelerates on a very short distance to a very high velocity (over 1000 Km/h), leaves the 
gap region and enters the exit region flowing in the direction of the impact ring. After 
passing through this region, the fluid exits through the outlet (Figure 2.3) [26-28]. 
 
Figure 2.3 Schematic representation of the hot HPH technique (at right) [29]. The 
homogenizing valve of the homogenizer (at left) consists of three main regions, namely, 
the inlet region (also referred to as the entrance region), the gap and the exit region (also 
called the impact region or the impingement zone). Adapted from reference [28].  
 
The mechanism for HPH-action is not thoroughly clear, but includes high-pressure 
gradients/rapid decompression (the pressure begins at a high value and remains high 
until the flow enters the gap region, where the pressure falls very quickly), turbulence, 
cavitation collapse (the rapid increase in velocity with a corresponding decrease in 
pressure generates high shear stress as well as gas bubbles to implode when the 
pressure downstream of the gap recovers) and strong impact and impingement [27, 30]. 
It is effective even for the homogenization of highly concentrated (up to 40% of lipid 
content) dispersions [31].  
HPH can be used in two different production techniques: at elevated temperature,  
hot HPH, or below room temperature,  cold HPH. 
For the hot HPH technique, the lipid is melted at approximately 5°C to 10°C above its 
melting point, and the drug is dissolved or finely dispersed. Afterwards, this molten lipid 
phase is dispersed in a hot surfactant solution by a high-shear mixing device 
(Ultraturrax). The obtained coarse pre-emulsion is then homogenized using a high 
pressure homogenizer also above the lipid melting point, generally at a pressure ranging 
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from 100 to 1500 bar and submitted to one to three homogenization cycles (APV Gaulin 
LAB 40) or operated continuously for a certain period of time (Emulsiflex C3, Avestin). A 
hot nanoemulsion is obtained, which after cooling leads to recrystallization of the lipid 
and formation of lipid nanoparticles [20, 23]. This technique can be successfully applied 
to lipophilic drugs, while for hydrophilic compounds the cold homogenization is a 
preferred technique [18]. 
 
2.2 Characterization 
 
An appropriate characterization of the solid lipid nanodispersions is required to 
control the product quality. However, it represents a challenge due to the small size of 
these colloidal carriers and the complexity of the system. Important key parameters, 
which have direct impact on the release kinetics and stability need to be considered. 
These include mean particle size, zeta potential, entrapment efficiency and drug loading, 
degree of lipid crystallinity and lipid modification [19].  
 
2.2.1 Size 
 
Several methods are available to characterize particle size, but none of them are fully 
satisfactory. Therefore, a combination of at least two methods, one of which based on 
microscopy, is highly recommended. 
 
Dynamic light scattering  
 
Dynamic light scattering (DLS, also known as photon correlation spectroscopy or 
quasi-elastic light scattering, QELS) is a technique for measuring the size of particles 
typically in the submicron region, ranging from 0.3 nm to 10 µm in the case of Zetasizer 
Nano ZS (Malvern) [32] and 0.6 nm to 7 µm for Delsa Nano C (Beckman Coulter) [33, 
34], both of them available in the Pharmaceutics department DLS measures the 
fluctuation of the intensity of the scattered light of a laser beam caused by particle 
Brownian motion and relates this to the size of the particles. The larger the particle, the 
slower the Brownian motion will be. Thus, larger particles will diffuse more slowly than 
the smaller ones. The velocity of the particle Brownian motion is defined by a property 
known as the translational diffusion coefficient (usually given by the symbol, D). The size 
of a particle is then calculated from the translational diffusion coefficient by using the 
Stokes-Einstein equation, 
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 ( )   
   
    
                                                             (2.1) 
where  ( ) corresponds to the hydrodynamic diameter,    is Boltzmann’s constant, 
  the absolute temperature,   the viscosity and   stands for the translational diffusion 
coefficient. 
It should be noted that the diameter that is obtained by this technique corresponds to 
the diameter of a sphere that possesses the same translational diffusion coefficient as 
the particle, thus being denoted as hydrodynamic diameter [35-38].  
Size is obtained from the correlation function, which describes the decay of the 
intensity of scattered light as a function of time, and contains the diffusion coefficient 
information required to be entered into the Stokes-Einstein equation. The diffusion 
coefficient is obtained by fitting the correlation function with a suitable algorithm, such as 
cumulants analysis, which determines a mean size and polydispersity index (PI). The PI 
is a dimensionless measure of the broadness of the size distribution, ranging from 0 to 
1[35]. A PI value lower than 0.1 might be associated with a high homogeneity in the 
particle population (monodisperse), whereas high PI values suggest a broad size 
distribution (polydisperse) or even several populations (plurimodal).The latter situations 
suggest potential problems with the stability of the formulation, and the probability of 
aggregation of the particles has to be considered [39, 40].  
 
Static light scattering 
 
In a way similar to DLS, in static light scattering (SLS, or laser diffractometry, LD) the 
particles in a sample are illuminated by a light source such as a laser, with the particles 
scattering the light in all directions. But, instead of measuring the time dependent 
fluctuations in the scattering intensity, SLS is based on the dependence of the diffraction 
angle on the particle radius. The angle of the light scattered by a particle is inversely 
proportional to the size of that particle, so that smaller particles cause more intense 
scattering at high angles than do larger ones.  
A clear advantage of LD is the coverage of a broad size range from the nanometer to 
the lower millimeter range, allowing to detect the presence of microparticles or particle 
agglomerates. Despite the simultaneous use of DLS and LD is highly recommended, it 
should be stressed that both methods are based on the detection of light scattering 
effects to “indirectly” calculate particle sizes. As such, difficulties may arise from 
nonspherical lipid particle shapes [41] or the presence of several populations of different 
size. Some of these limitations could be overcome by using additional techniques, such 
as high-resolution microscopy [42]. 
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2.2.2 Morphology  
 
Three types of high-resolution microscopy, scanning electron microscopy (SEM), 
transmission electron microscopy (TEM) and atomic force microscopy (AFM) are 
available for imaging of lipid nanoparticles. 
 
Scanning electron microscopy 
 
SEM is a microscopy technique that can yield information about the topography 
(surface features), morphology (shape and size of the particles) and even composition 
(elements and the relative amounts of them), allowing for an instrumental resolution on 
the order of 1-5 nm [39].   
In SEM, a beam of highly energy (ranging from 0.1 to 30 keV and an acceleration 
voltage between 2 and 50kV) is focused in vacuum into a fine probe that is rastered over 
the surface of the specimen.  
The electron beam passes through scan coils and objective lens that deflect 
horizontally and vertically so that the beam scans the surface of the sample. As the 
electrons penetrate the surface, a number of interactions occur that can result in different 
types of signals produced, including secondary electrons, backscattered electrons, 
characteristic x-rays, and other photons of various energies. Detectors of each type of 
electrons are placed in the microscope in proper positions to collect them. The imaging 
signals of greatest interest are the secondary and backscattered electrons because 
these vary primarily as a result of differences in surface topography [43]. 
Some constraints of the technique is that for the observation, the sample must be 
dried and coated with a thin layer of gold or platinum, when it is not conductive [19].  
 
Transmission electron microscopy 
  
Transmission electron microscopy (TEM) is a technique where an electron beam 
interacts and passes through a thin specimen (typically of the order of 5-100 nm for 100 
keV electrons). The electrons are emitted in the electron gun and focused by a 
condenser-lens system onto the sample surface. The electrons that are elastically 
scattered consist the transmitted beams which are imaged by a lens system onto a 
fluorescent screen [44]. 
The operation of TEM requires an ultra-high vacuum and a high voltage (an 
acceleration voltage of routine instruments ranges from 100 to 200kV), allowing a 
resolution of 0.15-0.3 nm for conventional microscopes [44]. Additionally, it is a 
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technique that requires several steps of sample preparation, also involving high cost [39, 
45]. 
 
Atomic force microscopy 
 
AFM is a microscopy technique relatively not invasive that provides the three-
dimensional topography as well as physical properties of a surface, by measuring forces 
between a sharpened probing tip, supported on a flexible cantilever, and that surface at 
very short distance (0.2-10 nm probe-sample separation) [46, 47]. It allows a spatial 
resolution of up to 0.01 nm for imaging [48].  
Three modes can be used in atomic force microscopy depending mainly on the 
sensitivity of the tip to the respective forces used for imaging, i.e., contact mode 
(repulsive Van der Waals interactions), non-contact mode (attractive Van der Waals 
interactions) and intermittent or tapping mode. In contact mode, the tip touches the 
sample surface, which is good for rough samples. However, it may promote particle 
surface alterations (soft samples deformation or removal of particles from the area under 
investigation). In these cases, tapping mode or non-contact could be use, whereby the 
probe maintains a constant oscillation amplitude or does not contact the sample surface, 
respectively, although the latter mode is also associated with lower resolution [46, 47].   
Apart the ability to magnify in the X, Y and Z axes, AFM allows imaging under 
hydrated conditions without pre-treatment of the samples as no vaccum is needed during 
operation and the samples does not need to be conductive [46, 49, 50]. 
 
2.2.3 Zeta potential   
 
Zeta potential is a physical property which is exhibited by any particle in suspension, 
being related to its surface charge. It is a helpful parameter in predicting colloidal 
systems long-term stability [51]. Specifically, when a particle is in a medium, the liquid 
layer surrounding it exists as two parts: an inner region where the ions are strongly 
bound, the Stern layer, and an outer region where they are less firmly associated, the 
diffuse layer. Within the latter, there is a notional boundary inside wherein the ions and 
particles form a stable entity, so that, when a particle moves, ions within the boundary 
move it. Those ions beyond the boundary stay with the bulk dispersant. Zeta potential is 
considered the potential at this boundary, that is, at the slipping plane (Figure 2.4) [51].  
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Figure 2.4 Schematic representation of the zeta potential. Adapted from reference [51]. 
 
The magnitude of the zeta potential gives an indication of the potential stability of the 
colloidal system, which is determined by the sum of attractive forces (Van der Waals) 
and repulsive forces (electrostatic) which particles experience as they approach one 
another. If the zeta potential is high, the particles are stable due to high electrostatic 
repulsion between particles. Conversely, a low zeta potential value (approaching zero) 
increases the probability of particles colliding, therefore, forming particle aggregates. 
Thus, zeta potential is used as an index of the dispersion stability of particles. A zeta 
value higher than |30| mV is generally taken to consider a suspension as stable [40, 51].  
 
Electrophoretic light scattering 
 
Electrophoretic light scattering (ELS) is a technique used to measure the 
electrophoretic mobility of particles in dispersion, based on the fundamental physical 
principle of electrophoresis. 
The zeta potential, z, is related to the electrophoretic mobility, UE, by the Henry 
equation 
    
       (  )
   
                                                            (2.2) 
where ε is the dielectric constant, η the viscosity, and f(κa)  Henry’s function. In many 
aqueous solutions containing an electrolyte, zeta potential can be calculated from the 
Smoluchowski equation, for which a value of 1.5 for  (  ) is considered [51, 52]. 
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2.2.4 Entrapment efficiency and drug loading 
 
Drug entrapment efficiency and loading capacity are important parameters to 
evaluate the suitability of a carrier system. The former expresses the percentage of drug 
which is entrapped inside the lipid nanoparticles, being most frequently determined 
indirectly, that is, by quantifying the non-incorporated drug in the external aqueous 
phase after separation from the nanoparticles. It can be calculated by 
      
                     
           
                                            (2.3) 
where              stands for the total drug amount determined in the dispersion, 
            is the amount of free drug detected in the external aqueous phase after 
separation of the nanoparticles, and       is the weight of the lipid phase. 
The separation of the nanoparticles can be carried out by ultrafiltration-centrifugation, 
using centrifugal filter units with a specific molecular weight cut-off. According to this 
technique, nanoparticles are retained in the membrane, while the external aqueous 
phase is collected in the outer chamber after a certain optimized time of centrifugation. 
Note that the presence of drug crystals should be inspected by adequate techniques, 
such as polarized light microscopy, otherwise it will be retained together with 
nanoparticles, thus conducting to an increased mislead entrapment efficiency. In the 
latter situation, a suitable solvent should be added to the lipid nanoparticles dispersion.  
The amount of free drug in the aqueous phase, after isolation of the system, can be 
quantified by an adequate method, such as high performance liquid chromatography 
(HPLC).  
On the other hand, the drug loading capacity is calculated in percent of the lipid mass 
[20] by 
     
                     
      
                                               (2.4) 
where       stands for lipid weight. 
For lipophilic drugs, the entrapment efficiencies are typically between 90% and 98%, 
while for hydrophilic compounds, the loading capacity and the entrapment efficiency are 
obviously lower [20]. Several factors affect the loading capacity of drug in the lipid, 
especially the solubility of drug in melted lipid, the chemical and physical structure of 
solid lipid matrix and polymorphic state of lipid material. A high solubility of the drug in 
the lipid melt is a prerequisite, in order to assure a sufficient drug loading [42]. 
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2.2.5 High performance liquid chromatography  
 
High performance liquid chromatography has been established as the premier 
technique for the analysis and purification of a wide range of molecules. The enormous 
success of this technique can be attributed to several features such as the high 
reproducibility, ease of selectivity manipulation and high recoveries. Furthermore, in a 
single step process it can separate a mixture into its individual components and 
simultaneously provide a quantitative estimate of each constituent. Among the 
respective features, the most significant is the excellent resolution that can be achieved 
under a wide range of conditions for very closely related molecules as well as structurally 
distinct molecules, which arise from several interactive modes of chromatography.  
The separation of a mixture of molecules in interactive modes of chromatography 
arises from the differential adsorption of each solute according to their respective affinity 
for the immobilized stationary phase. Thus, molecules with higher affinity to the 
stationary phase will be retained to a greater extent than other molecules with low affinity 
for the stationary phase. The degree and nature of the binding affinity is highly 
dependent on the structure of the solute and the immobilized ligands as well as the type 
of interaction established between the molecule and stationary phase. For instance, in 
case of affinity chromatography, binding involves a mixture of hydrophobic, electrostatic, 
and polar forces whereas in the case of ion-exchange chromatography is through 
electrostatic interactions. In the case of reverse –phase chromatography, separations 
are based primarily on hydrophobic interactions being the polarities of mobile (polar) and 
stationary phases (hydrophobic) reversed and mobile phases employed are mostly 
water-based solutions. Thus, the key factor that supports the development and 
employment of a successful separation protocol is the ability to manipulate the retention 
of the target molecule that it can be resolved from other non-target components [53].  
 
2.2.6 Crystallinity and lipid modification  
 
Special attention must be paid to the characterization of the crystallization behavior 
and the polymorphic lipid transitions occurring throughout the storage time, since these 
parameters are strongly related to drug incorporation and release rates [19]. These 
parameters can be inspected by differential scanning calorimetry (DSC) and attenuated 
total reflectance infrared spectroscopy (ATR-FTIR).  
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Differential scanning calorimetry 
 
Differential scanning calorimetry (DSC) is a thermal analysis technique which allows 
determining, among others, the temperature and enthalpy associated with transitions 
involving heat transfer, as a function of time and temperature. 
In a basic DSC experiment, energy is supplied simultaneously to the sample and to 
the reference cell, and temperatures of both are raised simultaneously over time. The 
difference in the input energy required to match the temperature of the sample to that of 
the reference will be the amount of excess heat absorbed or released by the sample 
material, depending whether the thermal event is endothermic or exothermic, 
respectively. This explains the introduction of the concept of heat excess, since more 
energy is required to bring the sample to the same temperature as the reference  [54].  
There are two types of DSC instruments, according to the mechanism of operation: 
power compensation or heat flux. In a power compensation DSC, the sample and 
reference pans are placed in separate furnaces heated by separate heaters. The sample 
and reference are maintained at the same temperature, and the respective difference in 
power, when a thermal event occurs, is measured and plotted as a function of 
temperature or time, according to 
    
  
  
                                                                    (2.5) 
where 
  
  
 is the heating rate, the   current applied to the heater, and   the resistance 
of the heater [55]. 
In turn, heat flux DSC uses a single furnace which supplies heat to both the sample 
and reference, measuring the differential temperature and the consequent heat flow is 
determined by the thermal equivalent of Ohm’s law 
   
  
 
                                                                      (2.6) 
where   is the sample heat flow,    the temperature difference between sample and 
reference, and R the thermal resistance of the cell [54, 56].  
DSC can be used to investigate the status of the lipid matrix in nanoparticles, 
providing information about the respective crystallization behavior, the occurrence of 
polymorphic transitions, the melting temperature and associated enthalpy [57].  
It should be noted that nearly all lipid excipients exist under various polymorphic 
forms. In particular for glycerides, the main crystalline structures are hexagonal (α), 
orthorhombic (β′) and triclinic (β).These structures differ by their thermal properties 
(transition and melting temperature), depending also on the thermal history of the lipid 
[58]. In addition, the lipid packing density and the thermodynamic stability increase, while 
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drug incorporation rates decrease, in the following order: supercooled melt, α 
modification, β′ modification, β modification [19]. 
Thus, the lipid crystallization after nanoparticles preparation and throughout storage 
is an important point to monitor, since several polymorphic forms will condition different 
capacities of drug incorporation and particle shapes [19]. 
Additionally, DSC can be used to investigate the physical state of drug inside lipid 
nanoparticles matrix, allowing to infer about its localization by the presence or absence 
of melting peak transition.  
 
Attenuated total reflectance infrared spectroscopy  
 
Infrared spectroscopy is a technique that allows obtaining structural information by 
studying the vibration modes of specific molecular groups as a result of the interaction 
between infrared (IR) light and matter. Attenuated total reflectance (ATR) is a fast and 
non-destructive sampling technique for obtaining the IR spectrum of a material surface 
[59].  
In ATR, the sample, usually not requiring preparation, is placed in a special crystal of 
a material with a high refraction index (e.g., ZnSe). The IR beam from the spectrometer 
is directed onto the crystal, wherein successively reflections occur and, subsequently, 
directed to the detector [60]. 
The use of ATR in spectroscopy is based on the fact that although complete internal 
reflection occurs at the sample–crystal interface, radiation only penetrates a few microns 
into the sample, which is designated as the evanescent wave. As such, there must be a 
good contact between the sample and the crystal surface. The interaction between the 
sample and the evanescent wave results in the absorption of radiation, allowing to obtain 
the corresponding spectrum [60].  
ATR-FTIR allows obtaining information about the arrangement of lipid molecules in 
SLN and NLC, so as to complement information arising from DSC. It may also elucidate 
on how the components interact within such a complex matrix, e.g., whether the oil 
component penetrates into the solid lipid in NLC and how oil alters the conformation of 
the solid lipid hydrocarbon chains. [60, 61].  
Additionally, FTIR-ATR permits studying the structure of the stratum corneum at the 
molecular level and, in particular, elucidate the mechanism of action of various 
penetration enhancers on the SC barrier function [62]. 
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2.3 Optimization  
 
Optimization strategies are procedures which attempt to find the optimal settings or 
conditions, e.g., for a certain formulation, product, process, or an analytical method, 
considering a number of factors or independent variables. Factors are parameters than 
can be set at given levels, such as components concentration, homogenization time, 
etc., and that affect the responses or dependent variable, which correspond to the 
outcome of a method or procedure. In turn, the factors are studied at different level 
ranges, constituting the experimental domain within which the overall best conditions are 
tried to find. 
Complex systems usually require a multivariate approach, in which several factors 
are varied simultaneously. In this context, an experimental design, that is, an 
experimental set-up to simultaneously evaluate several factors at given numbers of 
levels in a predefined number of experiments, should be performed [63]. 
 
2.3.1 Factorial design 
 
Factorial design is a system of experimental design intended to elucidate the effects 
of many factors simultaneously, to assess their relative importance, and to determine 
whether the factors interact [64]. 
When optimizing a formulation or process, there are a number of different methods 
for tackling the problem and the resulting data may also be analyzed in a number of 
different ways. In what concerns experimental designs, a rough classification into 
screening designs, response surface designs and mixture designs can be carried out. 
Screening designs, e.g., full factorial, fractional factorial, and Plackett–Burman designs, 
allow screening a relatively large number of factors in a relatively small number of 
experiments. They are used to identify the most influencing factors influencing the 
system, being applied in the context of optimizing processes. Most often, the factors are 
evaluated at two levels in these designs. In turn, response surface designs are applied to 
find the optimal factor settings, while mixture designs are used to optimize, for instance, 
the excipients composition in formulations [63, 65].  
When the number of factors f is small, two-level full factorial designs might be applied 
for screening purposes. Focus will be given to these particular factorial designs, since 
they were often used for experimental planning throughout this work. 
Two-level full factorial designs include all possible combinations between the f factors 
and their L = 2 levels, leading to a number of experiments, N = Lf = 2f, to be performed. 
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These designs allow the simultaneous investigation of qualitative and quantitative factors 
[63, 65]. 
As example, the simplest design, which corresponds to two factors, X1 and X2, 
studied at two levels, 22, will be considered. First of all, the variables coding, that is, the 
process that brings the values of all factors into the same range, should be performed. 
For a two-level experiment, the lower is designated -1 and the upper level -1, thus 
yielding 4 different combinations (Figure 2.5). 
 
 
Figure 2.5 A two-factor, two-level experimental design, using coded values of the 
factors. 
 
The values for the interaction term are obtained by multiplying together the values for 
the individual factors, e.g., for the experiment (-1, -1), the value of the interaction is -1 x 
(-1) = +1. A design matrix is thus constructed. These designs allow the estimation of all 
main (i.e., corresponding to each  factor) and interaction effects  [63, 65]. 
Main effects represent the average result of changing one factor from -1 to +1, and 
the interaction terms affect the result when two or more factors are simultaneously 
changed. If none of the factors produced an  effect, then the responses would be 
scattered randomly around their mean value, given by the independent term [64].  
For the evaluation of the mean effects and interactions resulting from a factorially 
designed experiment, a multiple linear regression analysis can be applied. The coded 
factors are now represented by x1 and x2, and the response by y. Therefore, an equation 
which takes into account all the main effects and interactions is   
                                                                (2.7) 
where   is the response,    the intercept, and    and    the main regression 
coefficients, usually calculated using least squares regression,  
  (   )                                                  (2.8) 
wherein    is the transposed matrix of   [63], the latter built according to equation 
(2.7), with unit values in the first column, the level values imposed in the experiments for 
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the factors in the next two, and the respective product in the fourth column, now related 
with the interaction. This matrix is built according to a corresponding procedure for other 
models. 
The estimated coefficients are statistically assessed, to determine their significance, 
often by applying the t-test statistics. A t value for the factors is calculated and compared 
with a (tabulated) critical t value, tcritical, for a certain significance level (usually α = 
0.05). All effects with a t value larger than or equal to tcritical are regarded as significant 
[66]. 
Additionally, an ANOVA approach is frequently used to assess the model [64]. 
 
2.4 Hydrogel-based formulation  
 
Lipid nanoparticles dispersions can be incorporated into semisolid preparations such 
as hydrogels, in order to provide the appropriate consistency for administration [67, 68]. 
Generally, hydrophilic semi-solid gels present several advantages, such as low toxicity, 
unique physical properties, availability, biocompatibility and adhesiveness [40]. These 
can be prepared by using natural (e.g., chitosan, dextran) semi-synthetic (e.g., cellulose 
derivatives) or synthetic polymers (e.g., carbopols) [68]. 
The influence of the formulation components upon consistency should be critically 
monitored, since they will impact upon the drug release profile and, consequently, the 
therapeutic outcome. 
In this context, rheology measurements and texture analysis are valuable tools for 
semi-solid product quality control. 
 
2.4.1 Rheology 
 
Rheology is formally defined as the study of deformation and flow behavior of various 
materials [69]. Thus, rheological techniques assess the molecular interactions, but may 
also to describe the dynamic properties, in particular the viscosity.  
Multiphase systems, such as lipid nanoparticles dispersions may be considered 
viscoelastic systems, i.e. they exhibit a combination of viscous and elastic properties, 
being solid at short time deformation and liquids at long times of deformation [40]. 
To understand viscoelasticity, it is helpful to consider first the cases of perfect 
elasticity or viscosity, referring to relationships of Hooke law for solids and Newton-
Stokes law for liquids, respectively. For an elastic solid, Hooke’s law states that the 
applied shear stress ( ) is proportional to the produced shear strain ( )  
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                                                                     (2.9) 
where shear stress ( ) is the shear force per unit area and the strain ( )  the 
deformation. The proportionality constant (G) is called the Young modulus and is an 
intrinsic property of an elastic solid.  
On the other hand, Newton-Stokes law of viscosity for liquids states that the shear 
stress ( ), that is, the force per unit area required to produce the motion is proportional to 
the velocity gradient or shear rate ( ̇)  
      ̇                                                          (2.10) 
The proportionality constant ( ) is defined as the viscosity of the material. 
Thus, the rheological measurements convey the information of how “fluid-like” or how 
“solid-like” a material is as a function of shear rate or frequency of deformation. Two 
different methods are available to determine viscoelastic properties: rotational and 
oscillatory tests. 
In rotational tests, the material is forced to flow by applying a controlled stress, and 
the resulting deformation is measured along the time (shear rate) or as a function of 
temperature. The rotational speed depends on the viscosity of the sample, which is 
calculated in these tests by dividing the stress by the shear rate. It is usually termed as 
shear viscosity [70]. 
In oscillatory tests, information about the structure and elasticity of the samples is 
obtained. These tests are supposedly not destructive, since the material does not move. 
Instead, a constant sinusoidal varying stress (at one or more frequencies) is applied to 
the sample and the equally varying strain is measured. The deformation of the sample 
depends on both frequency and stress applied, as such, and will increase with 
decreasing frequency, when measuring at a constant stress, and it will increase with 
stress, when frequency is kept constant. The complex viscosity, storage and loss 
complex moduli are the main parameters extracted, which can be measured as a 
function of frequency, time or temperature [70, 71].  
Complex viscosity,   , is a mathematical representation of the viscosity in oscillatory 
tests and can be expressed as 
    
√          
 
                                                       (2.11) 
where    is the storage modulus, a measure of the energy stored and recovered per 
cycle of sinusoidal deformation,     is the loss modulus, a measure of the energy 
dissipated or lost per cycle, and   the angular frequency of deformation [70, 72]. 
Since oscillatory measurements are conducted with the aim at studying the structure 
of a material, the deformation has to be kept small. Additionally, the measurements must 
be performed in the linear viscoelastic regime, otherwise, the results of the frequency 
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sweep experiments will depend not only on the frequency but also on the applied stress 
or deformation. As such, a linearity test, the oscillation stress sweep, is carried out to 
obtain the values of shear stress for which the viscoelastic functions are independent 
from the magnitude of the applied stress [73]. Since such regions are usually observed 
at very low stresses, no important changes in the structure of the material will occur [71].  
. 
2.4.2 Texture analysis 
 
The use of texture profile analysis (TPA) is relevant for the mechanical 
characterization of a pharmaceutical semisolid formulation, in order to determine 
interactions between formulation components, so as to complement the rheological 
information.  
TPA is a technique that resorts to a texturometer, whereby a solid cylindrical probe 
executes two passes into the product with a predefined pause, allowing to obtain a 
typical force-time curve from which the textural properties of the product may be 
calculated. These include [74, 75] (Figure 2.6): 
- hardness, given by the maximum peak force during the first compression 
cycle; 
- compressibility, i.e., the work required to deform the sample during the first 
compression of the probe and calculated from area under the force–time curve 1 
(AUC1); 
- adhesiveness, the work required to overcome the attractive forces between 
the surface of the sample and the surface of the probe and is indicated as the negative 
force area for the first compression cycle and calculated from AUC2; 
- cohesiveness, the ratio of the area under the force–time curve produced on 
the second compression cycle to that on the first compression cycle, where both 
compressions are separated by a defined recovery period; 
- elasticity, the ratio of the time required to achieve maximum structural 
deformation on the second compression cycle to that on the first compression cycle. 
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Figure 2.6 Graphical output from Texture Profile Analysis. Key: H=hardness; AUC1= 
compressibility; AUC2=adhesiveness. In addition, AUC3 / AUC1 corresponds to the 
cohesiveness and the elasticity is given by time diff 3:4/time diff 1:2. [74] 
 
In the development of pharmaceutical semisolid preparations for transdermal 
application, several desirable product characteristics may be defined. These include 
optimal mechanical properties (such as spreadability), bioadhesion (prolonged contact 
time at administration site) and an acceptable viscosity [76].  
 
2.5 Percutaneous absorption 
 
In vitro permeation studies constitute a key assay in the assessment of product 
therapeutic performance. In vitro investigations are advantageous, since the 
experimental conditions can be controlled precisely, such that the only variables are the 
skin and the test formulation.  Most common methods designed for evaluation of 
percutaneous absorption use diffusion cells, such as static (i.e. no flow) vertical Franz 
cells, which is a simple, reliable, and reproducible system of measuring drug release 
from dosage form and skin permeation.  
 
2.5.1 Franz diffusion cells 
 
Static Franz diffusion cells consist of two chambers, a donor and a receptor chamber, 
separated by an artificial or biological membrane and held together by a clamp (Figure 
2.7). Formulations are applied in the donor compartment, while the receptor 
compartment contains a receptor fluid kept at a temperature regulated by 
thermostatically controlled water circulating through a jacket surrounding the chamber, in 
order to maintain the skin surface at 32ºC. Homogenous temperature distribution in the 
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receptor solution is maintained by a magnetic stirring bar. Drug absorption is measured 
by periodically sampling the receptor fluid through a lateral arm.   
 
 
Figure 2.7 Schematic representation of a static vertical Franz diffusion cell. 
 
The conditions under which skin absorption in vitro tests are performed are suitably 
documented in specific guidelines [77-79]. The test system includes a wide range of 
parameters, including species, membrane type, receptor fluid, integrity testing, test 
vehicle, dose applied, time points and experimental duration.  
The choice of skin depends on the purpose of the test and the availability of skin 
samples. Although excised human skin is regarded as the ‘‘gold standard” for in vitro 
penetration experiments, animal skin, such as that of pig or rat, has been widely used as 
a substitute for human skin. In particular, pig skin could be used because of its similarity 
to human skin in terms of its morphology and permeability characteristics, making it a 
practical alternative [78].  
Different methods can be used to prepare skin for in vitro experimentation, and 
usually three types of membranes can be employed in the Franz diffusion cell: full-
thickness skin (incorporating the SC, viable epidermis, and dermis), dermatomed skin (in 
which the lower dermis has been removed), and epidermal membranes, comprising the 
viable epidermis and the SC, extracted by heat separation [80]. To prepare heat-
separated epidermal membranes, full-thickness skin is immersed in water at 60ºC for 60 
seconds. Following removal from the water, the epidermis is gently detached using a pair 
of blunt curved forceps [81]. 
The choice of membrane is mainly dependent on the nature of the permeant. 
Although in vivo the presence of blood flow will remove a considerable amount of the 
permeant reaching the dermis, in vitro, in the absence of blood flow, the relatively 
aqueous nature of the dermis, will represent an “artificial” barrier, thus reducing the 
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penetration of lipophilic compounds. Hence, the use of dermatomed or epidermal 
membranes is more appropriate for particularly lipophilic permeants [80].  
Once obtained, the skin can be stored at -20 °C, providing the samples are not overly 
hydrated [82]. However, the membrane barrier integrity should be evaluated after 
storage. Although simple visual examination of specimens could give a qualitative 
indication of skin integrity, methods for a quantitative evaluation of its state should be 
employed, such as the measurement of skin conductance, transepidermal water loss, or 
the flux of a marker compound such as tritiated water. The skin samples found to be 
outside the “normal” range of values for such measurements must be discarded [80].  
In what concerns the receptor medium, it must have adequate solubility for the 
compound under study, so that sink conditions can be ensured throughout the length of 
the study (the receptor media should not exceed 10% of the saturation solubility) [79]. 
This will allow the rate of absorption to proceed as it would normally under in vivo 
conditions, assuming a continuous removal by the circulatory system. In the case of 
water-soluble compounds, isotonic saline or buffered isotonic saline (pH 7.4) are 
considered the rational choice for the maintenance of a physiological environment. For 
lipophilic compounds, serum albumin or appropriate solubilisers can be added in 
amounts which do not interfere with membrane integrity [77, 83]. 
The exposure time should reflect in-use conditions. Permeation experiments are 
normally conducted for 24 or 48 h, although for long-term transdermal delivery systems, 
it could be prolonged up to 72 h or longer. In relation to the frequency of sampling, it will 
depend on the rate/extent of percutaneous absorption. It should be chosen adequately to 
allow estimating the steady-state and lag-time, that is, the time needed to attain steady-
state. [80] 
Regarding the test material, a suitable application procedure should be followed. 
There are two basic approaches to applying substances to the skin: finite and infinite 
methods. Finite dose techniques are designed to reproduce in-use conditions, involving 
the application of a dose that may show marked depletion during an experiment. 
Depletion occurs when the proportion of permeant entering the membrane is large, 
relative to the amount applied. With finite dosing, the permeation profile may exhibit the 
characteristic plateauing effect that accompanies donor depletion (Figure 2.8) [81]. 
On the other hand, infinite-dose techniques involve application of sufficient permeant 
to make negligible any changes (caused by diffusion or evaporation) in donor 
concentration, during the experimental period. This is desirable when the experimental 
objectives include calculation of diffusional parameters or for investigation of 
mechanisms of penetration enhancement [81]. 
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Figure 2.8 Typical permeation profiles obtained from experiments conducted under 
infinite and finite dose regimes. Note that under infinite dose, permeation usually 
reaches a steady-state flux region, whereas under finite dosing the permeation profile 
exhibits a plateau region instead, as a result of donor depletion. Adapted from [81].  
 
In the case of infinite-dose studies, the objective will be to obtain constants that can 
define the kinetics of permeation, such as the permeability coefficient, Kp, and the lag 
time, tlag. According to the profile depicted in Figure 2.7, after an initial lag period, the 
cumulative amount of drug in the receptor fluid will increase linearly with time, that is, the 
flux across the skin will reach a steady state. The value of tlag can be determined from 
extrapolation of the linear portion of the plot to the x-axis [84], while Kp can be extracted 
indirectly from the slope,    , of the terminal portion of the plot of cumulative amount 
penetrated versus time, through the following equation 
                                                             (2.12)  
where    is the drug concentration in the donor compartment. This Equation is 
readily obtained from Equation (1.1).   
 
2.6 Molecular dynamics simulation 
 
Molecular dynamics (MD) simulations provide, in this work, a route to studying the 
dynamics of lipid bilayers at the atomistic or near atomistic resolution, with the aim of 
understanding and predicting the respective macroscopic properties. These can be 
divided in (i) static equilibrium properties, such as the radial distribution function in a 
liquid, and (ii) dynamic or non-equilibrium properties, such as the diffusion process in a 
membrane [85]. 
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MD essentially calculates forces acting on the particles of a single input system, by 
solving classical Newton’s equations of motion,  
   
     
   
                                                             (2.13) 
with N interacting atoms, to update their positions (r) and velocities. These forces are 
calculated on the basis of a force field, which provides the functional form and the 
parameters needed for the calculation of the different potential energy terms. 
MD simulations may, therefore, be used to provide insight into the interplay between 
penetration chemical enhancers and a model lipid membrane, such as 
dipalmitoylphosphatidylcholine (DPPC), at a level not attainable by experiment [86].  
MD trajectories of bilayer systems are generally discussed in terms of standard 
analyses, such as area per lipid (AL), deuterium order parameter (Scd), probability 
density profile, radial distribution function (rdf) and mean square displacement (msd). 
Information on the area per lipid and deuterium order parameter are frequently used 
as a starting point to validate the used model. The AL gives an idea of the lateral 
separation between the lipid heads, while Scd allow to characterize the degree of order 
along the lipid acyl chains. In this case, the order parameter for each CH2 is proportional 
to the respective conformational freedom. Additionally, probability density profiles for 
different key-atom groups return a very complete description of the bilayer structure, 
elucidating on the vertical positioning of characteristic atom groups relative to the inter-
leaflet region. Radial distribution function is a more general analysis that describes the 
probability of finding a pair of atoms at a distance r apart, relative to the probability 
expected for a completely random distribution at the same density. Interacting systems 
are characterized by peaks and valleys describing regions of high and low density, 
respectively. Among several other applications, this parameter was convenient to assess 
the ability of water to penetrate bilayer surface. Lastly, mean square displacement is also 
used to calculate the lateral diffusion of lipid components, as well as the diffusion 
behavior of other molecules inserted in the bilayer [87]. 
Once achieved equilibration conditions for the system, many of these parameters are 
expected to be stable with time, which means that average values can be extracted and 
used as a rationale for the molecular dynamics. Relevant information on the structuring 
or disordering effect promoted by each solute can thus be obtained combining 
information from the different analyses [87]. 
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2.7 Stability  
 
Assessing the physical stability of aqueous lipid nanodispersions involves, among 
other aspects, the monitoring of the presence of particle aggregation, that may lead to 
creaming and sedimentation phenomena, as a function of temperature and storage time.  
Additionally, lipid modifications might also change the structure of the system, 
influencing the load and/or release capability, the interfacial properties, and the in vivo 
performance. Thus, the consequences on size control and nanoparticle growth are 
important for preparing dispersions, and particular attention has to be focused on their 
evolution. The predictability in administration will also depend on the homogeneity of the 
product. If precipitation occurs during storage, the quantity of drug delivered for each 
administration is unknown [57].  
 
Analytical centrifugation 
 
Analytical centrifugation is a technique used to monitor dispersion modifications, that 
combine the centrifuge force with a NIR detector. Light is passed through the sample 
cells under centrifugation and the distribution of local transmission is recorded at preset 
time intervals over the entire sample length. By measuring the intensity of the transmitted 
NIR light, data are displayed as function of the radial position and as distance from the 
centre of rotation. The shape and progression of the transmission profiles contain the 
information on the kinetics of the separation process, as well as evaluation of particle–
particle interactions [88]. 
The separation behavior of the individual samples can be compared and analysed in 
detail by tracing the variation in transmission at any position within the sample [89]. 
This technique is helpful in screening formulations, since by submitting samples to 
stress conditions, it can help predict the respective phase behavior.   
Additionally, particle size, zeta potential, and entrapment efficiency measurements 
should also be monitored as a function of time and storage temperature, so as to 
complement stability information.  
 
2.8 Cytotoxicity 
 
Skin irritation refers to a reversible inflammatory reaction produced by the 
arachidonic acid cascade and cytokines in the viable keratinocytes and fibroblasts of the 
skin, following the application of a test chemical [90, 91]. The assessment of skin 
irritation has typically involved the use of laboratory animals, particularly  rabbits via the 
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Draize test method [92]. However, due to increasing concern over animal 
experimentation, validated in vitro or ex vivo alternative test methods are now being 
developed, thus avoiding the pain and suffering of animals [93]. 
Cell culture has been applied as an in vitro technique for the assessment of skin 
irritancy [94]. Skin cultures are useful, because they allow the design of safer, more 
efficient and cost effective human skin irritation tests. However, despite the advantages 
of in vitro models, it should be noted that cell culture lacks some of the properties of 
intact skin, such as the selective barrier role or the interaction between different cell 
types. In any case, and although the irritation potential may be overestimated, these 
tests may function as a helpful prescreening tool [90, 95, 96]. 
In spite of the fact that lipid systems, as the ones probed in this work, are usually 
characterized by a low toxicity, due to their composition based on physiological lipids, 
especially when compared to other nanoparticulate systems (e.g., polymeric particles), 
assessment of the potential of skin irritation arising from the surfactants/stabilizers used 
or drugs incorporated should be performed [25]. 
In the present work, skin irritation of the optimized formulation was assessed using 
two cell lines: a spontaneously immortalized human keratinocyte cell line, HaCaT, and 
human adult dermal fibroblasts cells, Df, aiming at describing the effect upon human 
epidermis and dermis. 
 
2.9 Pharmacokinetics  
 
After in vitro studies, in vivo skin permeation data constitute a step further in terms of 
transdermal system development. A typical pharmacokinetic (PK) profile obtained with a 
transdermal system (single dose) includes three phases: the time to reach the steady-
state plasma concentration (period of onset), the steady-state plateau, and a declining 
phase post system removal. The plasma concentration vs. time profiles allow to extract 
PK parameters, such as AUC0–t (area under the time concentration curve from time 0 to 
time t, referring to systemic exposure to drug), AUC0–ф (area under the time 
concentration curve from time 0 to infinity), Cmax (maximal plasma drug concentration), 
tmax (time to maximal plasma drug concentration), and Css (plasma concentration at 
steady state) [97]. Cmax and AUC are useful to characterize the rate and extent of drug 
delivery (Figure 2.9).  
Chapter 2 – Methods and techniques  
 
 62 
 
Figure 2.9 Idealized PK profile. Adapted from [98]. 
 
Since the TDDS is overloaded with drug in order to maintain a steady-state drug flux 
over the application time (the Fickian diffusion being the driving force), a large part of the 
drug TDDS content remains in the TDDS at removal. Therefore, absolute bioavailability 
is not quite relevant to characterize the TDDS performance. However, it can give an 
insight of the percentage of the drug that is effectively delivered. The steady-state 
concentration, Css, however, is the most relevant PK parameters, because it can give 
access to the permeation rate provided by the TDDS (and, therefore, allows a 
comparison with in vitro studies). Indeed, since Css is reached when the steady-state 
skin absorption rate, Ra, equals the steady-state elimination rate, Re, the steady-state 
flux through skin,      , can be calculated using the following equation: 
                                                                      (2.14) 
where   is the area of TDDS in contact with the skin,     the steady-state plasma 
concentration (which should correspond to the blood level target for therapeutic 
efficiency) and    the systemic clearance, since Ra =         and Re =        , and Ra 
= Re. 
The conditions of application of this equation are that either PK of the drug is linear, 
or, if such a linearity is unknown, Cl has been determined from concentration ranges 
close to the Css concentration obtained with the TDDS.  
For the in vivo experiments, the rat is a commonly used species [78]. Thus, a 
comprehensive PK study of in vitro/in vivo relations for animal skin was carried out using 
rat tissue for the assessment of the feasibility of the developed TDDS (Chapter 4). 
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Chapter 3 
 
Optimization of solid lipid nanoparticles 
by solvent emulsification-evaporation 
 
 
 
3.1 Introduction  
 
Solid lipid nanoparticles are systems of remarkable technological relevance from a 
pharmaceutical perspective. The production of SLN can be carried out using different 
methods, including high shear homogenization, ultrasound, high pressure 
homogenization, or via microemulsion and solvent emulsification-evaporation 
techniques, as discussed in Chapter 2. Some of these can be combined in order to 
obtain stable particles, with suitable properties, such as particle size and size distribution 
[1, 2]. Since skin hydration and the occlusion effect depend on the small size of lipid 
nanoparticles, these characteristics are crucial in SLN production, and result from both 
the preparation method and, to a larger extent, the particle composition [3].  
In the work presented in this chapter [4], SLN production was studied using a 
modified solvent emulsification-evaporation method, in which high shear homogenization 
and ultrasound were also employed. The aim was to systematically assess how different 
parameters, such as lipid type and concentration, amount of solvent, emulsifier type and 
concentration, influence the size of solid lipid nanoparticles. This has been addressed 
using a factorial analysis, which allows not only to extract the maximum amount of 
information from the collected data, resorting to a limited number of experiments, but 
also to establish the influence of multiple factors on the formulation properties. The direct 
effect of each factor was studied, and the respective interaction with other factors was 
also assessed in detail. Designs in different factor domains were additionally carried out, 
in order to describe the system behavior under different compositions. A detailed 
physicochemical characterization of the systems and a rationale for the observations are 
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also provided. It should be noted that the usefulness of experimental design in the 
formulation of lipid nanoparticles (see e.g., ref. [5]) is being increasingly acknowledged.  
SLN loaded with simvastatin, as a model of a poorly water-soluble drug, were firstly 
prepared. Its influence on particle size, zeta potential and entrapment efficiency in the 
previously optimized formulation was also assessed.  
 
3.2  Materials and methods 
 
3.2.1 Materials 
 
Glyceryl tripalmitate (tripalmitin, T8127, melting point 66ºC) was purchased from 
Sigma, Compritol® 888 ATO (glyceryl behenate, melting point: 71–74 ◦C), and Precirol® 
ATO 5 (glyceryl palmitostearate, melting point: 53–56 ◦C) were kindly provided by 
Gattefossé (Saint-Priest, France). Polyvinyl alcohol 87-89% hydrolyzed (PVA, typical 
MW 13.000-23.000) and polysorbate 80 (Tween® 80) were purchased from Sigma-
Aldrich. Simvastatin was kindly provided by Labesfal - Laboratórios Almiro, S.A. 
(Santiago de Besteiros, Portugal). All other chemicals were of analytical grade or 
equivalent.  Water was purified (Millipore®) and filtered through a 0.22 μm nylon filter 
before use. 
 
3.2.2 Preparation of SLN 
 
The SLN were prepared using a modification of the widely used emulsification-
solvent evaporation method described elsewhere [2]. Briefly, the lipid was dissolved in 
dichloromethane (DCM) and then added dropwise to 30 mL of emulsifier solution in a 
high shear homogenizer (L5M-A, Silverson, UK) at 12 300 rpm for 7 min. In the final, 
optimized, method of preparation, the inner lipid phase was added dropwise to the 
external phase under ultra-sonication (40W, 5 min; Branson, Sonifier 250). The pre-
dispersion obtained was then high-shear homogenized (12 300 rpm, 7 min). The 
dispersion obtained in both cases was then magnetically stirred at 200 rpm for 4 h, in 
order to allow the solvent evaporation. In the drug loaded SLN, the lipid and simvastatin 
were dissolved in DCM, and subjected to the conditions described above.  
 
3.2.3 Dynamic light scattering 
 
Particle size was determined by dynamic light scattering, which yields the mean 
particle size (Z-average), and the polydispersity index, which measures the width of the 
size distribution. DLS was performed with Zetasizer Nano S (Malvern Instruments, 
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Malvern, UK) at a detection angle of 173º, at 25ºC. Samples were suitably diluted in 
ultrapurified water. Each value was measured in triplicate. The results are shown as 
mean ± standard deviation. 
 
3.2.4 Zeta potential 
 
ZP was determined using a Zetasizer 2000 (Malvern Instruments, Malvern, UK) at 
25ºC. For the measurements, samples were diluted appropriately with ultrapurified water 
(pH≈5.5). 
 
3.2.5 Factorial design  
 
An experimental design with a two-level, three-variable, 2k full factorial planning was 
performed for the optimization of the particles composition. The experimental design and 
the polynomial models were solved resorting to the GNU Octave software  [6], with 
specific programs developed by the authors. The mathematical model 
                                                          (3.1) 
was applied in two different situations, to describe the principal effects and 
interactions among the identified variables. Coded (-1, +1) levels were used for each 
independent variable, x1, x2, and x3, in which the -1 level corresponds to the lower value 
of each variable and +1 to the upper one. The choice of these limits was based on 
acceptable domains for each variable, considering a therapeutic application, and the 
optimization procedure was carried out within these domains. In Equation (3.1), β0 is the 
arithmetic mean response, β1–β3 are the coefficients of the respective independent 
variables and β12, β23 and β13 their respective interaction terms, and D, the mean particle 
size, is the dependent variable or response. ANOVA and Student’s t-test were applied to 
test the fitted models. Statistical analysis was considered significant if the p values were 
less than 0.05. 
 
3.2.6 Laser diffractometry  
 
Laser diffractometry (LD) was additionally performed in order to detect the presence 
of microparticles, using a laser diffraction particle size analyzer (Beckman Coulter® LS 
13 320, Miami, Florida) with polarization intensity differential scattering (PIDS). The real 
refractive index and the imaginary refractive index were set to 1.54 and 0.1, respectively. 
The LD data were expressed using volume distributions, and given as diameter values 
corresponding to percentiles of 10%, 50%, and 90%. The span value is a statistical 
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parameter useful to characterize the particle size distribution, and was calculated using 
[7] 
      
         
    
                                       (3.2) 
A high value of span indicates a wide size distribution and a high polydispersity. 
 
3.2.7 Determination of residual PVA 
 
The amount of residual PVA associated with the SLN surface was determined using 
a colorimetric method based on the formation of a colored complex between adjacent 
hydroxyl groups of PVA and an iodine molecule [8]. For this determination, only a few 
formulations were selected. Briefly, a 250 μL volume of the nanosuspensions was 
ultrafiltered-centrifuged for 30 minutes through Amicon® Ultra-4 centrifugal filter units 
(100KDa MWCO, Millipore, Ireland) and 50 μL of the particles collected in the inner 
chamber were treated with 2 mL of 0.5 M NaOH for 15 min at 60 ºC. Each sample was 
neutralized with 900 μL of 1 N HCl and the volume was adjusted to 5 mL with distilled 
water. To each sample, 3 mL of a 0.65 M solution of boric acid, and 0.5 mL of a solution 
of I2/KI (0.05 M/ 0.15 M) were added. The final volume was adjusted to 10 mL with 
distilled water. Finally, the absorbance was measured at 690 nm after 15 min incubation 
at room temperature. A standard curve for PVA was prepared under identical conditions. 
 
3.2.8 Differential scanning calorimetry 
 
The crystal structure was inferred from the thermal behavior of the tripalmitin SLN 
using DSC equipment (Pyris 1 DSC, Perkin-Elmer, Massachusetts, USA). Lyophilized 
SLN (1.5-2.5 mg) were placed in aluminium pans and hermetically sealed. Empty pans 
were used as reference. The individual components of SLN were also analysed as raw 
materials. Each sample was heated from 10ºC to 80ºC, at 10ºC/min, and then cooled 
down to 10ºC at the same rate. A physical mixture of the components was also analysed 
as a control.  
 
3.2.9 Attenuated total reflectance infrared spectroscopy  
 
In order to obtain information about the structure of the particles, ATR infrared 
spectra of the particles were recorded using an FT-IR/FT-NIR spectrometer (Spectrum 
400, Perkin-Elmer, Massachusetts, USA) with an ATR accessory fitted with a Zn-Se 
crystal plate. Lyophilized samples were placed in the ATR device without previous 
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treatment, and measured using 4 scans for each spectrum, with a resolution of 1 cm-1 
and a scan speed of 0.5. Spectra were collected between 4000 and 650 cm-1.  
 
3.2.10 Atomic force microscopy 
 
A NanoWizard II equipment (JPK Instruments, Germany) mounted on the top of an 
Axiovert 200 inverted microscope (Carl Zeiss, Germany) was used for imaging and 
atomic force spectroscopy experiments. The AFM head is equipped with a 15 μm z-
range linearized piezoelectric scanner and an infrared laser. The SLN optimized 
formulation was diluted in ultrapurified water (1:100) and deposited on a poly-L-lysine 
treated glass slide. After approximately 20 min, the preparation was washed with 
ultrapurified water and air-dried. 
SLN imaging was performed in air by tapping mode. Oxidized sharpened silicon tips 
with a tip radius of 6 nm, resonant frequency of about 60 kHz and a spring constant of 3 
N/m were used for imaging. Imaging parameters were adjusted to minimize the force 
applied on the scanning of the nanoparticles topography. This low force is particularly 
useful to study soft or easily deformable samples. Imaging data were analyzed with the 
JPK image processing v.3 (JPK Instruments, Germany). 
 
3.2.11 Scanning electronic microscopy  
 
The SEM analysis was also performed in order to investigate the morphological 
characteristics of the particles. Prior to analysis, the sample was diluted with ultrapurified 
water, placed on a double-side carbon tape mounted onto an alumium stud, and dried in 
a desiccator. The sample was then sputter coated with gold in order to make it 
conducting. SEM images were recorded on a Jeol, JSM 5310, (Tokyo, Japan) scanning 
electron microscope, with an acceleration voltage of 25kV. 
 
3.2.12 Fluorescence microscopy 
 
The Nile red (NR) staining assay was used to confirm the SLN particle size. A stock 
solution of NR 0.5 mg/mL in acetone was previously prepared. Subsequently, a working 
solution was obtained by adding 0.05 mL of stock solution to 50 mL of a 75:25 glycerol-
water mixture. A drop of the working solution was added to the particles. The SLN were 
observed using an Olympus BX51 M microscope, equipped with a UplanFL N 100×/1.30 
oil-immersion objective lens (∞/0.17/FN26.5) and a filter set type MNIBA3 (470-495 nm 
excitation and 505 nm dichromatic mirror). Images were scanned to a computer through 
a video camera (Olympus digital camera DP70) and analyzed with an image processor 
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(Olympus DP Controller 2.1.1.176, Olympus DP Manager 2.1.1.158). All observations 
were carried out at 25 ºC. 
 
3.2.13 Stability studies 
 
The optimized SLN formulation (see below) was studied for stability at 4ºC and 25ºC. 
PCS particle size and zeta potential values were monitored for a period of 6 months. The 
stability of the formulation was also assessed using the LUMiFuge (L.U.M.GmbH, 
Germany) stability analyzer, which measures the intensity of transmitted near infrared 
(NIR) light over the full length of the sample, as a function of time. All data are stored and 
displayed in real time as a function of radial position, thus enabling analysis at the 
micron level, signaling changes in the dispersion characteristics. The separation 
behavior of individual samples can be compared and measured in detail by detecting 
changes in light transmission at any part of the sample, or by following the movement of 
any phase boundary [9]. The formulation stability was analyzed after 126 minutes of 
centrifugation, at an acceleration of 2600 x g and 20ºC. 
 
3.2.14 Entrapment efficiency and drug loading  
 
The simvastatin entrapment efficiency was determined indirectly by measuring the 
concentration of the free drug in the aqueous phase of the nanoparticle dispersion. The 
ultrafiltration-centrifugation method was carried out through centrifugal filters (Amicon® 
Ultra-4, Millipore, Germany) with a 100 kDa molecular weight cut-off. Briefly, 1 mL of 
SLN loaded with simvastatin plus 1 mL of methanol were placed into the upper chamber 
of the centrifuge filter, which was centrifuged at 4,000 x g for 90 min at 4ºC. Methanol 
was added in order to dissolve crystals possibly present in the external phase of the SLN 
dispersion. The amount of free drug in the aqueous dispersion phase, collected in the 
outer chamber of the centrifugal filter after separation, was determined by high 
performance liquid chromatography (HPLC) as described below. The entrapment 
efficiency (EE) and drug loading (DL) of SV nanoparticles were calculated according to 
Equations (2.3) and (2.4), wherein            ’ refers to the amount of SV initially used 
for the assay. 
 
3.2.15 HPLC determination of simvastatin 
 
The HPLC analysis was carried out by a Shimadzu LC-2010CHT apparatus 
equipped with a quaternary pump, an autosampler unit, and a L2450 UV/Visible dual 
wavelength detector. A RP18 (4.6mm×125mm) Lichrospher® 100 analytical column 
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(Merck KGaA, Germany) was used for the analysis. The mobile phase consisted of a 
90:10 (v/v) mixture of methanol/water pumped and a constant flow rate of 0.8 mL/min 
was used for 5 min. The detection was carried out at 238 nm. An injection volume of 10 
μL was used for all standards and samples.  For these conditions, simvastatin is eluted 
at a retention time of 3.1 min. 
 
3.3  Results and discussion 
 
Before the experimental design was constructed, preliminary formulation studies 
included the selection of the appropriate lipid phase and emulsifier type, and are 
described in what follows. 
 
3.2.16 Preliminary factor screening  
 
The effect in particle size of three different lipids was studied using Precirol®, 
tripalmitin and Compritol® (Table 3.1). Tripalmitin was chosen due to the smaller particle 
size and narrow size distribution of the resulting SLN. 
 
Table 3.1 Mean particle size (Z-average) of formulations containing Precirol®, 
Compritol®, and tripalmitin. Values are indicated for 5 mL DCM/250 mg lipid (ratio 1:50) 
and 1 mL DCM/100 mg lipid (ratio 1:100) preparations. A concentration of 1.25% (w/V) of 
the emulsifier was used. 
Formulation 
Z-av. 
(nm) 
PI Formulation 
   Z-av.      
(nm) 
PI Formulation 
Z-av. 
(nm) 
PI 
Precirol
®
 
1:100 
Tween
®
80 
754.1 0.746 
Compritol
®
      
1:100 
Tween
®
80 
 
1402.0 
 
0.325 
Tripalmitin     
1:100 
Tween
®
80 
1642.0 0.878 
Precirol
®
 
1:100 
PVA 
 
1253.0 
 
0.523 
Compritol
®
      
1:100 
PVA 
 
838.0 
 
0.516 
Tripalmitin     
1:100 
PVA 
602.7 0.595 
Precirol
®
    
5:250 
Tween
®
80 
 
403.5 
 
0.820 
Compritol
®
      
5:250 
Tween
®
80 
 
1321.0 
 
0.635 
Tripalmitin     
5:250 
Tween
®
80 
542.5 1.000 
Precirol
®
   
5:250 
PVA 
908.9 0.483 
Compritol
®
      
5:250 
PVA 
 
728.8 
 
0.402 
Tripalmitin     
5:250 
PVA 
253.0 0.314 
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The choice of the emulsifier is of utmost importance in the optimization of any 
nanoparticles formulation. This component contributes not only to control the particle 
size and stability of the dispersions, but also to control the crystallization behaviour, 
including polymorphs [2, 10]. The effect upon particle size of two different emulsifiers, 
polysorbate 80 (Tween® 80) and polyvinyl alcohol (PVA) was studied, indicating that 
PVA generally leads to smaller particles with narrower particle size distributions (Figure 
3.1), which has prompted experiments to be carried out within a broader emulsifier 
concentration range.   
 
 
Figure 3.1 Mean size of particles and polydispersity indexes (PI) in formulations 
containing Tween® 80 (A and C) and PVA (B and D), as a function of emulsifier 
concentration. Values are indicated for 5 ml DCM/250 mg lipid (ratio 1:50) and 1 ml 
DCM/100 mg lipid (ratio 1:100) preparations. 
 
3.2.17 Factorial design 
 
The preliminary results clearly indicated that this system is highly influenced by the 
lipid type, emulsifier type and concentration. It should be noted that these are widely 
recognized as major factors influencing the size of SLN [1]. In this design, the lipid and 
emulsifier types were imposed (tripalmitin and PVA), as a consequence of the 
preliminary results, constituting the lipid concentration the first design variable. The 
solvent:lipid ratio represented the second variable, and the emulsifier concentration the 
third one.  
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The choice of variables is a task of paramount importance, because it conditions both 
results and interpretation. The choice must be based on the particular characteristics of 
the system. The current option was to use one composition variable, the lipid 
concentration, that establishes a relationship between the inner phase and the system 
as a whole and, implicitly, between the inner and external phases. The emulsifier 
concentration also uses the whole system as reference, and the respective choice was 
based on the fact that the emulsifier is an interface component, which can be found in 
both the inner and external phases. Finally, the influence of the solvent was assessed 
through the solvent:lipid ratio, as selected variable. As such, it allowed the 
characterization of the inner phase, and focused, implicitly, on the respective properties 
(the amount of lipid dissolved per volume of organic solvent influences, for example, the 
viscosity, at least in the initial stages of the particle formation).  
Table 3.2 describes the composition of SLN, prepared according to a double 23 
factorial planning. It includes a low, a medium and a high level of the lipid phase 
concentration, that are combined in a low/medium (L1 to M6) and a medium/high (M1 to 
L4) designs. Combining the information of the two designs, a general approach can be 
extracted from the first one, in which a wider particle size range is presented, while in the 
second one a fine tuning of the optimization can be performed. For the factorial designs, 
M2 and M5 formulations were not included. These additional experiments were carried 
out in order to complete the formulation optimization process (see below).  
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Table 3.2 SLN composition for the different levels considered in the two 23 factorial 
designs. Key: L, lower level; M, middle level; H, higher level of lipid phase concentration. 
Composition: Weightlipid:VolumeDCM:Concentration(%w/V)PVA; Ratio: VolumeDCM:Weightlipid; 
PI: Polydispersity Index. Results include standard deviation (n=3). 
Formulation 
Composition 
(Wlipid
a
:VDCM:CPVA) 
Ratio 
WDCM:Vlipid 
Particle 
Size (nm) 
PI 
Zeta 
Potential 
(mV) 
L1 100:1:0.5 1:100 789±80 0.618 -17.9±0.5 
L2 100:1:1.5 1:100 892±64 0.707 -16.1±0.4 
L3 100:2:0.5 1:50 287±34 0.330 -17.5±0.6 
L4 100:2:1.5 1:50 334±13 0.367 -16.0±0.5 
M1 250:2.5:0.5 1:100 261.±5 0.240 -26.2±0.2 
M2 250:2.5:1 1:100 300±14 0.385 -35.3±0.6 
M3 250:2.5:1.5 1:100 437.±7 0.506 -26.0±0.6 
M4 250:5:0.5 1:50 264.±4 0.145 -28.67±0.06 
M5 250:5:1 1:50 226.±3 0.187 -36.2±0.4 
M6 250:5:1.5 1:50 275.±3 0.295 -24.6±0.9 
H1 500:5:0.5 1:100 300.±3 0.175 -19.33±0.06 
H2 500:5:1.5 1:100 296.4±0.8 0.307 -16.0±0.3 
H3 500:10:0.5 1:50 380.9±1.3 0.268 -18.3±0.4 
H4 500:10:1.5 1:50 269.±3 0.226 -15.4±0.6 
a
Note that, in this table, the total weight of the lipid is used for simplicity.  The formal values 
for lipid concentration (w/V) are, respectively, 0.33%, 0.83%, and 1.67% for the L, M and H levels 
(see also Table III). 
 
The lipid concentration, solvent:lipid ratio and emulsifier concentration are denoted 
respectively as x1, x2 and x3 in Equation (3.1), and the combined terms describe the 
respective interaction. Table 3.3 defines the coded values.  
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Table 3.3 Coding of factorial design variables. 
Factorial design Coded level 
Lipid Weight/Solvent:Lipid 
Ratio/Emulsifier 
Concentration 
L/M -1 100/1:100/0.5% 
 +1 250/1:50/1.5% 
M/H -1 250/1:100/0.5% 
 +1 500/1:50/1.5% 
 
In order to evaluate the influence of each variable, and the respective combination in 
the response term, the polynomial coefficients of Equation (3.1) were determined. The 
higher the magnitude of each coefficient, the higher is the respective main effect on the 
system. A positive coefficient sign indicates that an increase in the parameter level leads 
to an increase in particle size. Taking into account the interaction coefficients, the 
response must be analysed in terms of how the variation of one factor modulates the 
effect of another factor. To illustrate this point, consider the coefficient for variable 1, 
affected by the interaction with variable 2 (and neglecting other possible interaction 
terms), 
(β1 + β12x2)x1 
If we take β12>0 and x2<0, three situations are possible, depending on the value of β1: 
i) for β1<0, the interaction reinforces the negative effect of x1; 
ii) for β1 >0, and β1 > |β12x2|, the influence of x1 decreases;  
iii) for β1 >0, and β1 < |β12x2|, the effect of x1 is reversed in signal. 
A similar reasoning can be presented for x2>0, or in case β12<0. When the number of 
interaction terms increases, the analysis becomes more complicated but proceeds along 
the same lines. 
Table 3.4 gathers the values of the coefficients obtained for the low/medium and 
medium/high designs, as well as the corresponding levels of confidence, while Figure 
3.2 displays the response surfaces as a function of the major factors for the two designs 
under consideration. To test whether the terms were statistically significant in the 
regression model, t-tests were performed using a 95% (α=0.05) level of significance. The 
Student’s t-test analysis shows that the parameters are highly significant, with the single 
exception of the β13 interaction coefficient for the medium/high design. Additionally, 
ANOVA results are gathered in Table 3.5, as a further characterization of the fittings.    
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Table 3.4 Parameters of the response surfaces for size obtained from a 23 factorial 
planning in the indicated formulations and Student’s t-test analysis.  
Formulations β 0 β1 β2 β3 β12 β23 β13 
L1 to M6 442.2 -133.0 -152.4 42.3 112.6 -27.7 4.6 
Significance 
level 
100.0 46.6 100.0 100.0 100.0 100.0 100.0 
t 53.2 -16.0 -18.3 5.1 13.6 -3.3 0.6 
M1 to H4 310.4 1.2 -13.3 8.9 26.5 -34.2 -37.9 
Significance 
level 
100.0 100.0 100.0 100.0 100.0 99.6 41.2 
t 164.2 0.6 -7.0 4.7 14.0 -18.1 -20.1 
 
 
 
Figure 3.2 Particle size response surfaces for the two more significant factors at 
each fitted mathematical model. a) Low/medium design; b) medium/high design. The 
value of the third, least significant, factor was set to zero.  
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Two Fisher’s tests were used to assess the validity of the models fitting. According to 
the F1= MSREG/MSPE test, a ratio much larger than 1 indicates a good correlation 
between the experimental and predicted responses and that the model is adequate to 
describe the response variations. In turn, for F2 = MSLOF/MSPE test, the validity of the 
regression model is indicated by a ratio close to 1. 
ANOVA analysis (Table 3.5) of the model fitting procedure for the low/medium design 
suggests that the estimated responses are well described by the model, as evidenced by 
both F1 and F2 tests. In contrast, for the medium/high design, there are statistically 
significant deviations from the mathematical model, as evidenced by the F2 test. 
However, according to the F1 test, the model itself is still highly significant and explains 
the major part of the deviations of the responses from their mean value [11]. 
 
Table 3.5 ANOVA parameters for the characterization of the fitting in Equation (3.1). 
L1 to M6 
Degrees 
of 
freedom 
(DOF) 
Sum of 
squares 
(SS) 
Mean 
square 
(MS) 
 
F 
Significance 
p value 
Total 23 1.38x10
6
    
Regression 
(REG) 
6 1.35x10
6
 2.25x10
5
 151.89
a
 3.43x 10
-13
 
 
Residual 17 2.82x10
4
 1656.20   
Lack of fit 
(LOF) 
1 4488.10 4488.10 3.03
b
 0.10 
 
Pure error 
(PE) 
16 2.37x10
4
 1479.20   
 
M1 to H4 
Degrees 
of 
freedom 
(DOF) 
Sum of 
squares 
(SS) 
Mean 
square 
(MS) 
 
F 
Significance 
p value 
Total 23 8.71x10
4
    
Regression 
(REG) 
6 8.56x10
4
 1.43x10
4
 989.79
a
 1.22x10
-19
 
 
Residual 17 1457.60 85.74   
Lack of fit 
(LOF) 
1 1226.90 1226.90 85.11
b
 8.33x10
-8
 
Pure error 
(PE) 
16 230.66 14.42   
  
a
F1 = MSREG/MSPE; 
b
F2 = MSLOF/MSPE 
 
The low/medium design results were analyzed as follows, focusing specifically in the 
model description and in the assessment of the importance of factors. 
It is seen that the main parameter influencing mean particle size was the lipid:solvent 
(dichloromethane) ratio, followed by the lipid concentration and, to a lesser extent, the 
emulsifier concentration. It is also seen that, in this model, the isolated effect of each 
parameter is stronger than the corresponding interactions. 
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In fact, the mean particle size depends on the lipid concentration in the organic 
phase, since a higher lipid content results in a more viscous dispersed phase, and thus 
decreases the efficiency of homogenization [2]. Naturally, a higher lipid content in each 
initial DCM droplet will also promote larger particles after solvent evaporation, as 
represented in Figure 3.3. 
 
Figure 3.3 Influence of the solvent:lipid ratio upon particle size. The size of the 
droplets pertaining to the internal phase is, in the initial stages, governed mainly by the 
solvent. After evaporation, a lower lipid content in each droplet results in smaller 
particles. Viscosity effects also contribute to this result. 
 
These effects were evident in the L formulations, when the ratio 1:100 was switched 
to 1:50, as clearly indicated in Figure 3.2(A) by the marked negative slope and the color 
change of the surface response plot. The effect was also present, but less marked, for 
higher lipid concentrations. A closer inspection of Table 3.1 suggests that this was a 
general trend, present irrespectively of lipid- and surfactant-types.   
Comparing the matching L and M formulations, the decrease in particle size 
originated by an increase in lipid content becomes evident (remember the negative 
signal in β1). Note that, for these matching formulations, the lipid:solvent ratio remained 
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constant. Various studies have reported that increasing the lipid content results in larger 
particles and broader particle size distributions [1, 12, 13]. However, this increase in the 
amount of lipid is usually associated to an increase of its relative amount with respect to 
external phase, which makes it difficult to discriminate among factors. Other authors 
have observed an increase in lipid concentration associated to a concentration-
dependent increase in particle size, but only when the lipid concentration exceeds a 
critical value [5, 14]. Below this value, an increase in lipid concentration has only a minor 
impact upon particle size. A similar observation was contained in the present results, in 
the case of moving between the L and M formulations with a 1:50 solvent:lipid ratio. It is 
seen that the slope is negligible, when compared to the opposite side of the response 
surface.  
A closer inspection of Figure 3.2(A) reveals a further trend. The highest size obtained 
corresponded to a formulation with a low amount of inner phase. If this amount is 
increased, either by augmenting the lipid content, the organic solvent content or both, 
the size markedly diminished. This may be ascribed to a deficient dispersion if the size of 
inner phase is too small. Another aspect is related to the solvent diffusion rate, and thus 
the rate of evaporation. A higher solvent content maintains the inner phase less viscous 
for a longer time, and therefore originates smaller particles. Similar findings have been 
obtained in previous works, although remaining largely unexplained [15, 16]. The above 
considerations allowed concluding that the characteristics of the pre-emulsion affect, to a 
larger degree, the properties of the nanoparticles ultimately obtained.  
Focusing now in the emulsifier effect at the L/M design, this was the factor with the 
lowest importance for particle size, as indicated by the relatively small coefficient. Its 
contribution became clear in the increase of particle size when comparing the L and M 
formulations with 0.5% and 1.5% of PVA, while keeping constant the other parameter. A 
possible explanation is that an excess of emulsifier in solution for the L formulation leads 
to supersaturation of the emulsifier at the interface, induced by a diffusion process [3], 
resulting in an increase of particle size, as will be detailed below. 
The second factorial planning was applied to the medium/high design (M1 to H4 
formulations) and yielded the parameter values presented in the second half of Table 
3.3. A representation of the response surface is given in Figure 3.2(B). 
In this design, the effect of the different parameters in particle size was much lower 
than in the previous one. The solvent:lipid ratio was again the dominant factor, followed 
by the emulsifier and lipid concentrations. Also, the interaction between the parameters 
had a higher influence than the isolated factors.   
Particle size tends to increase mainly for a lower solvent:lipid ratio combined with a 
higher emulsifier concentration and, less markedly, when a higher solvent:lipid ratio and 
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lower emulsifier concentration are associated. The opposite conditions tend to decrease 
particle size. This behavior was applicable irrespectively of the lipid concentration, i.e. 
both for the M and H formulations, although for different reasons. In the case of the H 
formulations, and similarly to what was explained above, increasing the inner phase for a 
low amount of emulsifier may render this amount insufficient and results in an increase of 
particle size. On the other hand, an increase in the emulsifier concentration from 0.5 to 
1.5% tends to reduce the size markedly for higher solvent:lipid ratios, although the effect 
is less important for the lower ratios. This behavior could be attributed simply to the need 
of a larger amount of surfactant when a higher amount of inner phase is present [17]. 
Regarding the M level, the changes induced by the different compositions were less 
relevant, with the exception of the M3 formulation. In this case, the presence of a higher 
number of emulsifier molecules tends to increase particle size, probably due to a higher 
degree of deposition on its surface and because of bridging effects promoting 
aggregation.  
 As stated above, the emulsifier concentration was, in relative terms, the less 
significant parameter in the L/M design. However, it should be stressed that the 
respective effect was, in absolute value, more important in the M/H design. Overall, three 
distinct regions can be identified: one in which the system is above the optimal surface 
coverage, one in which it is close to this optimal value, and another in which it is below 
that level [17]. The L formulations are in the first region, and a direct correlation was 
observed between particle size and emulsifier concentration. The same occurs for the M 
formulations with a lower amount of solvent. The M4-M6 formulations display an almost 
constant size, which means they are close to the optimal surface coverage. Finally, the H 
formulations are below this optimal value, and particle size decreases with emulsifier 
concentration. Figure 3.4 summarizes, pictorially, the above considerations. 
 
Figure 3.4 Schematic representation of the influence of the emulsifier amount for 
situations in which the systems are above (L), close (M) and below (H) optimal surface 
coverage. (a) A large excess of emulsifier, relative to the lipid content, incorporates in the 
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particles, making them larger. This leads to bridging and, eventually, coalescence, 
resulting in further growth. (b) For situations in the vicinity of the optimal surface 
coverage, an increase in the amount of emulsifier produces a negligible effect. (c) For 
high lipid concentrations, an increase in the emulsifier amount leads to an increase in the 
surface area and, thus, to a reduction in size. The latter is the behavior commonly 
reported in the literature.  
 
Table 3.2 reveals that, according to the zeta potential measurements, the most stable 
formulations were in the M level. Both L and H formulations were located above -20 mV. 
If this result is combined with the overall output of the experimental design, taking into 
account both the L/M and M/H designs, there is a clear indication that a close to optimal 
formulation is found for compositions in the M level. Note that the intention was not to 
extrapolate beyond the domain of the experiments: it was selected (see above) so as to 
establish acceptable amounts in terms of the subsidiary substances, namely emulsifier 
and organic solvent. The choices in the amount of lipid were, in contrast, more arbitrary. 
In terms of selecting an ‘optimal formulation’, the M level was further detailed with the 
introduction of formulations M2 and M5. The latter corresponds both to the smaller size 
and the more negative value for the zeta potential. It is located in intermediate value of 
the lipid amount, emulsifier concentration and DCM amount (albeit not solvent:lipid ratio, 
for which it is an extreme value). In what follows, this is considered as the optimal 
formulation, but others are also subjected to study for comparison purposes. 
 
3.2.18 Optimization of the preparation method 
 
It is known that the effect of ultrasound waves in a liquid macroscopic dispersion is  
generating cavitation bubbles, which tend to implode, and thus provide sufficient local 
energy to generate nanometric-scaled droplets [3]. Thus, once selected the optimal 
composition according to the factorial design results, a sonication step was introduced in 
the method of preparation, so as to further reduce particle size. A final mean particle size 
of 209.±3 nm, with a very small PI value of 0.094, and a zeta potential value of -32.±3 
mV were obtained. This formulation is denoted, in what follows, as M5/S.   
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3.2.19  Physicochemical characterization 
 
Additional size measurements 
 
Laser diffractometry (LD) was used in order to discard the presence of large 
aggregates in the optimized formulation. This technique was also applied to other 
selected formulations (Table 3.6). 
 
Table 3.6 Particle size determined by laser diffractometry. 
 
 
 
 
 
 
LD and PCS yield different results, with the former identifying larger aggregates in 
the L1 formulation, as a consequence of the wider size range allowed by the technique 
(0.040-2000 μm). However, the results are in good agreement for the optimized 
formulations, M5 and M5/S. Note that in LD, an analysis by % volume was carried out, 
which renders a higher contribution for larger particles. The exclusive presence of 
nanoparticles is warranted by the d90% value, which is lower than 458 nm for the M5/S 
formulation. Note, additionally, that the sonicated formulation presents the lowest span 
value, which indicates a narrower size distribution, again in agreement with the PCS 
findings and determined PI. The effect of the sonication step was also evident on the 
volume distribution profile (Figure 3.5), in which a small population with diameters larger 
than 1 μm, present in the M5 formulation, was no longer visible after sonication. 
 
Formulation d10% (μm) d50% (μm) d90% (μm) Span Value 
L1 0.405 4.113 18.31 4.353 
M5 0.113 0.325 0.979 2.665 
H1 0.236 0.396 1.039 2.028 
M5/S 0.112 0.255 0.458 1.357 
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Figure 3.5 Particle size distribution profiles of L1, M5, H1 and sonicated 
formulations. 
 
Determination of residual PVA 
 
The results for the determination of residual PVA, i.e. the amount of PVA which 
remained associated to the particles, are presented in Table 3.7. For this determination, 
only one formulation of each level of the factorial design and the sonicated formulation 
were selected. The results support the particles surface supersaturation phenomena 
suggested for the L formulations (high amount of PVA in the external phase). The 
amount of PVA in the particles obviously increased with the lipid concentration. M5 and 
M5/S formulations correspond to the intermediate state, being the residual PVA values 
for the M5/S formulation slightly higher than for M5, probably because of the wider 
available surface area, as a consequence of the larger number of particles formed. 
 
Table 3.7 Percentage of PVA that remains associated to particles.  
Formulation % Residual PVA 
L1 47.8±1.1 
M5 61.8±3.1 
H1 70.0±4.2 
M5/S 68.0±0.3 
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Differential scanning calorimetry 
 
The crystal structure of the lipid matrix, here inferred by the thermal behaviour, is 
considered to influence the shape of SLN, as mentioned in previous studies [17]. DSC 
thermograms of tripalmitin SLN usually exhibit two polymorphic transitions, α to β’ and β’ 
to β, represented in the heating cycle as two exothermic peaks at 47 and 52ºC and three 
endothermic peaks at 43-44 ºC, 55 ºC and 62-64 ºC (Figure 3.6) [18]. The latter peaks 
correspond to the melting of each form. In the thermograms, the transition β’ to β was 
often absent, since its formation and conversion to β is likely to be too fast to be detected 
by the instrument. These transitions are related with a shape change from spherical lipid 
crystals to needle or platelet-like particles, thereby increasing the hydrodynamic radius of 
SLN [17, 19].  
 
Figure 3.6 SLN and tripalmitin thermograms. 
 
The heating step was performed to investigate the effect of the emulsifier packing 
and concentration in the crystal structure and, consequently, in the size of the particles. 
As such, enthalpies for each transition and the molar fractions (xβ) of the polymorphic 
forms were calculated (Table 3.8). The molar fractions were obtained using the molar 
enthalpies from reference [20]. 
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Table 3.8 Molar faction (x) associated to the β polymorphic form. For completeness, 
all formulations are included. 
Formulation xβ Formulation xβ 
L1 86.5 M5 65.2 
L2 57.2 M6 46.9 
L3 75.9 H1 59.1 
L4 61.4 H2 54.9 
M1 66.0 H3 68.5 
M2 47.4 H4 38.0 
M3 49.2 M5/S 39.0 
M4 51.6   
 
According to the results, in most cases, the β form was dominant, although there 
were a few exceptions. Also, there was a general tendency for a decrease in the amount 
of β form as the emulsifier concentration increased from 0.5% to 1.5%. This behavior is 
supported by some findings of Bunjes et al [21]. According to these authors, PVA seems 
to act by causing an immobilization of the triglyceride molecules in the interfacial region, 
avoiding its structural reorientation to β form. This effect was clearly exacerbated when 
the amount of emulsifier was increased. In some cases, however, for which the 
intermediate 1% concentration was also assessed, the behavior was slightly more 
complex. The highest content of the β form was found for formulations with lower 
amounts of lipid (L1 and L3). Sonication promoted a clear increase in the content of the 
α form. The relationship between particle size and polymorphic forms was not trivial. 
Although in a significant number of cases, particle size tends to increase with the amount 
of α form, it is possible that this only reflects a common emulsifier action on both size 
and polymorphism [21]. This suggests a correlation between the lipid crystal matrix and 
the emulsifier packing which could explain the increase in mean particle size in the cases 
above mentioned.  
 
Attenuated total reflectance infrared spectroscopy 
 
The intermolecular interaction in the SLN systems was also assessed resorting to 
ATR-FTIR. The FTIR spectrum of pure PVA displays a broad peak around 3325 cm-1, 
corresponding to the stretching of the hydroxyl groups and peaks at 2923 cm-1 and 2850 
cm-1 due to C-H stretching.  In what concerns the spectrum of pure tripalmitin, the peaks 
for the C-H stretching are visible at 2851 cm-1 and 2919 cm-1, that corresponding the 
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stretching of C=O is found at 1735 cm-1, while the stretching of C-O appears at 1473 cm-
1 (Figure 3.7). 
 
Figure 3.7 FTIR spectra of PVA, tripalmitin and some SLN formulations. 
 
In the SLN spectra, a broad peak was detected around 3425 cm1, corresponding to 
the stretching of the hydroxyl groups of PVA. Most of the remaining profile can be 
directly related to features arising from tripalmitin (Figure 3.7). 
Overall, these results are extremely coherent, and are also consistent with the 
previously discussed DSC data. For a full characterization, results for all formulations are 
presented. Pure tripalmitin is essentially found in the more stable β crystalline form. Note 
that the features present in the spectra and related to both the C=O and C-H stretching 
have been used to discriminate between α, β’ and β forms [20]. Focus is firstly directed 
to the former (see Figure 3.8). In these FTIR spectra, this region is characterized by two 
well separated peaks (at ca. 1728 and 1737 cm-1), while a small shoulder is visible 
connected to that at 1734 cm-1. Variations in the amount of PVA seem to strongly 
influence the spectra in this region. While in formulations containing lower amounts of 
PVA, this region was very similar to that found for pure tripalmitin, when the amount of 
PVA was increased, especially for the lower lipid contents, the two separated peaks 
evolved into a convoluted structure that, in some cases, can better be described as a 
single, broad peak. It should be noted that this evolution clearly followed the one 
previously extracted from the DSC results. As such, a lower presence of the β form gave 
rise to less discrete peaks, probably as a result from the coexistence of the different 
forms, originating slightly different frequencies. This observation can be extended to 
formulations subjected to sonication. For these, DSC indicated a lower β content and 
FTIR showed convoluted C=O peaks. 
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Figure 3.8 C=O stretching observed for all formulations.  
 
Atomic force microscopy  
 
Figure 3.9 shows the AFM images and the cross-section profiles from the height and 
error images of the optimized SLN. Particle sizes obtained using AFM images were 
similar to those established from the PCS analysis. A thorough inspection of 3D image 
and the cross-section profiles, in which the diameter of the particles corresponds to the 
width of the peak at the base of the graphic and the height to the particles surface, 
indicates that particles present an irregular and rough surface. Note that a slight increase 
in particle size may result from the deposition of the particles upon the glass slide. Also, 
the poly-L-lysine slide surface, conversely for instance to mica, is detectable in the height 
profiles (see the initial and terminal zones of the height curve). 
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Figure 3.9 AFM images: (a) error trace, (b) height trace and (c) 3D and respective 
cross-section height profiles from the optimized formulation (M5/S). 
 
Scanning electronic microscopy  
 
SEM analysis (see Figure 3.10) was also performed to complete the information 
about particle size and morphology. The SEM image shows a relatively homogenous 
system which is consistent with the polydispersity index observed. The presence of the 
emulsifier, covering the particles surface, is evident, stressing the importance of this 
parameter in the lipid packing and in the shape modeling. 
 
Figure 3.10 SEM images from the optimized formulation (M5/S).  
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Fluorescence microscopy 
 
Fluorescence images allowed also inspecting SLN directly in the suspension 
medium. The images confirm previous observations. As seen in Figure 3.11 (A-D), a 
reduction in particle size was evident from the L and H formulations to the M ones. This 
illustrates the influence of the different compositions on the system. In the L1 
formulation, larger particles were formed as a consequence of the low amount of inner 
phase. For the H1 formulation, the number of particles tended to increase due to a 
higher lipid concentration, although with a slightly larger particle size. Conversely, a well-
structured and homogeneous system can be observed in the M5 and M5/S formulations, 
for which a balance for the amount of three different components was found. This not 
only contributed to reduce the particle size, but also to increase the respective stability. 
Note that for formulation M5/S there is additional difficulty in the observation of the 
particles, probably due to their smaller size. Larger aggregates are visible in some of the 
formulations (panels A-B). This, again, corroborates the findings from PCS and LD. 
 
 
Figure 3.11 Fluorescence microscopy images depicting differences among SLN 
formulations. A: L1 formulation; B: H1 formulation; C: M5 formulation; D: M5/S 
formulation. 
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Stability studies 
 
The physicochemical stability of the optimized formulation (M5/S) was evaluated at 
4 ºC and 25ºC for 6 months via PCS particle size and zeta potential (Table 3.9).  
Results reveal that the SLN size was not affected by storage temperature within the 
range tested and did not significantly change after 6 months. The stability of the 
particles, indicated by the zeta potential, remained essentially unaltered, once stored at 
low temperature (4ºC). 
 
Table 3.9 PCS particle size and zeta potential of the optimized formulation for 6 
months.  
Storage Conditions Particle Size (nm) PI Zeta Potential 
After preparation 
 
 209.3±2.7 0.094 -31.6±3.3 
6 months 
        25ºC  
 4 ºC 
 
217.1±4.9 
218.1±6.5 
 
0.114 
0.110 
 
-20.1±0.1 
-31.5±0.9 
    
 
The M5/S formulation stability was also assessed through LUMiFuge stability 
analyzer, which combines the centrifuge force with near infrared transmission 
measurements. This technique allows the separation process to be measured rapidly 
and thus gives a fast and accurate means of evaluating nanoemulsion dispersion 
stability.[9] 
The graphic representation of the transmission as a function of the local position 
reveals the corresponding transmission profile. By Figure 3.12, it can be concluded that 
the M5/S formulation is relatively stable, due to the low transmission profiles, even after 
submitted at a high centrifuge force for 126 min. The evolution of the transmission 
profiles during the centrifugation allows detecting local alterations of particles 
concentration, which are reflected as changes in light transmission. Zones of well mixed 
dispersions scatter and absorb the light, so transmission is low. In contrast, any 
separation process (clarification) allows more light to pass and transmission rises.  
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Figure 3.12 Progression of transmission profiles of the M5/S formulation. The 
corresponding sequence of profiles is shown from red for the first profiles to green for the 
last ones. 
 
Drug-loaded SLN  
 
Simvastatin was encapsulated as a model drug, in order to assess its influence upon 
particle properties, such as particle size, zeta potential and entrapment efficiency.   
According to the results, increasing the amount of drug in the particles lead to an 
increase in the mean particle size and in the polydispersity, and a decrease of the 
absolute value of the zeta potential (Figure 3.13(A-B)). In contrast, the entrapment 
efficiency remained almost constant (Figure 3.13(C)). Note also the existence of two 
distinct regions, respectively 5-10 and 12.5-17.5 mg. The increase either in particle size 
or polydispersity associated with the decrease of the zeta potential observed in the 
frontier of these two regions suggests matrix saturation with the accumulation of the drug 
at the particle surface. This also impacted on the zeta potential, which became less 
negative and indicates some instability. 
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Figure 3.13 Characterization of solid lipid nanoparticles loaded with increasing 
amounts of simvastatin (S), ranging from 5 mg to 17.5 mg. Key:  A – Particle size and 
polydispersity index. B – Zeta potential. C – Entrapment efficiency and drug loading. 
(n=3; mean ± SD) 
 
3.3 Conclusion 
 
Factorial design enabled to successfully formulate solid lipid nanoparticles with an 
optimized nanometric particle size, and good stability. A clear assessment of the 
importance of factors was provided by this analysis. Solvent:lipid ratio represented the 
main factor influencing particle size, and did not seem to depend on lipid or surfactant 
molecule. The amount of emulsifier had a non-trivial impact upon size, depending on 
whether systems were located below, above or close to the optimal surface coverage 
and, finally, the amount of lipid had a limited influence upon particle size. The 
mathematical analysis clearly showed that the influence of the composition parameters is 
crucial for determining the particle size of the SLN prepared by the emulsification-solvent 
evaporation method developed, and also facilitated the interpretation of the underlying 
physicochemical phenomena. The results were supported by the complementary 
analyses by DSC and FTIR, which provided some insight in the molecular structure and 
arrangements, compatible with rationales extracted from the experimental design, while 
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microscopy techniques allowed direct visualization of particle size and morphology, 
corroborating size measurements by PCS and LD.  
The SLN have also proved being an effective lipophilic drug carrier. In the present 
experimental conditions, simvastatin loading only promoted minor changes upon SLN 
properties.  
Finally, the design planning methodology has clearly shown its usefulness in this 
optimization process, and this research constituted a solid framework for the 
understanding of SLN formation.  
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Chapter 4 
 
Optimization of co-encapsulating nanostructured lipid carriers by 
high pressure homogenization:  
in vitro, in silico and cellular viability approaches 
 
 
 
 
4.1 Introduction 
 
In this chapter, a dual objective is pursued: assessing the NLC as a vehicle for 
olanzapine and simvastatin co-encapsulation, and proposing a strategy for transdermal 
administration, combining these carriers with common penetration enhancers.  
The combination of chemical enhancers with nanocarriers is an innovative approach 
in the design of a transdermal formulation [16]. For that, the effect of classical terpenes, 
such as menthol, cineole, and limonene, in ethanol as co-solvent, was studied. The 
terpene screening was supported on experimental testing based on permeation studies, 
and rationalized by molecular dynamics simulation, as a computational approach.  
The design and optimization of a new transdermal delivery system based on NLC, 
prepared by the hot high pressure homogenization technique, for concomitant 
administration of OL and SV is thus presented. The final system was obtained by the 
incorporation of the NLC into a hydrogel containing terpene in ethanol, as vehicle. The 
overall process was addressed using a two-step factorial planning, firstly applied to NLC 
preparation, wherein an analysis of particle size, and also zeta potential and entrapment 
efficiency was conducted, and then to the final formulation, mainly focusing on the 
permeation rate as biological performance outcome. This experimental design tool 
allowed the simultaneous study of the influence of each independent variable upon the 
system and the respective interaction, using a limited number of experiments [17]. 
Finally, the NLC dispersion was assessed in what concerns cytotoxicity. 
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4.2 Materials and methods 
 
4.2.1 Materials 
 
Simvastatin was kindly provided by Labesfal - Laboratórios Almiro, S.A. (Santiago de 
Besteiros, Portugal). Olanzapine was purchased from Zhejiang Myjoy (Hangzhou, 
China). Glyceryl tripalmitate (tripalmitin, T8127), phosphate buffer saline pH 7.4, 
polysorbate 80 (Tween® 80), 1,8-cineole (99%) and (1R, 2S, 5S)-(-)-Menthol (99%) were 
purchased from Sigma. Miglyol® 812 (a mixture of triglycerides of caprylic and capric 
acid) was acquired from Axo (Wavre, Belgium). Labrafac PG (propylene glycol 
dicaprylocaprate) was a kind offer from Gattefossé (Gennevilliers, France). Oleic acid 
and limonene (>98%) were acquired from Fluka. Carbopol® Ultrez 10 NF was kindly 
provided by Lubrizol (Quimidroga, Barcelona, Spain). All other reagents and solvents 
were from analytical or high performance liquid chromatography (HPLC) grade. 
 
4.2.2 Drug-in-lipid solubility studies  
 
In a first stage, the solubility of SV and OL was determined in the solid lipid, 
tripalmitin, and in Mygliol®, Labrafac® PG and oleic acid as liquid lipids. For the solubility 
study in tripalmitin, 2 g of the solid lipid were previously melted at 10 ºC above the 
respective melting point in a controlled temperature water bath. Small amounts (ca. 2 
mg) of SV and OL were then successively added until the saturation of the lipid was 
achieved [18]. For the liquid lipids, an excess of drug was dispersed in screw-capped 
tubes containing the liquid compounds (5 mL each) and magnetically stirred for 48 h at 
25 ºC. The samples were then centrifuged for 10 min at 11 740 x g in a Minispin® 
(Eppendorf Ibérica S.L., Madrid, Spain), and 0.5 mL of the clear supernatant was 
suitably diluted with methanol and analysed by HPLC. Each determination was carried 
out in triplicate.  
 
4.2.3 Preparation of aqueous NLC dispersions and hydrogels  
 
The NLC were prepared by the hot high pressure homogenization technique 
described elsewhere [19]. Briefly, a pre-emulsion was obtained by the dispersion of the 
melted lipid phase, containing the solid and liquid lipids, tripalmitin and oleic acid, 
respectively, corresponding to a total amount of 750 mg, in 30 mL of a hot emulsifier 
solution (Tween® 80) at 80 ºC. This dispersion was prepared using an Ultra-Turrax 
X1020 (Ystral GmbH D-7801, Dottingen, Germany) at 25000 rpm for 2 min. It was further 
subjected to a hot high-pressure homogenization (HPH) procedure through an 
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Emulsiflex®-C3 (Avestin, Inc., Ottawa, Canada) at 1000 bar for a specific time (see 
below). The lipid dispersion thus obtained was cooled at 4 ºC to form the NLC. In the 
drug loaded formulation, which will be referred as Combo-NLC, the addition of both 
drugs (80 mg of each), SV and OL, was carried out in the initial lipid melted phase. 
These quantities were chosen based on maximization of the amount within a suitable 
entrapment efficiency, as established from preliminary tests. 
In order to obtain viscosity values adequate for transdermal application, a hydrogel 
was prepared. For that, 0.5% (w/V) of Carbopol® Ultrez 10 and the selected permeation 
enhancers, terpene (see section 4.2.14.) in 30% (V/V) of ethanol, were added to the 
NLC dispersion, and left to hydrate under gentle magnetic agitation for 1 h. The 
Carbopol dispersion was subsequently neutralized using triethanolamine, so as to 
promote gelation.  
 
4.2.4 Particle size analysis 
 
Particle size was determined by dynamic light scattering, yielding the mean particle 
size and the PI. DLS was performed in a Delsa Nano C Submicron (Beckman Coulter, 
Krefeld, Germany) apparatus at a detection angle of 160º and a temperature of 25 ºC. 
Samples were suitably diluted with ultrapurified water. Each value was measured in 
triplicate. Results are presented as mean ± standard deviation, extracted from the 
Cumulants algorithm [20, 21]. 
 
4.2.5 Zeta potential 
 
Zeta potential determinations were carried out by electrophoretic light scattering in a 
Delsa Nano C Submicron (Beckman Coulter, Krefeld, Germany) apparatus at 25 ºC. The 
ZP was calculated using the Helmholtz–Smoluchowsky equation. For the 
measurements, samples were diluted appropriately with ultrapurified water (pH≈5.5). 
 
4.2.6 Entrapment efficiency and drug loading  
 
The entrapment efficiency of SV and OL in the NLC was determined indirectly by 
measuring the concentration of free drug in the aqueous phase of the nanoparticle 
dispersion, as described elsewhere [17]. Simultaneously, the total drug amount present 
in the system was also calculated. For that, a specific volume of the dispersion was 
suitably diluted with mobile phase (ammonium acetate (0.02 M in water), methanol, and 
acetonitrile mixture, 30:35:35 (V/V/V)) and heated at 60 ºC for 15 min. This dispersion 
was further centrifuged and the supernatant filtered by a 0.22 µm membrane. This 
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additional determination was performed in order to take into account the drug losses 
during the experimental procedures. All drug determinations were carried out by HPLC, 
as described below. The EE and DL were calculated using the Equations (2.3) and (2.4). 
 
4.2.7 Factorial design  
 
Two experimental designs with a two-level, three- and two-variable 2k full factorial 
plannings were performed, respectively, for the optimization of the nanoparticles 
preparation and final formulation. The experimental designs and the polynomial models 
were solved using the GNU Octave software [23], with specific programs developed by 
the authors, that included ANOVA and Student’s t-test applied to the fitted models. The 
mathematical models applied for the first and second cases were R = β0 + β1x1 + β2x2 + 
β3x3 + β12x1x2 + β23x2x3 + β13x1x3 (NLC) and R = β0 + β1x1 + β2x2 + β12x1x2 (final 
formulation), respectively. Coded (−1, +1) levels were considered for each independent 
variable, x1, x2, and x3, the latter in the case of the three-variable model, as described in 
sections 4.3.2 and 4.3.6, respectively, in which the −1 level corresponds to the lower 
value of each variable and +1 to the upper one. β0 is the arithmetic mean of the 
response, β1–β3 are the coefficients of the respective independent variables and β12, β23 
and β13 the interaction terms, and similarly for the second equation. As responses or 
dependent variables (R), particle size and permeation rate indicated by the flux at steady 
state (Jss) were selected, respectively, for the first and second factorials.  
 
4.2.8 Transmission electron microscopy  
 
The shape and surface morphology of the Combo–NLC were observed by 
transmission electron microscopy. The sample was prepared by placing a drop of the 
dispersion onto Parafilm®, upon which a copper grid was applied for 2 min. 
Subsequently, it was dried with paper filter and treated with 7% (w/V) uranium acetate in 
50% (V/V) of ethanol for 1 min followed by lead citrate. The grids were then observed in 
a transmission electron microscope JEOL 1010 (Tokyo, Japan) at 80 KV, coupled to a 
Morada Olympus SIS numerical camera. 
 
4.2.9 Atomic force microscopy 
 
The surface properties of Combo-NLC were also examined by atomic force 
microscopy in a FlexAFM (Nanosurf, Basel, Switzerland). A drop of the Combo-NLC 
dispersion previously diluted (1:10) was deposited on a glass slide and left to dry. The 
experiments were carried out in air, operating in contact mode (constant force). Oxidized 
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sharpened silicon tips and a spring constant of 0.2 N/m were used for imaging. Imaging 
data were analyzed with the Easyscan 2 software. 
 
4.2.10 Confocal laser scanning microscopy (CLSM) 
 
In order to investigate the structure of NLC before and after hydrogel incorporation, 
0.05% (with regard to the lipid matrix) Nile red-labeled Combo-NLC were prepared and 
inspected by CLSM. For that, a drop of glycerol was applied upon samples and 
examined using a confocal FV-1000 station installed on an inverted microscope IX-81 
(Olympus, Tokyo, Japan). Images were obtained with an Olympus UplanSapo x60 w, 
1.2 NA, objective lens (800 x 800 pixels, 0.088 µm/pixel). Samples were excited with 
543 nm line of a HeNe laser. The emitted fluorescence was detected through spectral 
detection channel 555-655 nm.  
 
4.2.11 In vitro release studies 
 
In vitro release studies were performed using static Franz diffusion cells (PermeGear, 
Inc., PA, USA) with a diffusion area of 0.636 cm2 and a receptor compartment of 5 mL. A 
dialysis cellulose membrane (MWCO~12000, avg. flat width 33 mm, D9652, Sigma-
Aldrich), as artificial membrane, was placed between both compartments and a receptor 
solution composed of PBS (pH = 7.4) with 30% (V/V) of ethanol to warrant sink 
conditions was used. This receptor phase was stirred at 600 rpm and maintained at 37 ± 
0.5 ºC by a thermostatic water pump, which circulated water through each chamber 
jacket. By maintaining the receptor solutions at 37 ºC, a temperature of 32 ºC at the 
surface was assured, thus mimicking human skin conditions. 400 μL of the formulations 
were applied in the donor compartments, and occluded with Parafilm® to prevent 
evaporation. The experiments were carried out over a period of 48 h and at 
predetermined time points, 300 μL aliquots of the receptor compartment was collected 
and replaced with fresh medium. All drugs were determined using the HPLC method 
described below. 
 
4.2.12 In vitro permeation studies: skin preparation and integrity tests 
 
In vitro permeation studies were performed in static Franz diffusion cells, in the same 
conditions of the in vitro release studies, but using newborn pig epidermis as skin model, 
clamped between the donor and receptor compartments, with the stratum corneum side 
facing up. The newborn pig (3 weeks, ~6 kg) was provided by a local slaughterhouse. 
The subcutaneous fat was sectioned off, and the epidermis separated from the 
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underlying dermis using the heat separation technique [24-26]. The use of heat-
separated epidermal membranes is more appropriate for permeants that are poorly 
water soluble [27]. Briefly, the skin was immersed into hot water at 60 ◦C, for 1 min, and 
subsequently, the epidermal layer was gently separated from the dermis. The epidermis 
sheets were cut into 2.5x2.5 cm2 pieces, wrapped with aluminum foil and stored at 
−20 ◦C until used. The storage time for the skin samples was less than 3 months. Prior to 
the experiments, the frozen skin pieces were thawed, and hydrated by placing in PBS 
(pH=7.4) overnight in a refrigerator (at about 4 °C). The barrier function of the skin was 
monitored by measuring the transepidermal water loss (TEWL). Only those skin samples 
that were found below 15 g/m2.h, the usual range of TEWL values for such 
measurements, were used for the experiments. 
 
 
Figure 4.1 In vitro permeation studies: preparation of newborn pig epidermis (A), 
measurement of TEWL as skin integrity test (B), and Franz diffusion cells system (C).  
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Chapter 4 – Optimization of NLC 
 
 107 
4.2.13 Calculations  
 
The cumulative amount of olanzapine and simvastatin diffused per unit area of the 
excised skin (  ) [28]  
   
      ∑    
   
     
 
                                      (4.1) 
expressed in μg/cm2, was plotted as a function of time (t, h). In equation (4.1),    
corresponds to the drug concentration of the receptor medium at each sampling time, Ci 
is the drug concentration of the ith sample, A the effective diffusion area, V0 and Vi stand 
for the volumes of the receptor compartment and the sample, respectively. The total 
quantities of the drugs obtained after 24 h (Q24) and 48 h (Q48) were used for 
comparison among formulations. The slope of the linear region on the representation of 
the amount of drug permeated by unit area versus time was used to calculate the flux at 
steady state [29]. According to Fick’s first law of diffusion, the flux (Jss, μg/cm
2/h) can be 
expressed by Equations (1.1) and (2.12). The permeability coefficient, Kp, and the lag 
time of permeation, tlag, a parameter related to the time required to achieve the steady-
state flux of a drug through the skin, were also taken into consideration. It was 
determined from the extrapolation of the linear portion of the plot to the x-axis [30].  
In the case of the release studies, only the cumulative percentage of drug was taken 
into consideration and represented, following an approach similar to that described 
above for the permeation assays. 
 
4.2.14 Screening of terpenes 
 
Terpenes are naturally occurring compounds derived from essential oils, which 
contain repeated isoprene (C5H8) units. Menthol (monoterpene alcohol, log P 3.23 [31]) 
limonene (monoterpene hydrocarbon, log P 4.58) and cineole (monoterpene ether, log 
P 2.82) [32] were the terpenes considered for the screening studies. They have been 
considered as very effective penetration enhancers, generally regarded as safe (GRAS) 
materials in transdermal delivery. [33, 34] 
Permeation enhancement  
 
The terpenes (menthol, limonene and cineole) were tested at two different 
concentrations, 2 and 5% (w/V). They were dissolved in ethanol and added to NLC 
dispersions in a final proportion of 30:70 (V/V). All formulations were uniform upon visual 
inspection. The effect of ethanol without terpene was also investigated, in order to 
assess its own influence on the interaction with SC. The permeation studies were 
conducted according to the procedure described in section 4.2.12. 
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Simulation details 
 
System The effect of a number of terpene molecules of different hydrophobicity on a 
fully hydrated dipalmitoylphosphatidylcholine (DPPC) bilayer was studied by molecular 
dynamics (MD) simulation. DPPC is a relatively common lipid often chosen to monitor 
membrane structure and dynamics when exposed to external agents [35-37]. 
Consequently, comparison with relevant results from the literature is largely facilitated. 
This simple and well-characterized model has been used specifically in studies similar to 
that described in this work, so as to assess effects over the permeation and membrane 
behavior [38-42]. DPPC and SPC water were described using the original definitions of 
the GROMOS 53a6 force field [43]. This force field and variants have been extensively 
used for modeling membrane properties along with a variety of organic molecules [35, 
44-46]. Supported on this force field, topology for each solute (menthol, cineole and 
limonene) was generated by the ATB [47] platform. A DPPC bilayer, consisting of 128 
phospholipid molecules equally distributed by two leaflets and 3655 SPC water 
molecules, was used as made available by Kukol [37]. It should be noted that, for 
simplicity, a single solute molar fraction of ca. 5% was consider in this study. Such 
approach is suitable for studying the interaction of each solute with the surrounding 
lipids, as well as assessing the preferential positioning and respective action on the 
bilayer. The system was solved resorting to the GROMACS package, version 4.5.4 [48], 
that is one of the most frequent choices for problems akin to that addressed here [49].   
 
Parameters and data analysis  
 
All MD simulations were carried out in the NPT ensemble and under periodic 
boundary conditions. A standard time step of 2 fs was used for both the equilibration and 
production runs. Non-bonded interactions were computed on the basis of a neighbor list, 
updated every 10 steps. Long-range electrostatics was computed using the particle 
mesh Ewald (PME) method, as recommended for charged polymer simulations. For 
Lennard-Jones energies, a cut-off of 1.4 nm was applied. Temperature and pressure 
were coupled to the Berendsen external baths maintained at 325 K and 1 bar, with 
coupling constants of 0.1 and 0.5 ps, respectively. To obtain a starting configuration, 
each system was firstly subjected to an energy minimization step. The systems were 
then left to evolve up to 100 ns, using the LINCS algorithm [50] to keep bonds containing 
H atoms under positional restraint conditions. The first 40 ns were considered sufficient 
to attain equilibrated systems, while the last 60 ns of production runs were subsequently 
subjected to standard analysis, such as atom-atom (group-group) distance distributions 
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and radial distribution functions (rdf). MD trajectories were visualized, and configuration 
images extracted using the VMD 1.8.6 software [51]. 
 
4.2.15 HPLC determination of simvastatin and olanzapine 
 
The quantification of the two drugs was performed using a validated HPLC method 
[52] (see Chapter 5) by a Shimadzu LC-2010 CHT apparatus equipped with a quaternary 
pump, an autosampler unit, and a L2450 UV/visible dual wavelength detector. For the 
determination of olanzapine, simvastatin and its main metabolite, simvastatin acid, a 
Luna Phenyl-Hexyl (5 μm; 150 mm × 3 mm) Phenomenex (USA) analytical column was 
used. The mobile phase consisted of a 30:35:35 (V/V/V) mixture of aqueous ammonium 
acetate solution 0.02 M: methanol:acetonitrile at a constant flow rate of 0.8 mL/min. A 
run time of 7 min was established for separation of the compounds. The detection was 
carried out at 230 nm. An injection volume of 10 µL was used for all standards and 
samples. For these conditions, simvastatin acid, olanzapine and simvastatin were eluted 
at 1.7, 2.0 and 5.5 min, respectively. Note that the former corresponds to the active form 
of the pro-drug simvastatin, and is a result of the metabolic conversion of the latter. The 
hydroxy acid form should be considered, since the receptor compartment medium is 
composed by PBS pH 7.4 plus 30% (V/V) of ethanol, a pH that favors the conversion of 
simvastatin into simvastatin acid [53, 54]. The partial validation of the method in this 
medium is described in Appendix 1.  
 
4.2.16 Cytotoxicity studies 
Cell culture conditions 
 
Human adult dermal fibroblasts cells Df (ZenBio, Inc.,USA), and a spontaneously 
immortalized human keratinocyte cell line, HaCaT, (CLS, Germany) were grown in 
RPMI-1640® (Gibco, UK) medium supplemented with 10% (w/V) fetal bovine serum 
(FCS, Life Technologies, Inc., UK), penicillin (100 IU/ml), and streptomycin (100 μg/ml) 
in a humidified 95% O2/5% CO2 environment at 37 ºC. For the subculture, cells growing 
as monolayer were detached from the tissue flasks by treatment with 0.05% (w/V) 
trypsin/EDTA (Invitrogen, UK). The viability and cell count were monitored routinely using 
Trypan blue dye exclusion method [55]. 
Cytotoxicity assays  
 
To determine in vitro drug effects on cell viability, cells (cultured in 96-well 
microplates) were incubated with drugs, vehicle (DMSO), NLC containing drugs and 
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empty NLC for 72 h and the cell viability was determined by the reduction of MTT (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) into a blue formazan salt that is 
quantitatively measured after extraction from cells [56]. Briefly, the day before 
experiment, human adult dermal fibroblasts cells Df (ZenBio, Inc., USA), and a 
spontaneously immortalized human keratinocyte cell line, HaCaT, (CLS, Germany) were 
seeded in 96 well tissue culture plates at a cell density of 2,5x104 cells/well, in RPMI 
1640 culture medium supplemented with 10% fetal serum bovine, 100 units of penicillin 
G (sodium salt) and 100 μg/mL of streptomycin sulfate and 2 mM L-glutamine. On the 
next day, cells were incubated with drugs, vehicle (DMSO), NLC containing drugs and 
empty NLC for 72 h. After time of incubation, cell media containing DMSO (for control 
cells) or tested compound solution (for test cells) was removed and replaced with fresh 
medium containing MTT dye to a final concentration of 0.5 mg/mL. After 3 h of incubation 
the media was removed and the intracellular formazan crystals were solubilized and 
extracted with DMSO. After 15 min at room temperature the absorbance was measured 
at 570 nm in Microplate Reader (Infinite M200, Tecan, Austria) [56, 57]. Within an 
experiment, each condition was assayed in triplicate and every experiment was 
performed at least three times, with a total of nine replicates. The percentage of viable 
cells was established relatively to cells treated with vehicle, for drug in solution, and 
culture medium for drugs into NLC. Inhibitory concentrations (IC50) were calculated by 
applying non-linear regression procedure to the concentration-response data using 
GraphPad PRISM software (GraphPad Software, Inc., USA).  
 
Cell uptake studies 
 
For evaluation of cell uptake, Nile red-labeled Combo-NLC and hydrogel containing 
Nile red-labeled Combo-NLC plus permeation enhancers, were added to HaCaT cells 
(CLS, Germany) grown on glass 4 wells Chamber slides (Lab-Tek II, Nunc, USA). Cells 
were exposed for 1 hour to formulations. After the incubation period, cells were washed 
with 10 mM phosphate buffer saline (PBS) containing 10 mM glycine, fixed with 4% (w/V) 
solution of paraformaldehyde for 15 min in dark, followed by three times washing with 10 
mM PBS. Glass Chamber slides containing cells were treated with fluorescent mounting 
medium (ProLong Antifade, Invitrogen, UK) including DAPI for nucleus labeling. The 
cells were observed and microphotographed in a Zeiss Axioskop 4.0 fluorescence 
microscope (Zeiss, Germany). The uptake of Nile red-labeled Combo-NLC and hydrogel 
by HaCaT cells was quantified by flow cytometry in an EasyCyte 5HT equipment 
(Guava, Millipore, Germany). 
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4.2.17 Stability studies 
 
The optimized NLC formulation was studied for stability at 4ºC and 25ºC. Particle 
size, zeta potential values and entrapment efficiency were monitored for a period of 6 
months. 
 
4.2.18 Statistical analysis 
 
The significance of differences was evaluated using Student’s t-test at the probability 
level of 0.05. This analysis was performed using Microsoft Excel® (Microsoft Corp., 
Redmond, WA). 
 
4.3 Results and discussion 
 
An optimization process supported on two experimental designs applied to the NLC 
preparation and final formulation, based on the hot high pressure homogenization 
technique and permeation studies, respectively, will be described. Before the 
experimental designs were constructed, preliminary screening solubility studies were 
performed for the selection of the appropriate lipid, described in what follows. 
 
4.3.1 Screening of the lipid phase composition 
 
The choice of tripalmitin as solid lipid was based on previous studies [17]. The 
solubility of simvastatin in tripalmitin (34.5±4.1 mg/g) was considerably higher than that 
of olanzapine, which is below 12 mg/g. Solubility of the drug in the melted lipid is known 
to be an important precondition to obtain sufficient EE [58]. Since the focus of this study 
was the co-encapsulation of both drugs, to maximize olanzapine solubility, liquid lipids 
were included. Thus, the choice was Miglyol® 812, as medium chain (C8-C10) 
triglycerides, Labrafac® PG (propylene glycol dicaprylocaprate) as polyalcohol esters of 
fatty acids, and oleic acid as long chain fatty acid. The solubility of the drugs in the 
different lipids is presented in Table 4.1.  
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Table 4.1 Solubility of the drugs in the different liquid lipids. Data are expressed as 
mean ± standard deviation (SD), n=3. 
Liquid lipid Simvastatin 
solubility (mg/mL) 
Olanzapine 
solubility (mg/mL) 
Mygliol® 10.±1 7.8±0.3 
Labrafac® PG 14.7±0.3 9.7±0.5 
Oleic Acid 17.1±0.2 177.±5 
 
According to the results, oleic acid was selected as liquid lipid to include in the 
formulation, because it allowed maximal solubility for both drugs. In addition, oleic acid is 
also a well-established skin permeation enhancer [59]. Its penetration enhancing effects 
are attributed to an intercalation into the structured lipids of the SC and disturbance of 
the lipid packing order [60]. 
 
4.3.2 Optimization of the NLC preparation  
 
The optimal conditions for the preparation of NLC were selected using a two-level, 
three-variable, 2k full factorial planning. For that, the most critical independent variables 
were identified. These included the liquid:solid lipid ratio, the emulsifier concentration 
and the HPH time (see Table 4.2). This choice is thus based on two composition 
variables, one which influences the inner phase behavior, the liquid:solid lipid ratio, and 
another one related to the external phase, with impact on the interface stabilization, the 
emulsifier concentration. The third variable considered, the HPH time, is a production 
condition with impact on the whole system. As dependent variables, the present work 
focused on particle size, but zeta potential and entrapment efficiency were also 
analyzed. The 2k factorial design yielded 8 different experiments, for which the response 
are summarized in Table 4.2. 
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Table 4.2 NLC composition according to the two-level, three-variable, 23, factorial 
design. Key: F: Formulation; PI: Polydispersity Index; EE SV: Entrapment Efficiency for 
simvastatin; EE OL: Entrapment Efficiency for olanzapine. Results are expressed as 
mean ± SD (n = 6). The coded values (-1) and (+1) correspond, respectively, to 150 and 
300 for the HPH time (sec), 25:75 and 50:50 for the liquid:solid lipid ratio (w/w), and 1.5 
and 3.0 for the emulsifier concentration % (w/V). Index for coefficients in model follow the 
same order: β1, β2 and β3 corresponds to HPH time, liquid:solid lipid ratio, and emulsifier 
concentration, respectively. The interaction terms follow the same notation.   
 Independent Variables Dependent Variables 
F 
HPH  
time 
(sec) 
Liquid:solid 
lipid ratio 
%(w/w) 
Emulsifier 
concentratio
n %(w/V) 
Particle 
Size 
(nm) 
PI 
Zeta 
Potential 
(mV) 
EE SV 
(%) 
EE OL 
(%) 
1 150 25:75 3.0 191.±2 0.249 -29.±1 96.±2 93.±2 
2 150 25:75 1.5 180±18 0.257 -26.±1 99.6±0.1 96.6±0.2 
3 150 50:50 3.0 149±18 0.271 -36.±2 99.72±0.05 97.0±0.5 
4 150 50:50 1.5 209±14 0.283 -29.2±0.7 99.6±0.1 97.65±0.04 
5 300 25:75 3.0 206±20 0.161 -34.±0.8 98.6±0.6 95.3±0.9 
6 300 25:75 1.5 224±62 0.123 -30.8±0.6 99.1±0.5 96.23±0.04 
7 300 50:50 3.0 140±12 0.270 -31.±2 99.7±0.1 97.14±0.06 
8 300 50:50 1.5 156.±7 0.249 -30.7±0.8 99.65±0.05 97.9±0.2 
 
In order to evaluate the influence of each variable, and the respective combination in 
the particle size as response term, the polynomial coefficients for the first design (NLC) 
were determined and are displayed in Table 4.3. The higher the magnitude of each 
coefficient, the higher is the respective main effect upon the system. A negative 
coefficient sign indicates that an increase in the parameter level leads to a reduction in 
particle size [17]. 
 
Table 4.3 Parameters of the response surfaces for size obtained from a 23 factorial 
planning in the indicated formulations and results of Student’s t-test analysis. 
Response 
term 
β0 β1 β2 β3 β12 β23 β13 
Particle size 181.78 -0.46 -18.49 -10.37 -15.10 -8.35 1.79 
Significance 
level 
100.00 9.29 100.00 98.81 99.96 95.97 34.83 
t value 46.13 -0.12 -4.69 -2.63 -3.83 -2.12 0.45 
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To test whether the terms were statistically significant in the regression model, t-tests 
were performed using a 95% (α=0.05) level of significance. The Student’s t-test analysis 
showed that the parameters are highly significant, with the exception of the β1 and β13 
coefficients. Additionally, ANOVA parameters were calculated and gathered in Table 4.4, 
as a further characterization of the fittings. ANOVA analysis of the model fitting suggests 
that the model is highly significant. 
 
Table 4.4 ANOVA parameters for the characterization of the fitting from the 23 design 
of section 2.7. 
F1-F8 
Degrees of 
freedom 
(DOF) 
Sum of 
squares 
(SS) 
Mean 
square 
(MS) 
F 
Significance 
p value 
Total 47 
6.6579 x 
104 
   
Regression 
(REG) 
6 
3.6024 x 
104 
6004.0 9.0640a 0 
Residual 41 
3.0555 x 
104 
745.24   
Lack of fit 
(LOF) 
1 4059.0 4059.0 6.1277b 0.017640 
Pure error 
(PE) 
40 
2.6496 x 
104 
662.40   
a F1 = MSREG/MSPE 
b F2 = MSLOF/MSPE 
 
Regarding the estimated coefficients (Table 4.3), it is seen that the main parameter 
influencing mean particle size is the liquid:solid lipid ratio, followed by the emulsifier 
concentration and, to a lesser extent, the HPH time. This suggests that the composition 
of the system has a dominant effect on particle size, when compared to the production 
conditions. In fact, the lipid phase is described on the basis of the combination of lipids in 
different physical states at room or body temperature. If the proportion of liquid lipid is 
increased in relation to the solid lipid, a reduction in size is observed. This can be 
attributed to a lower viscosity of the dispersed phase [61]. Also, it is described that the 
mean particle size is increased with higher melting point lipids [62]. Focusing now in the 
emulsifier concentration, a reduction in particle size is observed when the concentration 
is doubled. An increase in the emulsifier amount leads to an increase in the surface area 
and, thus, to a reduction in size [17, 63]. 
The HPH time is the parameter with less direct influence on size. However, its effect 
is marked in the interaction terms, particularly when combined with lipid ratio. An 
increase in the time of homogenization stresses the lipid ratio effect, mainly for a higher 
proportion of the liquid lipid. Shear stress and cavitation forces applied for a longer time, 
Chapter 4 – Optimization of NLC 
 
 115 
with a higher proportion of liquid lipid phase, will cause the disruption of the particles to 
nano size, and thus promote the increase in homogenization efficiency [2]. On the other 
hand, the HPH time reveals a small interaction with the emulsifier concentration, 
corresponding to the less significant interaction term. All these observations emphasize 
the need of a balance between composition and production variables to obtain particles 
with optimal size. 
Finally, a significant interaction between inner and interface/external composition 
variables is also detected. Both the isolated effects and the interaction promote a 
reduction in the mean particle size, if the lipid ratio and emulsifier concentration are 
increased. 
It should be noted that the PI values for the studied formulations were lower than 0.3, 
which is considered an optimal value for the dispersion and homogeneity of these 
nanoparticles [64]. 
Regarding the zeta potential and entrapment efficiency as response terms, small 
amplitude differences were found, indicating a minor influence of the preparation 
conditions on the surface and loading properties. 
Based on the results from the factorial design, formulations F3 and F7 display the 
lowest particle sizes. These formulations only differ on HPH time. F3 was selected 
because of the lower HPH time, allowing reducing production time and cost, with only a 
marginal particle size increase relative to F7. Note also that the F3 formulation is the 
more stable, as indicated by the lowest negative value obtained for zeta potential. It also 
assures an entrapment efficiency closer to 100% for both drugs, associated to a drug 
loading of 10.637±0.005% for simvastatin and 10.34±0.05% for olanzapine, which 
validates their application for co-encapsulation. An additional fine tuning of the 
optimization process was not deemed necessary. 
Note also that the diameter of the particles observed in the TEM and AFM images 
(Figure 4.1) corroborates the DLS measurements. AFM images of Combo-NLC also 
indicate an irregular and rough surface.   
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Figure 4.2 (A) TEM image of a particle present in the Combo-NLC formulation (scale 
bar 200 nm). (B) AFM images of the Combo-NLC: 3D (left) and respective cross-section 
height profiles (right) from the optimized formulation. 
 
4.3.3 Optimization of the NLC formulation  
 
Since the focus of the present work was the transdermal co-administration of OL and 
SV, in vitro permeation studies were firstly performed using the formulation previously 
selected. According to the calculated parameters for the Combo-NLC (Table 4.5), it is 
seen that the degree of permeation is small. This behavior can be attributed to the 
hydrophobic nature of the drugs, and thus a low partition between lipid (which 
corresponds only to 2.5% (w/V)) and external aqueous phase. This trend is more marked 
for simvastatin, the more hydrophobic drug. Thus, the composition of the vehicle may 
markedly influence the degree of penetration of the drug [65].  
A 
B 
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Table 4.5 Permeation parameters of the Combo-NLC formulation across newborn 
pig skin. Data are expressed as mean±standard error of the mean (SEM). (n=3)   
Permeation parameters OL SV 
Jss (μg/cm
2/h) 0.24±0.05 0.116±0.007 
Kp (cm/h) 1.1x10-4±0.2x10-4 0.48x10-4±0.03x10-4 
Q24 (μg/cm2) 3.5±0.7 1.0±0.1 
Q48 (μg/cm2) 9.±3 5.9±0.3 
% Drug permeated (48h) 0.7±0.1 0.38±0.02 
Lag time (h) 9.5±0.8 15.±2 
 
A simple strategy to overcome this solubility related limitation consisted on the use of 
ethanol, after a screening procedure involving also transcutol, propylene glycol and 
glycofurol (data not shown). For that, 30% (V/V) of the former alcohol was included in the 
formulation. This inclusion promoted an increase in the flux at the steady state of ca. 7.9 
for OL and 6.4 for SV (Table 4.6). Ethanol is known to be a skin penetration enhancer 
and therefore alters the barrier properties of the skin, which is partly responsible for the 
high flux values obtained [66]. 
 
4.3.4 Effect of chemical penetration enhancers 
 
To further enhance permeation, 2% (w/V) of menthol, cineole and limonene in the 
above NLC ethanolic dispersion were firstly studied. The co-incorporation of terpenes 
and ethanol promotes in general a higher flux when compared to the application of 
ethanol alone. The tertiary combination of NLC+ethanol+limonene yields the higher flux 
enhancement ratio, followed by cineole and, lastly, menthol (see Table 4.6). The 
cooperative effect of ethanol and limonene has already been reported to be an effective 
binary enhancer system [34].  
When this concentration was increased to 5% (w/V), permeation in the presence of 
limonene significantly augments, yielding a flux enhancement ratio of ca. 64 and 60 
respectively for OL and SV, when the NLC formulation is considered as reference. 
Conversely, for menthol and cineole, an increase in the concentration leads to a 
decrease in the permeation rate (Table 4.6). This behavior has already been observed 
for menthol, having been attributed to the limited solubility of hydrophobic terpenes in 
40% (V/V) of ethanol solution used in the experiments [67]. The same trend has been 
reported for other terpenes, although no clear explanation has been provided [68, 69].  
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Table 4.6 Olanzapine (OL) and simvastatin (SV) fluxes at steady state (Jss) along 
with the different chemical (ethanol and terpenes) enhancers used in combination with 
Combo-NLC. Key: Et: ethanol; M: menthol; C: cineole; L: limonene. The ethanol 
concentration is expressed in % (V/V), and that of terpenes is in % (w/V). a p<0.05 vs 
NLC as reference, b p<0.05 vs. NLC+30% ethanol as reference; n=3, for all the cases, 
with the exception of formulations signaled with asterisk, for which n=6. Data are 
expressed as mean±SEM.   
Formulations 
Jss OL   
(μg/cm2/h) 
ER    
Jss OL 
Jss SV 
(μg/cm2/h) 
ER         
Jss SV 
NLC 0.24±0.05 1.0 0.116±0.007 1.00 
NLC+30%Et* 1.9±0.4a 7.9 0.74±0.08a 6.4 
NLC+30%Et+2%M 1.9±0.8 8.0 0.8±0.4 7 
NLC+30%Et+5%M 1.4±0.2a 6.0 0.4±0.1a 4 
NLC+30%Et+2%C 4.3±0.9a,b 18 2.1±0.2a,b 18 
NLC+30%Et+5%C 2.8±0.1a 12 1.00±0.07a,b 8.60 
NLC+30%Et+2%L 9.±1a,b 37 3.3±0.6a,b 28 
NLC+30%Et+5%L* 15.±2a.b 64 7.0±0.8a,b 60 
 
All these observations are corroborated by the percentage of drug permeated after 
48 h, which are summarized in Figure 4.3.  
 
 
Figure 4.3 Different chemical (ethanol and terpenes) enhancers used in combination 
with Combo-NLC along with % olanzapine (OL) and simvastatin (SV) permeated after 
48h. Key: * p<0.05 vs NLC isolated as reference (REF). 
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4.3.5 Molecular dynamics simulations 
 
To rationalize the previous results and elucidate the mechanism of action of each 
terpene assayed, a molecular dynamics simulation study was performed.  
Figure 4.4 depicts the density profiles for some relevant groups and molecules 
across the bilayer. From these profiles, it is clear that the limonene and cineole 
molecules are mostly embedded in the hydrophobic region, while menthol molecules are 
preferentially positioned close to the interface. Limonene is likely to be found at the 
interleaflet region, easily switching between the two leaflets as suggested by the mean 
square displacement (MSD) profile (panel (a) of Figure 4.5). Cineole molecules are 
found in an upper position, but yet well embedded in the hydrophobic region. Menthol is, 
among the three terpenes under study, the one that appears to interact more strongly 
with the lipid polar heads, with evidence of establishing hydrogen-bonding, and 
displaying a reduced probability of crossing the center of the bilayer. Accordingly, 
diffusion of these menthol molecules is relatively slow compared with that of the two 
other. Representative snapshots, Figure 4.6, illustrate the described preferential position 
of each solute.  
Note that the above observations (i) are compatible with the fact that one of the 
terpenes contains hydrogen bonding donor groups (menthol), one other a hydrogen-
bonding acceptor group (cineole), and a last one that does not form hydrogen bonds 
(limonene). Note also that although (ii) terpenes can in principle, weaken the hydrogen-
bonding interactions at the membrane–water interface, the present results suggest that 
the effects of terpenes on the membranes do not necessarily depend on direct 
competition for H-bonds with the polar headgroups. Finally, (iii) these results suggest 
that the effects of terpenes do not relate to specific characteristics of SC membranes and 
that the basic characteristics for terpenes to affect membranes are their ability to 
penetrate the bilayer. These points have already been addressed in previous work [70], 
and a rationale is now provided from the simulation results.  
Extending the MSD analysis to the DPPC molecules, panel b) of Figure 4.5 clearly 
shows that the incorporation of ca. 5% of limonene is responsible for a significant 
increase in the DPPC lateral diffusion, when compared with the small increase prompted 
by cineole. In turn, a slight decrease in the lateral diffusion of the DPPC molecules is 
found in the presence of menthol.  
No significant differences were found in terms of the hydration of the carbonyl-ester 
atoms of DPPC tails (Figure 4.7A), this corresponding to the upper part of the 
hydrophobic region. However, a close up of the first hydration shell reveals that limonene 
is responsible for an increase in the water content, closely followed by cineole. In 
contrast, a decrease in the amount of water is observed for the incorporation of menthol. 
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Such behavior is compatible with an increase of the order promoted by the presence of 
menthol.  
A more detailed analysis on the order of the membrane is presented from the 
estimated deuterium order parameter (Figure 4.7B). This shows that both the cineole 
and menthol molecules induce an increased organization along the alkyl chains. For the 
limonene molecules, an opposite effect is found close to the bilayer center. Although the 
differences are small, the order found for the DPPC/terpene systems is in good 
agreement with the experimental results, pertaining to permeation. Based on the 
membrane perturbation results retrieved by MD, and for the concentration regime 
considered, menthol is identified as the least and limonene as the most effective 
permeation enhancer of the study. Nevertheless, the effectiveness of menthol has been 
suggested for enhancing the permeation of hydrophilic drugs [33]. This can be explained 
by the ability of menthol to drag water into the bilayer, also visible in the simulation, as 
illustrated in the snapshot (Figure 4.8). This indicates that the lipophilicity of the 
permeant, as well as the enhancer molecule play an important role in determining the 
penetration promoting mechanism [34]. 
 
Figure 4.4 Probability density profiles for the terminal methyl groups of the DPPC 
tails (black solid line) and respective headgroups (black dashed line), SPC water (black 
dotted line), and for the center of mass of the inserted molecules (solid colored lines) 
relative to the Z-axis. Note that the Z-coordinate represents the normal to the bilayer 
plane and each distribution is normalized to unity. 
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Figure 4.5 Mean square displacement (MSD) of (A) DPPC and (B) molecules under 
study. 
 
   
Cineole Limonene Menthol 
Figure 4.6 Snapshots illustrating typical positioning of the residues embedded in the 
bilayer. Key: water, terpenes and DPPC are represented in red, green and blue, 
respectively.  
 
 
Figure 4.7 Results from MD analysis: (A) radial distribution function (RDF) of water 
hydrogens around the carbonyl-ester atoms for the sn1 and sn2 chains of DPPC. (B) 
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deuterium order parameter, SCD, estimated along the bilayer depth for DPPC chains 
(and averaged over the sn1 and sn2 chains) in the presence of the indicated solutes. 
 
 
Figure 4.8 Snapshot illustrating menthol dragging water molecules into the DPPC 
bilayer. 
 
4.3.6 The combined effect of NLC and a chemical enhancer  
 
Factorial design 
 
Based on the above findings, limonene was the terpene included in the final 
formulation. The next step was to quantify the permeation enhancement coming from 
each of the main skin penetration strategies employed, nanocarriers and chemical 
enhancers, represented by NLC and limonene plus ethanol as co-solvent, respectively. 
Their isolated and combined effects were assessed using a second factorial planning, 
two-level, two-variable, 22. As independent variables, the absence (-1 level) or presence 
(+1 level) of limonene (5% (w/V)) and NLC were considered. For that, four different sets 
of experiments were carried out, in which 30% (V/V) of ethanol was included. In the 
experiments without nanoparticles, saturated solutions of both drugs were prepared. As 
dependent or response variables, olanzapine and simvastatin fluxes at steady state, 
permeability coefficient, Q24 and Q48h were analysed (Table 4.7). 
 
 
 
 
 
 
 
 
 
Chapter 4 – Optimization of NLC 
 
 123 
Table 4.7 Formulations and respective permeation parameters for olanzapine 
according to the 22 factorial design. Key: Et: Ethanol; L: Limonene; Jss = Flux at steady-
state; Kp = Permeability coefficient; Q24 and Q48 = Cumulative amount of olanzapine 
permeated after 24h and 48h, respectively; ER = Enhancement ratio. Again, the ethanol 
concentration is expressed in % (V/V), and that of terpenes in % (w/V). For the 
calculation of ER, experiment 1 was considered as reference. Data are expressed as 
mean±SEM. (n=6) 
 
Exp. 
# 
Formulation 
 
Jss 
(μg/cm
2
/h) 
ER 
(Jss) 
Kp (cm/h) 
(x 10
-3
) 
ER 
(Kp) 
Q24 
(μg/cm
2
) 
Q48 
(μg/cm
2
) 
Lag 
time 
(h) 
Time* 
(h) 
OL 
1 
Saturated solution 
(30%Et) 
0.32±0.05 1.0 2.1±0.3 1.0 9.±2 15.±3 - 6.±1 
2 NLC + 30%Et 1.9±0.4 5.9 1.2±0.2 0.57 29.±7 79±18 9.±4 3.9±0.8 
3 
Saturated solution  
(30%Et +5%L) 
0.49±0.04 1.5 1.9±0.2 0.91 10.6±0.8 20.±2 - 3.5±0.8 
4 
NLC + 30%Et + 
5%L 
15. ±2 48 10.±1 4.6 261±51 534±33 7.±5 1.3±0.3 
SV 
1 
Saturated solution 
(30%Et) 
0.34±0.05 1.0 1.6±0.2 1.0 8.±2 15.±3 - 7.±2 
2 NLC + 30%Et 0.74±0.08 2.2 0.42±0.05 0.26 13.±3 31.±5 10.±4 7.±2 
3 
Saturated solution  
(30%Et + 5%L) 
0.22±0.05 0.64 1.±1 0.5 7.±1 12.±2 - 7.2±0.3 
4 
NLC + 30%Et + 
5%L 
7.0±0.8 21 3.9±0.5 2.4 82±19 249±36 14.±4 2.9±0.7 
* Estimate of time after which drug is detected in the receptor compartment. 
Considering the flux at steady-state as response, the polynomial coefficients for the 
second design (final formulation) were calculated (see Table 4.8). 
 
Table 4.8 Parameters of the response surfaces for flux at steady-state obtained from 
a 22 factorial planning in the indicated formulations and Student’s t-test analysis. 
Response  
Term 
β0 β1 β2 β12 
OL Jss (μg/cm
2/h) 4.498 3.395 4.093 3.307 
Significance level 100.0 100.0 100.0 100.0 
t value 9.059 6.836 8.242 6.660 
SV Jss (μg/cm
2/h) 2.077 1.537 1.797 1.598 
Significance level 100.0 100.0 100.0 100.0 
t value 9.665 7.150 8.361 7.437 
 
Chapter 4 – Optimization of NLC 
 
 124 
The coefficients obtained from the factorial design stress the higher importance of the 
presence of NLC in the formulation, relative to that of limonene, for the permeation 
enhancement, within the working ranges under consideration. This suggests that NLC 
acts as a drug reservoir, thus assuring a high driving force upon the drug, suitable for 
transdermal delivery, in comparison to the corresponding saturated solutions. Moreover, 
the interaction terms point to a synergistic effect between both permeation enhancement 
strategies (Table 4.8). The increase in the flux corresponds to an increase in the product 
of the diffusion coefficient (D) by the partition coefficient (K) and the concentration in the 
vehicle (C0). The NLC, acting as a reservoir system, promote an increase in C0. 
However, it is difficult to estimate the real value of the drug concentration throughout the 
experiment. Assuming that the drug is fully available, which clearly corresponds to an 
overestimation, it is still possible to check if there is an increase in the D x K value. If that 
is the case, there is no doubt that there are two contributions for the enhancement of the 
flux: one provided by the NLC reservoir and the other by the disruption promoted by the 
permeation enhancers, that probably increase both drug diffusion and partitioning. This 
is what is observed when limonene is added to the system, yielding a flux enhancement 
ratio of 48 and 21, respectively for olanzapine and simvastatin, relative to the reference 
saturated system. Also, this system promotes a significantly lower enhancement ratio in 
what concerns Kp, 4.6 and 2.4, in the same order (Table 4.7). The latter values are 
undoubtedly underestimated because of the use of a majorant for C0, i.e., the reservoir 
effect has been withdrawn after division by an excessive gradient.  
Note that adding limonene to the water/ethanol saturated solution promotes only a 
marginal increase in the flux of olanzapine, and a slight decrease in that of simvastatin. 
This suggests that the hydroalcoholic solution does not favor the incorporation of the 
enhancer into the skin. It is possible that limonene is not homogeneously distributed in 
the solution, affecting particularly the partitioning of the most hydrophobic drug, with 
affinity for limonene rich domains that do not efficiently contact with the skin. 
On the other hand, the NLC/ethanol system is a better medium to transport and 
incorporate limonene into the skin. It promotes a homogeneous distribution of the 
enhancer in the formulation, as a result of the affinity of the hydrophobic limonene to the 
lipid nanoparticle. Additionally, the increased contact with the skin surface determined by 
the small size of the particles enforces the effect of limonene, significantly increasing 
permeation of both drugs. 
 
 
 
Chapter 4 – Optimization of NLC 
 
 125 
Simvastatin vs. olanzapine  
 
Focusing now on the differential behavior of the co-encapsulated drugs, the slower 
permeation observed with simvastatin can be attributed to a difference in the solubility of 
the drugs in the lipids used as internal phase. Since simvastatin has a higher solubility in 
the solid lipid, due to its solid matrix nature, the release is further sustained. In the case 
of olanzapine, due to its higher solubility in the liquid component, the release tends to be 
less controlled, thus showing a positive influence in the respective penetration degree.  
Another topic that should be remarked is related to the parameters Q24 and Q48. 
According to the current oral dosing regimen, a daily dose of 5 to 10 mg for olanzapine 
and 20 to 40 mg for simvastatin is required for a therapeutic effect. Since oral 
bioavailability is approximately 60% for OL and 5% for SV, the estimated transdermal 
dose should be approximately 3-6 mg and 1-2 mg per day, respectively. Thus, the target 
transdermal flux, according to in vitro permeation evaluations should be 3.1-6.2 μg/cm2/h 
for OL and 1.04-2.08 μg/cm2/h for SV, considering a 40 cm2 patch. This yields an amount 
permeated per day of 75-150 μg/cm2 and 25-83 μg/cm2, respectively for OL and SV. In 
addition, the amount permeated after 48 h (Q48) was approximately twice the amount 
permeated after 24 h (Q24), which suggests a constant delivery over time, even for a 
long-term administration. The flux can also be established from Jss = Css x Cl/A, now 
taking into consideration literature values for the therapeutic blood level (Css, 0.0093 
μg/mL [71] and 0.0003 μg/mL [72] for OL and SV, respectively) and clearance (Cl/F, 
26100 mL/h [73] and 3749160 mL/h [72] for OL and SV, respectively, where F 
corresponds to the bioavailability) of typical administered oral doses of OL and SV for a 
specific area of skin application (A, 40 cm2). This yields an estimated flow rate of 3.64 
μg/cm2/h for OL and 1.42 μg/cm2/h for SV, which is in good agreement with the previous 
calculations. The in vitro results obtained in the present work are above these target 
values and although a fine-tuning of the doses can be easily performed, it should be 
noted that the present results are very promising for most common therapeutic 
indications.  
Along with the significant enhancement action, the lag time for OL is also shorter 
than that of SV, and no significant difference was found for OL when limonene was 
added to the NLC. Although the time reported to achieve steady state for simvastatin is 
increased with limonene inclusion, it should be noted that the flux is higher, and starts 
earlier (see Table 4.7). A similar observation is made for OL. In turn, saturated solutions 
do not allow the estimation of this parameter, due to the small flux. It should be noted 
that, due to the chronic nature of these particular diseases, the relatively long lag times, 
are not considered an issue if the therapeutic response is ensured.   
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Permeation, EE and release 
 
Complementary studies for the assessment of the effect of ethanol and limonene in 
the EE and release behavior were also performed. Ethanol decreases both the 
entrapment efficiency for SV and OL, relative to the NLC dispersion, as demonstrated in 
the supplementary information (see Table 4.9). Interestingly, the further addition of 
limonene increases this EE, although values are still below those found for the aqueous 
dispersion. This could be ascribed to the hydrophobic nature of limonene, characterized 
by a high partition coefficient. The NLC dispersion, in turn, displays the lowest release 
rate (Figure 4.9), both for SV and OL. When ethanol is added, the release rate markedly 
increases. Upon the addition of limonene, the release decreases for OL, although the 
values are still clearly above those corresponding to the dispersion. In the case of SV, 
the release profiles for NLC+Et and NLC+Et+L are very similar. It should be noted that 
this behavior cannot be directly related with that found for permeation. In fact, there is 
only a relatively small increase in the total drug released after 48 h when the NLC 
dispersion is successively added with ethanol and limonene. However, a drastic increase 
in the permeation rate, respectively, 8 and 10 times higher for OL and SV, by the 
addition of limonene, is observed. As such, while ethanol favors both the permeation and 
release, the further addition of limonene increases permeation, but has a deleterious 
effect on release. Note that this reinforces the findings from the experimental design, 
above in this section, indicating a synergistic effect between NLC and permeation 
enhancers. Note also that these results point to a direct permeation enhancement effect 
of limonene, rather than a simple effect upon the release rate. 
 
Table 4.9 OL and SV entrapment efficiency for the NLC dispersion and after the 
addition of the permeation enhancers. Results are expressed as mean±SD, n=3. 
Formulation EE (%) SV EE (%) OL 
NLC 99.74±0.08 96.4±0.3 
NLC + 30%Et 86.±2 84.±2 
NLC + 30%Et + 5%L 97.3±0.2 90.7±0.3 
Chapter 4 – Optimization of NLC 
 
 127 
 
 Figure 4.9 Release profiles of NLC before and after the addition of ethanol and 
limonene. (A) olanzapine, (B) simvastatin. Results are expressed as mean±SEM (n=3) 
 
4.3.7 Effect of hydrogel 
 
From the factorial design based on permeation, the optimal formulation was selected 
to be incorporated into a Carbopol® Ultrez 10 hydrogel. Comparing the permeation 
profiles obtained from Combo-NLC+Et+L dispersions and hydrogels (Figure 4.10), a 
decrease in the flux (15±2 to 7.5±0.3 μg/cm2/h for OL and 7.0±0.8 to 3.6±0.3 μg/cm2/h 
for SV) and permeability coefficient (10x10-3±1x10-3 to 4.8x10-3±0.2x10-3 for OL and 
3.9x10-3±0.5x10-3 cm/h to 2.1x10-3±0.2x10-3 for SV) roughly by half was observed for 
both drugs. This behaviour might be due to the release retarding effect of the polymeric 
matrix and the increasing viscosity promoted by the gelling agent. Similar effects have 
already been observed [74]. However, the values obtained still remain above the target 
flux described above, which corroborate the feasibility of transdermal delivery. 
 
 Figure 4.10 Permeation profiles obtained for the previously optimized dispersion 
and respective hydrogel: (A) olanzapine, (B) simvastatin. (mean±SEM; n=6) 
 
In order to elucidate the structure of the hydrogel, Nile red-labeled Combo-NLC were 
prepared and analyzed by CLSM, before and after incorporation into hydrogel (Figure 
4.11). 
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Figure 4.11 Fluorescence images of the Nile red-labeled Combo-NLC dispersion (A) 
and after incorporation into hydrogel (B).  
 
The fluorescence image of NLC corroborates the DLS results, illustrating a 
homogeneous dispersion. After incorporation into the hydrogel, nanoparticles were 
entrapped in the entanglements of the gelling polymer forming grain domains, although 
preserving a relatively uniform distribution.  
 
4.3.8 Cytotoxicity and cell uptake studies 
 
To investigate the potential cytotoxicity of the NLC dispersions, the cell viability was 
evaluated using Df and HaCaT cell lines in a MTT assay. Firstly, the effect of the pure 
compounds, OL and SV, was assessed, and subsequently, that of the NLC dispersions, 
including unloaded NLC, SV-NLC, OL-NLC and Combo-NLC formulations. Hydrogel 
formulations, with and without permeation enhancers and Combo-NLC were also 
analyzed for completeness.  
SV and OL presented different behaviors in terms of cell toxicity, depending on the 
cells tested. OL is not cytotoxic in both Df and HaCaT cells on the range of 
concentrations tested, 7-216 μM (Table 4.10). SV is only cytotoxic for HaCaT cells in the 
range tested (5-161 μM), presenting an IC50 of 12.±1 μM (Table 4.10). This value is not 
significantly altered in the presence of OL (IC50 13.±1 μM, see Table 4.10). The NLC 
encapsulating 10 μM of SV (Figure 4.12), either alone or co-encapsulated with OL at the 
same concentrations, present a cytotoxicity similar to that of the free drug, which is 
compatible with release throughout the assay.  
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Table 4.10 IC50 calculated for the drug solutions considered in the cytotoxicity studies 
using Df and HaCaT cell lines.  
IC50 (μM) 
Drug solution 
                    Cell lines 
Df HaCaT 
OL >216 >216 
SV >161 12.±1 
OL+SV >161 13.±1 
 
 
Figure 4.12 Viability of HaCaT cells after 72 h of incubation with SV in the 
concentration of 10 μM, either in the free form or incorporated into the NLC. Results 
pertaining to the hydrogel permeation enhancers are also presented. For these 
formulations, a concentration of 7 μM of SV was considered as a result of the 
incorporation of enhancers. Data are expressed as mean±SD. (n=9) * p < 0.05 vs 
medium. 
 
The incorporation of NLC into the hydrogel did not increase the cytotoxicity, in 
contrast to what happens when ethanol and limonene were added to the formulation, in 
which some increase is observed. However, the respective amounts are generally 
reported as safe and used in different applications [75, 76]. Finally, the NLC hydrogel 
formulation containing both drugs and permeation enhancers did not result in additional 
cytotoxicity. Note that, according to the relevant OECD guideline [77], an irritant 
substance is predicted if the mean relative tissue viability is found below 50% of the 
mean viability of the negative controls for a 15-60 min exposition time. In the present 
assay, cells were exposed to test samples for 72 h with the cell viability above 50%, both 
for the NLC dispersion and gel. Thus, the formulations can be considered non-irritant. 
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The uptake by HaCaT cells of Nile red labeled Combo-NLC, both in dispersion and 
incorporated into the hydrogel containing the enhancers, was performed in order to 
assess the degree of NLC internalization (Figure 4.13). After 1h of incubation, the NLC 
aqueous dispersion led to a mean fluorescent intensity four times higher than that of the 
hydrogel (496 vs. 131, respectively). These results corroborate a good affinity and 
biocompatibility between the nanoparticles formulations and skin model cells. This 
conclusion holds even when internalization takes place, which is especially relevant in 
the case of contact with damaged skin. [78]  
 
 
Figure 4.13 Fluorescent microphotographies (40x) in Zeiss Microscope Axioskope 
40 (AxioCam HRc) of the nanoparticles Nile red labeled uptake by HaCaT keratinocyte 
cell line: (A) Combo-NLC; (B) Hydrogel Combo-NLC+Et+L (scale bar 20 µm).  
 
4.3.9 Stability studies 
 
The results pertaining to the physicochemical stability of the optimized formulation 
(Figure 4.14) reveal that the NLC size is not affected by storage temperature, within the 
range tested, and is not significantly altered after 6 months. The stability of the particles, 
indicated by the zeta potential, remains essentially unaltered, once stored at low 
temperature (4ºC). Regarding the entrapment efficiency, it remains higher than 95% for 
both drugs, although there is evidence of OL degradation when stored at 25ºC.  
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Figure 4.14 (A) Particle size, (B) zeta potential and (C) entrapment efficiency of the 
optimized formulation for six months. 
 
4.4 Conclusions 
 
Factorial design has proved to be a useful tool, both for rationalization of the system 
behavior and optimization of the formulation composition. NLC formulations were able to 
efficiently co-entrap olanzapine and simvastatin, and provide a reservoir system for long-
term administration. Molecular dynamics simulation provided direct insight on the 
mechanism of drug enhancement associated to some terpenes considered in the 
screening phase, and corroborated the experimental results. The combination of NLC 
plus ethanol and limonene yielded the best permeation rate, with a marked synergistic 
effect. In addition, the developed formulations can be considered non-irritant. 
Biocompatibility, the ability to sustainably deliver a broad range of APIs and the 
versatility to modulate formulation design turn these lipid nanoparticles into a delivery 
system very appropriate for a concomitant transdermal administration of olanzapine and 
simvastatin. 
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Chapter 5 
 
Development and validation of a rapid reversed-phase HPLC 
method for the simultaneous analysis of olanzapine and 
simvastatin in nanostructured lipid carriers 
 
 
 
 
5.1 Introduction 
 
The characterization of the Combo-NLC formulation described in the previous 
chapter requires a suitable and validated method for a critical assessment of 
pharmaceutical parameters such as drug content. Literature review reveals that HPLC 
methods have been reported for the quantitation of simvastatin [1] and olanzapine [2] 
separately, in combination with other drugs [3-5] and a few bioanalytical methods are 
also reported [6-9]. However, up to now, there have been no published reports about the 
simultaneous quantitation of simvastatin and olanzapine by HPLC in a pharmaceutical 
formulation. 
In the present chapter, the development and validation of a simple and time-saving 
RP-HPLC method with UV detection for simultaneous determination of OL, SV and SVA 
is described. The latter was also considered for analysis, since it is known that the 
lactone form of statins would be easily converted to their corresponding hydroxy acids in 
water and plasma, and the conversion would be enhanced in alkaline conditions [50]. 
The validated method was applied to quantify both the content of SV/SVA and OL 
incorporated in the NLC after preparation. 
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5.2 Materials and methods 
 
5.2.1 Materials 
 
Simvastatin (99.4%) was kindly provided by Labesfal - Laboratórios Almiro, S.A. 
(Santiago de Besteiros, Portugal). Olanzapine (98.9%) was purchased from Zhejiang 
MYJOY Import & Export Co.,Ltd (Hangzhou, China). Glyceryl tripalmitate (tripalmitin, 
T8127) and polysorbate 80 (Tween® 80) were purchased from Sigma. Oleic acid was 
acquired from Fluka. Carbopol® Ultrez 10 NF was a gift from Lubrizol (Quimidroga, 
Barcelona, Spain). All other reagents and solvents were from analytical or HPLC grade. 
 
5.2.2 Instrumentation and chromatographic conditions 
 
The HPLC analysis of OL, SV and the active form SVA was carried out in a 
Shimadzu LC-2010C HT apparatus (Shimadzu Co., Kyoto, Japan) equipped with a 
quaternary pump, a vacuum degasser, an autosampler, an oven and a variable 
UV/visible dual wavelength detector. The column used for the analysis was a Luna 
Phenyl-Hexyl, Phenomenex® (Torrance, USA), with 5 μm particle size, 3 mm internal 
diameter and 150 mm length, supported with a SecurityGuard™ cartridge Phenomenex® 
(Torrance, USA), with 3 mm internal diameter, in an oven at a temperature of 35ºC. The 
results were acquired and processed using Shimadzu LC-solution version 1.12 software. 
Chromatographic analysis was conducted in isocratic mode. The mobile phase consisted 
of a mixture of ammonium acetate aqueous solution 0.02 M:methanol:acetonitrile, 
30:35:35 (V/V/V), at a constant flow rate of 0.8 mL/min. A run time of 7 min was 
established for separation of the three compounds. The detection was carried out at 
230 nm. An injection volume of 10 µL was used for all standards and samples.  
 
5.2.3 Preparation of stock solutions, calibration standards and quality 
controls 
 
Three methanolic stock solutions at 1 mg/mL of OL, SV and SVA were prepared. The 
OL and SV stock solutions were prepared by accurately weighing approximately 10 mg 
of OL and SV in 10 mL of methanol. Regarding SVA, since it is reported that lactones 
are unstable at alkaline pH [10], it was obtained by alkaline hydrolysis of SV, according 
to references [11, 12]. Briefly, a SV methanolic solution of 2 mg/mL was firstly prepared. 
One volume of this solution was added to one volume of 0.04 M NaOH, heated at 60ºC 
for 45 min and kept overnight at room temperature. The mixture was subsequently 
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neutralized with 1M HCl, yielding a SVA solution with a concentration of ca. 1 mg/mL. 
The complete hydrolysis of SV was confirmed by the absence of the SV peak in HPLC. 
These results were also supported by LC-MS/MS, which presented a transition ion m/z 
at 459.5/343.3 in the positive-ion mode, comparable to what is reported in the literature 
[13]. Two working standard solutions containing OL, SV and SVA at concentrations of 
100 and 10 μg/mL were prepared by further dilution of each stock solution with mobile 
phase. Eight standard solutions (0.5, 1, 5, 10, 25, 50, 75 and 100 μg/mL) were obtained 
by appropriate dilution of the working standard solutions with mobile phase. As quality 
control (QC), six replicates of 0.5, 1.5, 50 and 100 μg/mL standards containing the three 
compounds were considered. For determination of the limit of detection (LD) and limit of 
quantitation (LQ) of the method, six standard solutions, namely, 0.1, 0.25, 0.5, 0.75, 1 
and 1.25 μg/mL were obtained from the 10 μg/mL working solution. All stock solutions 
were stored at -20 ºC and working solutions were freshly prepared each day. 
 
5.2.4 Method validation 
 
The HPLC method was validated according to the US Food and Drug Administration 
(FDA) regulations [14], including also some complementary aspects taken from the 
International Conference on Harmonization (ICH) guidelines [15]. The parameters 
considered for the validation included selectivity and specificity, linearity, accuracy, 
precision, recovery, limits of detection and quantitation, system suitability and stability.  
System suitability 
 
The system suitability parameters were determined by injecting six times the 
standard solution containing OL, SV and SVA at a concentration of 75 µg/mL. The 
acceptance limit was RSD ≤2% of the peak area and the retention time of the three 
compounds [16]. Other chromatographic parameters, such as capacity factor (k’), 
resolution (R) tailing factor (T) and theoretical plate number (N) were also analyzed [17]. 
The capacity factor is a measure of where the peak of interest is located with respect to 
the void volume, i.e., corresponds to the elution time of the non-retained components. R 
is a measure of the degree of separation of two peaks. The tailing factor is a measure of 
the peak symmetry, and the theoretical plate number is a measure of the column 
efficiency, that is, how many peaks can be located per unit run-time of the chromatogram 
[18]. 
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Limits of detection and quantification  
 
The limits of detection and quantitation were determined based on a specific 
calibration curve obtained from six standard solutions (0.1, 0.25, 0.5, 0.75, 1 and 1.25 
µg/mL) containing the three analytes at concentrations in the proximity of these limits 
values. LD and LQ were calculated according to LD = 3.3 σ/S and LQ = 10 σ/S, where σ 
is the standard deviation of the response and S is the slope of the calibration curve [15].  
Linearity  
 
Calibration curves were constructed with eight standard solutions, containing the 
three compounds simultaneously, ranging from 0.5 to 100 μg/mL. Linearity was 
determined through the calculation of a regression line by the method of least squares, 
representing the peak area as a function of the standard concentration. Data collected 
was analyzed using the Analysis ToolPak of Microsoft Excel® (Microsoft Corp., 
Redmond, WA) with linear regression by the least squares method. The analysis of the 
response factors, that is, the peak area divided by the concentration of each standard 
was also considered.     
Accuracy and precision 
 
Precision indicates the closeness of agreement, i.e., the degree of scatter between a 
series of measurements obtained from multiple sampling of the same homogeneous 
sample and it was determined by repeatability (intra-day) and intermediate precision 
(inter-day) for three consecutive days. Four standard solutions (quality controls), 0.5, 1.5, 
50 and 100 μg/mL, respectively, were prepared six times each and analyzed according 
to the proposed method (intra-day precision) and three consecutive days (inter-day 
precision). The relative standard deviation (RSD) determined at each concentration level 
should not exceed 15%, except for the lower limit of quantitation, where it should not 
exceed 20% [14]. 
The accuracy of the method expresses the closeness of agreement between the 
conventional true value and the value found. It was determined by measuring six 
replicates of the four quality controls and by calculating the percentage of bias for each 
compound according to the equation: % accuracy = observed concentration/nominal 
concentration) x 100. The mean value should be within 15% of the actual value, except 
at the LQ, where it should not deviate by more than 20% [3, 14]. 
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Specificity  
 
The specificity of a method may be defined as the ability to accurately measure the 
analyte in the presence of all potential sample components [17]. In this method, the 
response of OL, SV and SVA, the major metabolite of SV degradation was compared 
with the response of a solution containing only the analytes, and used as measure of its 
specificity. This comparison has been made both with the nanoparticles components and 
the respective supernatant, the latter containing excess of lipids and surfactants. 
Stability 
 
The stability of OL, SV and SVA quality controls was assessed after a short-term 
storage at room temperature (~25 ºC) for 12 h, after a long-term storage for 30 days at   
-20 °C, in order to simulate sample handling and after 24 h of storage in the autosampler 
for the autosampler stability. The effect of three freeze–thaw cycles on the stability of the 
analytes was also investigated. QC samples were stored at -20 °C for 24 h, thawed 
unassisted at room temperature and, when completely thawed, the samples were 
refrozen for 24 h under the same conditions until completion of the three cycles [14].  
 
Recovery 
 
The recovery of OL, SV and SVA from the nanoparticles supernatant was determined 
by comparing the respective concentrations with those of standard solutions in mobile 
phase at three concentration levels 1, 50 and 100 μg/mL by repeated analysis (n = 6).  
 
5.2.5 Method applicability 
 
Preparation of Combo-NLC dispersion  
 
The NLC were prepared by a hot high pressure homogenization technique, optimized 
as described in Chapter 4 [13].  
Determination of entrapment efficiency and drug loading  
 
The entrapment efficiency of SV and OL in the NLC was determined indirectly by 
calculating the total amount of drug and subtracting that of the free drug in the aqueous 
phase of the nanoparticle dispersion. The separation of the two phases was carried out 
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by ultrafiltration, using Amicon® Ultra-4 centrifugal filter units (Merck Millipore, Darmstadt, 
Germany) with a 100 kDa molecular weight cut-off. The amount of free drug present in 
the aqueous phase was collected in the outer chamber of the centrifugal unit after 
separation, suitably diluted with mobile phase, filtered by a 0.22 µm membrane and 
determined by HPLC. For the estimation of the total drug, a specific volume of NLC 
suspension was accurately taken, diluted with mobile phase and heated at 60 ºC for 
15 min. The dispersion was further centrifuged for 10 min at 11,740×g in a Minispin® 
(Eppendorf Ibérica S.L., Madrid, Spain), and the supernatant filtered by a 0.22 µm 
membrane and analysed by HPLC. The entrapment efficiency (EE) and drug loading 
(DL) were calculated using the Equations (2.3) and (2.4), respectively, as described in 
Chapter 2. 
As stated above, since statins exist, in general, in the lactone and hydroxy acid form, 
the respective conversion was taken into consideration, and both forms were quantified. 
Thus, SV entrapment efficiency is a result of the sum of SV (after stoichiometric 
conversion into SVA) and SVA contributions.  
 
5.3 Results and discussion 
 
5.3.1 Method development and optimization  
 
A high performance liquid chromatography method for the estimation of olanzapine, 
simvastatin and simvastatin acid in a nanoparticulate dosage form has been developed 
according to the principles of Good Laboratory Practices. Optimization trials were carried 
out using a Lichrospher C18, by testing different proportions of ammonium acetate 
aqueous solution (0.02M):methanol:acetonitrile. Since OL and SV are poorly water 
soluble and more soluble in organic solvents, a higher percentage of methanol and 
acetonitrile was considered to diminish the retention time. By changing the column to 
Phenyl-hexyl, the retention times became even shorter and the peaks sharper. The 
optimized mobile phase was 30:35:35 (V/V/V) of ammonium acetate aqueous solution 
0.02M:methanol:acetonitrile at a flow rate of 0.8 mL/min. For these conditions, 
simvastatin acid, olanzapine and simvastatin eluted at 1.7, 2.0 and 5.5 min, respectively. 
The method was validated over the range 0.5-100 μg/mL. 
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5.3.2 Method validation  
 
System suitability 
 
The RSD of peak area and retention time for OL, SV and SVA (Table 5.1, Figure 5.1) 
were lower than 2%, which indicates that the system is appropriate to simultaneously 
analyze the three compounds. The assessment of the column efficiency by the number 
of theoretical plates (N), the tailing factor (T), resolution (Rs) and capacity factor (k’) show 
that the peaks were symmetric and generally well resolved. Although a Rs ≥2 is reported, 
if the peaks are not significantly different in heights and possess nearly Gaussian 
shapes, the British Pharmacopoeia recommends Rs ≥1.5 [16] for their complete 
separation at the baseline level. 
 
Table 5.1 System suitability test parameters. 
Chromatographic 
Parameters 
OL (75μg/mL) SV (75μg/mL) SVA (75μg/mL) 
Acceptance 
criteria 
Retention 
time 
(min) 
Peak 
area 
Retention 
time 
(min) 
Peak 
area 
Retention 
time 
(min) 
Peak 
area 
Mean (n=6) 2.035 4877.466 5.662 2903.323 1.671 2834.957 - 
S.D. 0.008 23.228 0.033 18.022 0.012 33.826 - 
%RSD 0.41 2.04 0.59 0.62 0.71 1.19 ≤2.0%
a
 
Theoretical 
plates (N) 
1661 4951 1340 >1000
a
 
Capacity factor 
(k’) 
1.07 4.86 0.73 > 2.0
b
 
Tailing factor (T) 1.71 1.18 1.67 ≤ 2.0
b
 
Resolution (Rs) 1.76 1.98 1.86 > 2.0
b
 
a (Épshtein 2004), b(FDA 1994)  
 
 
 
Figure 5.1 Chromatogram of the standard 75μg/mL solution of OL, SVA, and SV 
considered for the assessment of the system suitability. 
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Limits of detection and quantitation 
 
The estimated LD for OL, SV and SVA were 0.07, 0.12 and 0.09 μg/mL, respectively. 
The LQ found for OL, SV and SVA were 0.22, 0.36 and 0.27 μg/mL, respectively. 
Linearity 
 
Linearity was evaluated over the concentration range 0.5-100 μg/mL for the OL, SV 
and SVA (Figure 5.2A, C, and E), estimating the regression equation and the 
determination coefficient (R2) obtained from the least squares method (Table 5.2). The 
coefficients of determination for the calibration curves of the three compounds were 
higher than 0.999, which is generally considered as evidence of an acceptable fit of the 
data to the regression line [15, 17], and indicating a good linearity over the concentration 
range proposed. Moreover, from the analysis of the response factors (Figure 5.2B, D, 
and F) a slope close to zero was obtained (-0.0389, -0.0054 and -0.0377 , for OL, SV 
and SVA, respectively) and a relative residual standard deviation of 3.29%, 3.37% and 
4.31%, thus confirming the method as linear [19, 20].  
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Figure 5.2 Linearity studies for the developed HPLC method: calibration curves 
obtained with OL (A), SV (C) and SVA (E) standard solutions, and response factor 
versus OL (B), SV (D) and SVA (F) standard solutions concentrations, respectively. 
 
Table 5.2 Results obtained from the regression analysis by the least squares method 
for OL, SV and SVA.   
Analyte Mean R2 ± S.D. 
Mean slope ± S.D. 
(n=6) 
Mean intercepta ± S.D. 
(n=6) 
OL 0.9996 ± 0.0003 57.8358 ± 4.1183 3.8553 ± 3.8012 
SV 0.9998 ± 0.0002 37.1250 ± 2.1538 -0.3705 ± 5.1047 
SVA 0.9994 ± 0.0007 35.8302 ± 1.0523 3.0684 ± 2.1422 
a 
Intercept is expressed in μg/mL. 
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Accuracy and precision 
 
Accuracy and precision for the quality controls in the intra-day and inter-day run are 
shown in Table 5.3. All the data fulfill the acceptance criteria. The intra- and inter-day 
RSD values did not exceed 9.014%. The intra- and inter-day bias values were found in 
the interval -2.11 to 3.08%, -1.429 to 7.575%, and -4.15 to 1.91%, for OL, SV and SVA, 
respectively. These data indicate that the developed method is accurate, reliable and 
reproducible, since neither RSD nor bias exceeded 15%, which is in agreement with 
acceptance recommendations [14]. 
 
Table 5.3 Intra-day and inter-day precision and accuracy results for OL, SV and 
SVA. (n=6)    
Nominal 
concentration 
(μg/mL) 
Intraday (n=6) Interday (n=18) 
Measured 
Concentration 
(μg/mL)  
Mean±SD 
Precision 
% RSD 
Accuracy 
% Bias  
Measured 
Concentration 
(μg/mL) 
Mean±SD 
Precision 
% RSD 
Accuracy 
% Bias  
OL (0.5) 0.489±0.029 5.852 -2.109 0.506±0.034 6.812 1.122 
OL (1.5) 1.501±0.068 4.560 0.086 1.546±0.123 7.948 3.076 
OL (50) 49.347±0.222 0.449 -1.307 49.386±0.362 0.733 -1.229 
OL (100) 99.764±1.467 1.470 -0.236 100.367±1.673 1.667 0.367 
SV (0.5) 0.523±0.019 3.662 4.541 0.506±0.043 8.494 1.291 
SV (1.5) 1.600±0.117 7.325 6.692 1.581±0.105 6.627 5.414 
SV (50) 49.286±0.158 0.321 -1.429 49.408±0.840 1.701 -1.185 
SV (100) 107.575±0.815 0.757 7.575 103.798±3.200 3.083 3.798 
SVA (0.5) 0.506±0.023 4.453 1.144 0.492±0.044 9.014 -1.682 
SVA (1.5) 1.529±0.070 4.577 1.905 1.487±0.083 5.572 -0.879 
SVA (50) 49.609±0.361 0.728 -0.781 49.035±0.614 1.251 -1.929 
SVA (100) 99.888±0.891 0.892 -0.112 95.852±3.082 3.215 -4.148 
 
Specificity 
 
The specificity of the method was analyzed both in the presence of components and 
the supernatant of the nanoparticles, containing excess of lipids and surfactants (see 
chromatograms, Figure 5.3A and B, respectively). As shown, neither the nanoparticles 
content or supernatant exhibit peaks interfering with those of the analytes, thus 
indicating that the method is specific. 
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Figure 5.3 (A) Chromatograms of nanoparticles components (black) and total 
Combo-NLC (red). (B) Chromatograms of nanoparticles (black) and Combo-NLC (red) 
supernatants.   
 
Stability 
 
The stability data for OL, SV and SVA under conditions likely to be found during the 
analytical process and sample storage included short-term, long-term, autosampler and 
freeze-thaw stability analysis and are gathered in Table 5.4. According to the results, it 
can be inferred that the analytes are stable under the studied conditions, since the % 
mean concentration found was within the acceptance limit (90-110%) [3].  
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Recovery 
 
The % recovery of OL, SV and SVA from the NLC supernatant was comprised 
between 93.32 and 102.55, 94.02 and 97.60, and 91.71 and 97.95, respectively (Table 
5.5). This indicates that the developed method is adequate to simultaneously quantify 
the three compounds. 
 
Table 5.5 Percentage of recovery of OL, SV and SVA from nanoparticles 
supernatant (n=6). 
%
 
R
e
c
o
v
e
ry
 Nominal concentration (μg/mL) 
Olanzapine Simvastatin Simvastatin acid 
1 50 100 1 50 100 1 50 100 
102.7 92.1 92.5 97.3 94. 9 92.5 91.6 93.8 92.4 
 
5.3.3 Method applicability 
 
The method developed was used to determine the content of OL and SV in NLC with 
a mean particle size of 150 nm and a zeta potential of ca. -36 mV. To calculate the 
entrapment efficiency of Combo-NLC, nanoparticles were submitted to ultrafiltration-
centrifugation and the free drug determined indirectly in the filtrate, as described in 
Section 5.2.4. A total percentage of 77.±2 for OL and 96.±4 for SV (corresponding to the 
joint contribution of SV and SVA) was obtained from the nanoparticles dispersion. This 
yielded an EE of 99.72±0.05% for SV and 97.0±0.5% for OL, which corresponded to a 
drug loading of 10.637±0.005% for SV and 10.34±0.05% for OL [13], thus making these 
carriers suitable for co-encapsulation of drugs with a different polarity. 
 
5.4 Conclusion 
 
A specific, linear, accurate, reliable and reproducible new method for the 
simultaneous quantitation of OL, SV and SVA, the active form of SV, was developed and 
fully validated over the range 0.5-100 μg/mL. The method was successfully applied to 
measure the drug content in Combo-NLC formulation after preparation. The optimized 
Combo-NLC dispersion with a mean particle size of ca. 150 nm and a zeta potential of -
36 mV, renders an entrapment efficiency in excess of 97% for both drugs, which 
indicates that these nanoparticles are efficient carriers for co-encapsulation. 
 
Chapter 5 – Development and validation of a rapid RP-HPLC method 
 
 152 
References 
 
1. Abu-Nameh, E.S.M., R.A. Shawabkeh, and A. Ali, High-performance liquid 
chromatographic determination of simvastatin in medical drugs. Journal of Analytical Chemistry, 
2006. 61(1): p. 63-66. 
2. Raggi, M.A., G. Casamenti, R. Mandrioli, G. Izzo, and E. Kenndler, Quantitation of 
olanzapine in tablets by HPLC, CZE, derivative spectrometry and linear voltammetry. Journal of 
Pharmaceutical and Biomedical Analysis, 2000. 23(6): p. 973-981. 
3. Ali, H. and S. Nazzal, Development and validation of a reversed-phase HPLC method for 
the simultaneous analysis of simvastatin and tocotrienols in combined dosage forms. Journal of 
Pharmaceutical and Biomedical Analysis, 2009. 49(4): p. 950-956. 
4. Reddy, B., K. Reddy, J. Sreeramulu, and G. Kanumula, Simultaneous Determination of 
Olanzapine and Fluoxetine by HPLC. Chromatographia, 2007. 66(1): p. 111-114. 
5. Zhang, G., A.V. Terry, Jr., and M.G. Bartlett, Simultaneous determination of five 
antipsychotic drugs in rat plasma by high performance liquid chromatography with ultraviolet 
detection. Journal of Chromatography B-Analytical Technologies in the Biomedical and Life 
Sciences, 2007. 856(1-2): p. 20-28. 
6. Carlucci, G., P. Mazzeo, L. Biordi, and M. Bologna, Simultaneous determination of 
simvastatin and its hydroxy acid form in human plasma by high-performance liquid 
chromatography with UV detection. Journal of Pharmaceutical and Biomedical Analysis, 1992. 
10(9): p. 693-697. 
7. Kim, B.C., E. Ban, J.S. Park, Y.K. Song, and C.K. Kim, Determination of Simvastatin in 
Human Plasma by Column‐Switching HPLC with UV Detection. Journal of Liquid 
Chromatography & Related Technologies, 2005. 27(19): p. 3089-3102. 
8. Dusci, L.J., L. Peter Hackett, L.M. Fellows, and K.F. Ilett, Determination of olanzapine in 
plasma by high-performance liquid chromatography using ultraviolet absorbance detection. 
Journal of Chromatography B, 2002. 773(2): p. 191-197. 
9. Boulton, D.W., J.S. Markowitz, and C.L. DeVane, A high-performance liquid 
chromatography assay with ultraviolet detection for olanzapine in human plasma and urine. 
Journal of Chromatography B, 2001. 759(2): p. 319-323. 
10. Yang, D.-J. and L.S. Hwang, Study on the conversion of three natural statins from lactone 
forms to their corresponding hydroxy acid forms and their determination in Pu-Erh tea. Journal of 
Chromatography A, 2006. 1119(1–2): p. 277-284. 
11. Suchocka, Z., J. Swatowska, J. Pachecka, and P. Suchocki, RP-HPLC determination of 
paraoxonase 3 activity in human blood serum. Journal of Pharmaceutical and Biomedical 
Analysis, 2006. 42(1): p. 113-119. 
12. Madan, J., V. Thakkar, A.K. Dwivedi, and S. Singh, Ion pairing RP-HPLC analytical 
methods for simultaneous estimation of simvastatin and its (a)over-cap-hydroxy acid. Journal of 
Scientific & Industrial Research, 2007. 66(5): p. 371-376. 
Chapter 5 – Development and validation of a rapid RP-HPLC method 
 
 153 
13. Vitorino, C., J. Almeida, L.M. Gonçalves, A.J. Almeida, J.J. Sousa, and A.A.C.C. Pais, Co-
encapsulating nanostructured lipid carriers for transdermal application: From experimental design 
to the molecular detail. Journal of Controlled Release, 2013. 167(3): p. 301-314. 
14. FDA, Guidance for Industry: Bioanalytical Method Validation.2001: US Department of 
Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and 
Research and Center for Veterinary Medicine. 
15. ICH, Guidance for industry: Q2B validation of analytical procedures, methodology, ed. E. 
Center for Drug, et al.1996, Rockville, MD: U.S. Dept. of Health and Human Services, Food and 
Drug Administration, Center for Drug Evaluation and Research: Center for Biologics Evaluation 
and Research. 
16. Épshtein, N.A., Validation of HPLC Techniques for Pharmaceutical Analysis. 
Pharmaceutical Chemistry Journal, 2004. 38(4): p. 212-228. 
17. Shabir, G.A., Validation of high-performance liquid chromatography methods for 
pharmaceutical analysis. Understanding the differences and similarities between validation 
requirements of the US Food and Drug Administration, the US Pharmacopeia and the 
International Conference on Harmonization. J Chromatogr A, 2003. 987(1-2): p. 57-66. 
18. FDA, Center for Drug Evaluation Research, United States. Food Drug Administration, 
Reviewer Guidance: Validation of Chromatographic Methods1994: U.S. Department of Health 
and Human Services, Public Health Service, Food and Drug Administration. 
19. das Neves, J., B. Sarmento, M.M. Amiji, and M.F. Bahia, Development and validation of a 
rapid reversed-phase HPLC method for the determination of the non-nucleoside reverse 
transcriptase inhibitor dapivirine from polymeric nanoparticles. Journal of Pharmaceutical and 
Biomedical Analysis, 2010. 52(2): p. 167-172. 
20. LoBrutto, R. and T. Patel, Method Validation, in HPLC for Pharmaceutical Scientists2006, 
John Wiley & Sons, Inc. p. 455-502. 
 
 
 
  
  155 
 
 
 
Chapter 6 
 
Nanostructured lipid carriers characterization 
 based on physicochemical, rheological and mechanical properties  
 
 
 
6.1 Introduction 
 
The incorporation of NLC into a hydrogel, the latter acting as a semi-solid vehicle to 
provide an appropriate formulation consistency for application upon the skin is a 
common approach in transdermal administration. Thus, in previous chapter, a hydrogel 
composed by NLC as drug reservoir combined with classical skin enhancers, ethanol 
and limonene, in proportions optimized in what pertains permeation rate, was developed.  
Carbopol® Ultrez 10 NF was selected as the gelling agent for the preparation of the 
hydrogel. It is a carbomer (cross-linked high molecular weight polyacrylic acid) 
interpolymer, i.e., a carbomer homopolymer or copolymer that contains a block 
copolymer of polyethylene glycol and a long chain alkyl acid ester. The selection of this 
polymer was based on its self-dispersion grade which enables ease of handling and 
processing, specifically for hydroalcoholic gels. It allows for a larger versatility in 
formulating and processing because it quickly wets, yet hydrates slowly. In comparison 
with traditional carbomer polymers, Carbopol® Ultrez 10 NF provides dispersions in 
water that are much lower in viscosity prior to neutralization, which enables easier 
handling while mixing with other components. Moreover, compatibility with many 
excipients with different polarities, such as ethanol and limonene, constitutes an 
additional advantage. The aqueous dispersions of the carbomer are acidic (pH~3 for 
0.5 % w/w aqueous dispersion). Consequently, when the pH of the solution is above the 
respective pKa (around 6, according to information from supplier), it leads to a sol-gel 
transition [1]. Since the polymer is neutralized, it is a highly efficient thickener [2]. 
Additionally, carbomer polymers are known to exhibit good bioadhesive, thermostable, 
and organoleptic properties which make the systems attractive both from a 
pharmaceutical point of view and with respect to the patient acceptance [3]. 
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The physicochemical properties of these nanocarriers are governed, among other 
factors, by the interface/external medium, which condition parameters with a real impact 
on the in vitro/in vivo performance, such as the loading capacity, the release and 
permeation rates. The contribution of each component in what pertains permeation 
enhancement was the target of a previous chapter [4]. How the different co-solvents 
interact with the nanoparticle formulation and contribute to the system stability and 
product performance is of paramount importance in the perspective of pharmaceutical 
development, and is now analyzed. In the present chapter, an understanding of such 
interactions and a rational for such behavior is provided by the monitoring of the particle 
size and zeta potential, rheological and textural analysis and sedimentation profile as a 
function of temperature and formulation composition. Finally, a rationale for the 
permeation enhancement mechanisms associated to the current strategies is provided, 
based on the use of both NLC and chemical enhancers and relying on occlusivity and 
infrared studies of the SC/NLC/enhancers system. 
 
6.2 Materials and methods 
 
6.2.1 Materials  
 
Glyceryl tripalmitate (tripalmitin, T8127) and polysorbate 80 (Tween® 80) were 
purchased from Sigma. Oleic acid and limonene were acquired from Fluka. Carbopol® 
Ultrez 10 NF was kindly provided by Lubrizol (Quimidroga, Barcelona, Spain). 
Simvastatin was a kind gift from Labesfal (Santiago de Besteiros, Portugal). Olanzapine 
was purchased from Zhejiang Myjoy (Hangzhou, China). All other reagents and solvents 
are of analytical grade. 
 
6.2.2 Preparation of NLC by the hot high pressure homogenization 
technique  
 
The NLC were prepared by the hot high pressure homogenization technique 
previously optimized [5]. Although the general method has been already described, it is 
mentioned again so as to introduce some particular aspects pertaining to the present 
chapter. Briefly, a pre-emulsion was obtained by the dispersion of the melted lipid phase, 
containing tripalmitin and oleic acid  in a 50:50 ratio (2.5 % w/V in relation to external 
phase), in 30 mL of a hot surfactant solution (Tween® 80, 3 % w/V, 80 ºC) through an 
Ultra-Turrax (Ystral GmbH D-7801, Dottingen, Germany) at 25000 rpm for 2 min. This 
hot pre-emulsion was further subjected to hot high-pressure homogenization (HPH) 
using an Emulsiflex®-C3 (Avestin, Inc., Ottawa, Canada) at 1000 bar for 2 min 30 sec. 
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The lipid dispersion thus obtained was cooled at 4 ºC to form the NLC formulations. In 
the Combo-NLC formulation, the addition of 80 mg of both drugs, simvastatin and 
olanzapine, was carried out in the initial lipid melted phase. It should be noted that at the 
pH of this formulation (ca. 6), the oleic acid molecule is negatively charged, while that of 
tripalmitin is neutral. It should be also stressed that Tween® 80 was chosen as emulsifier 
to avoid interference of clouding effects within the working range temperatures. 
 
6.2.3 Composition of the formulations and preparation of hydrogels  
 
To assess the influence of each component present in the final formulation, different 
hydrogels were prepared according to the composition depicted in Table 6.1. For the 
preparation of the hydrogels, Carbopol® Ultrez 10 NF, ethanol and limonene were added 
to the NLC dispersions or to water in the case of reference hydrogels, and left to hydrate 
under gentle magnetic agitation for 1 h. The Carbopol® dispersions were subsequently 
neutralized (pH 7-8), using triethanolamine, to promote gelation.  
All formulations was prepared as 70:30 (V/V) of NLC dispersion combined with 
ethanol, to which 5 % (w/V) of limonene and 0.5 % (w/V) of Carbopol® Ultrez 10 NF were 
added, yielding the percentages in weight depicted in the Table 6.1.  
For comparison purposes, dispersions were also assessed. Therefore, formulations 
Combo-NLC – Combo-NLC+Et+L in Table 6.1 were considered in the analysis. 
 
Table 6.1 Notation for the formulations, and respective composition (% w/w). The 
following key is used for the components: NLC=unloaded NLC; Combo-NLC=drug 
loaded NLC; Et=ethanol; L=limonene; Gel=Carbopol® Ultrez 10 NF. 
Formulation 
Carbopol
®
 
Ultrez 10 NF 
 
Ethanol Limonene NLC 
Combo 
NLC 
Water 
q.s. 
Combo-NLC - - - - 100  
Combo-NLC+Et - 25.9 - - 74.1  
Combo-NLC+L - - 4.8 - 95.2  
Combo-NLC+Et+L - 24.6 5 - 70.4  
Gel 0.5 - - - - 100 
Gel+Et 0.5 24.5 - - - 100 
Gel+Et+L 0.5 24.5 5 - - 100 
NLC+Et+L Gel 0.5 24.5 5 70 - - 
Combo-NLC+Et+L Gel 0.5 24.5 5 - 70 - 
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6.2.4 Particle size analysis 
 
Particle size was determined by dynamic light scattering, using a Delsa Nano C 
Submicron (Beckman Coulter, Krefeld, Germany) at a detection angle of 160º and a 
temperature range of 25 – 50 ºC, for increments of 5 ºC. The effect of the enhancers in 
the particle size was also assessed. Samples (Combo-NLC – Combo-NLC+Et+L and 
Combo-NLC+Et+L Gel) were suitably diluted with ultrapurified water. Each value was 
measured in triplicate. Results are presented as mean ± standard deviation. 
 
6.2.5 Mercury porosimetry 
 
Mercury porosimetry (MP) measures the intruded volume of mercury in relation to the 
mass of the sample at a specific pressure [6]. Thus, it allows to calculating the average 
pore sizes in the range of 5.5 nm and 360 μm and their distributions. Porosity is a useful 
parameter, since it can influence the rate the drug is released. Mercury intrusion 
measurements were made in lyophilized unloaded and loaded-NLC using a 
Micromeritics Autopore IV 9500 mercury porosimeter. Samples were frozen at -80ºC and 
lyophilized in a freeze-dryer (Lyph-lock 6 apparatus, Labconco) for 48 h.  Gas was 
evacuated from the samples until a vacuum of 50 mmHg, and the samples were then 
immersed in mercury. A low pressure test, with increments from 0.5 to 25 psi, and a high 
pressure test, with increments from 25 to 33000 psi were performed. Pore size 
distribution was estimated according to Washburn equation, which correlates the 
pressure applied with the pore diameter. 
 
6.2.6 Rheological experiments 
 
Rheological experiments were conducted in a Haake Mars III (Thermo Scientific, 
Dias de Sousa, Portugal) rheometer, equipped with a Peltier system as temperature 
control unit. For the tests, a C35 mm cone, with an angle of 1º probe was used.  
Rotational measurements were carried out at 25 ºC between 1 and 100 Pa of shear 
stress, in order to investigate the effect of each formulation component on the Newtonian 
viscosity. For the evaluation of the thermal behaviour a constant shear stress of 0.25 Pa 
for the NLC dispersions and 8 Pa for hydrogels was used in steady state and within a 
temperature range of 20 ºC - 50 ºC interval, with increments of 5 ºC.  
Oscillatory measurements were also performed to study the structure of the materials 
at small deformations. The small amplitude dynamic tests provide information about the 
linear viscoelastic behaviour of materials [7, 8]. G’ and G’’ can be extracted from 
oscillatory tests. G’ is the storage (elastic) modulus, which is a measure of the energy 
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stored and recovered per cycle of deformation and reflects the solid-like component of 
the viscoelastic behaviour of the material, while G’’ is the loss (viscous) modulus, which 
is a measure of the energy lost per cycle and reflects the liquid-like component. In 
addition to the storage and loss moduli, an important consideration in oscillatory analysis 
is the loss tangent (tan δ), a dimensionless term that describes the ratio of the loss 
modulus (G’’) to the storage modulus (G’) and which may be usefully employed to 
convey information concerning the structure of the polymeric system in question. As the 
loss tangent approaches zero, the elastic structure of the system predominates, 
whereas, if the loss tangent exceeds unity, the system is considered to be primarily 
viscous [9]. The stress sweep tests were performed to find the resistance to deformation 
at a constant frequency of 1 Hz. The complex viscosity modulus η , a mathematical 
representation of the viscosity in oscillatory tests, was also obtained. The effect of 
temperature (25 ºC – 50 ºC, with increments of 5 ºC) was still assessed. 
 
6.2.7 Texture profile analysis 
 
A Texture Analyzer TA.XT Plus (Stable Micro Systems Ltd., Surrey, UK) was used to 
examine textural characteristics (hardness, elasticity, compressibility, adhesiveness and 
cohesiveness) of the hydrogels. TPA mode was carried out using an analytical probe 
(P/10, 10 mm Delrin) which was twice depressed into the sample at a defined rate 
(5 mm/s) to a desired depth (15 mm), allowing 15 sec of delay between consecutive 
compressions. The samples were placed into cylindrical tubes of the same dimension (at 
a fixed height). Six replicates were performed at 25 ºC in the temperature controlled 
Peltier Cabinet for each formulation. An analysis at 32 ºC, to simulate skin surface 
temperature, was also conducted (n=6) for the optimized formulation (Combo-NLC+Et+L 
Gel). Data collection and calculation were performed using the Texture Exponent 3.0.5.0 
software package of the instrument.  
 
6.2.8 Stability studies 
 
Analytical centrifugation 
 
Adding a new component can, to some extent, condition the stability of a formulation. 
This technique allows to retrieve stability information, even for colloidal systems, as the 
nanocarriers studied here. The multisample dispersion analyzer LUMiSizer (LUM GmbH, 
Berlin, Germany) was used to characterize the stability of the Combo-NLC, Combo-
NLC+Et+L and Combo-NLC+Et+L Gel formulations. This technique uses an analytical 
centrifugation system that measures the intensity of transmitted near infrared (NIR) light 
Chapter 6 – NLC characterization 
 
 
160 
while the sample is being centrifuged. The data are displayed in function of the radial 
position, as distance from the centre of rotation (transmission profiles). The shape and 
progression of the transmission profiles contains the information on the kinetics of the 
separation process by detecting changes in light transmission at any part of the sample, 
or by following the movement of any phase boundary [10-12]. From the kinetics of 
transmission profiles, the demixing behaviour and/or the dispersion stability can be 
traced.  
The stability of the three formulations indicated above was firstly analysed after 
3 h 30 min of centrifugation, at an acceleration of 2300 x g and 15 ºC. Subsequently, the 
time of centrifugation was increased up to 12 h for the two more stable formulations. 
Finally, the effect of temperature was assessed only in the most stable formulation. 
 
Zeta potential analysis 
 
The effect of the addition of each component on the zeta potential value was also 
assessed by electrophoretic light scattering through a Delsa Nano C Submicron 
(Beckman Coulter, Krefeld, Germany) at 25 ºC. The ZP was calculated using the 
Helmholtz–Smoluchowsky equation. For the measurements, samples (Combo-NLC, 
Combo-NLC+Et+L and Combo-NLC+Et+L Gel) were diluted appropriately with 
ultrapurified water. 
 
6.2.9 In vitro skin occlusivity test 
 
In order to study the effect of Combo-NLC on skin occlusivity, an in vitro occlusion 
test was performed. [13, 14] According to this test, the evaporation of water through a 
membrane was measured and the occlusion factor,  , was calculated. For that, beakers 
(50 ml) were filled with 30 g of water, covered with filter paper (cellulose acetate filter, 
90 mm, whatman nº6, cutoff size 3 μm), and sealed. 600 μL of NLC were spread 
homogenously with a spatula on the filter surface of 15.9 cm2 and stored at 32 ºC for 
48 h to simulate skin surface temperature. The weight of water remaining in the beakers 
was monitored at 6, 24 and 48 h. Beakers in the same conditions, but covered with 
600 μL of water was used as reference. [15] The tests were conducted in triplicate. The 
occlusion factor   of Combo-NLC was calculated according to the equation  
     (     )                                           (6.1)  
wherein   is the water loss without sample (reference) and   the water loss with 
NLC. An   value of 0 indicates no occlusive effect compared to the reference, while an   
value of 100 corresponds to maximum occlusiveness. 
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6.2.10 Attenuated total reflectance – Fourier transform infrared 
spectroscopy 
 
The effect of the Combo-NLC coupled with the selected ethanolic terpene upon the 
skin was also inspected. For that, epidermal samples were treated with this formulation 
for 48 h, washed and dried in a desiccator for 24 h [16]. The samples were then 
subjected to ATR–FTIR study using an FT-IR/FT-NIR spectrometer (Spectrum 400, 
Perkin-Elmer, Massachusetts, USA) with an ATR accessory fitted with a ZnSe crystal 
plate. The dried epidermal sheets were placed in the ATR device stratum corneum side 
down, and measured using 16 scans for each spectrum, with a resolution of 4 cm-1 and a 
scan speed of 1 cm/s. Spectra were collected in triplicate between 4000 and 650 cm-1. 
The C–H stretching, C=O stretching, and amide peak absorbances were analyzed for 
each sample [17]. Epidermal samples without treatment were considered for control. 
 
6.3 Results 
 
6.3.1 Mercury porosimetry 
 
Mercury porosimetry was first carried out, in order to investigate the porosity of the 
particles before and after drug incorporation. This is a parameter with particular interest, 
since it can affect the capillary action of the dissolved drug and consequently, influence 
the rate of release of drugs from nanoparticles. Thus, drug release is affected not only by 
particle size, but also by the respective porosity. Unloaded-NLC and Combo-NLC 
presented an average pore diameter of 9.4 nm and 9.8 nm, corresponding to a porosity 
of 6.040% and 7.085%, respectively. According to the results obtained, it can be inferred 
that the porosity after drug loading only slightly increased. This indicates that the 
composition remains generally unaltered, suggesting that the nanoparticles are quite 
stable. 
 
6.3.2 Particle size 
 
Size control and nanoparticle growth are important considerations when preparing 
NLC dispersions, and monitoring their evolution has to be taken when designing a 
formulation. The results obtained from particle size analysis as a function of temperature 
for NLC are shown in Figure 6.1a. The rise in the temperature up to 50ºC promoted an 
increase in the mean NLC particle size, although the polydispersity index (PI) remained 
between 0.10 and 0.15, the particles keeping their colloidal nature. This evidences the 
stability of the NLC when submitted to a heating procedure. 
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DLS results from the analysis of the formulations Combo-NLC – Combo-NLC+Et+L 
Gel revealed different effects of the enhancers addition on the particle size (Figure 6.1b). 
Ethanol generally tended to increase particle size, in contrast with limonene, which did 
not affect this parameter. The former effect seems to be associated to a swelling 
mechanism. The subsequent incorporation of the NLC into the hydrogel led to further 
increase in particle size. This may be ascribed to the existence of carbomer/NLC 
interactions, promoting bridging and particle aggregation. The nature of this interaction 
will be discussed below. Note, however, that the PI remained lower than 0.25, which 
reflects relatively low differences between particle sizes within the formulation, 
differences which could otherwise trigger potential problems in terms of stability of the 
system [18]. 
 
 
Figure 6.1 (A) Influence of temperature in the mean particle size of the Combo-NLC 
dispersion. (B) Particle size and polydispersity index for different formulations, including 
those with addition of permeation enhancers and gelling agent.   
 
6.3.3 Rheological measurements 
 
In order to understand the influence of the co-solvents in the steady-shear 
rheological behaviour of NLC as liquid dispersion, the measurement of the viscosity as a 
function of the stress applied and temperature was firstly carried out. According to Figure 
6.2a, the addition of ethanol to the formulations promoted an increase in viscosity. This 
result seemed to be consistent with the increase in particle size observed above, 
supporting the swelling mechanism of the particles promoted by ethanol. The same 
behaviour was observed when a screening of temperatures was performed (Figure 
6.2b).  
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 Figure 6.3 Dependence of shear viscosity on the shear stress, measured one week 
after the preparation of the dispersions (A) and hydrogels (C), at 25 ºC, and as a function 
of the temperature for a constant shear stress of 0.25 Pa (B) and 8 Pa (D), respectively. 
Note that an additional formulation containing 3% (V/V) of Tween® 80 (Cp/T/E/L) was 
introduced in (C), for comprehension of the system. 
 
The influence of the NLC, ethanol and limonene in the rheological properties of a 
0.5 % (w/V) Carbopol® Ultrez 10 NF hydrogel was subsequently investigated [19].  The 
inclusion of less hydrophilic co-solvents, such as ethanol and limonene led to a decrease 
in the viscosity (Figure 6.2c). It is known that the polymer conformation and thus the 
polymer entanglement and the gelation strongly depend on the compromise between 
polymer-polymer and polymer-solvent interactions [8, 20, 21]. Thus, a more apolar bulk 
will induce contraction of the polymer chains and reduction of the entanglements, giving 
rise to a less ‘viscous’ system. The yield stress, i.e., the onset of shear thinning 
behaviour was also lower for the hydrogels containing ethanol. The role of ethanol is 
therefore complex, and while it suggests inducing a swelling effect, and thus an increase 
in viscosity in polymer-free dispersions, it determines the opposite behaviour when the 
polymer is present, probably due to some dehydration [22].  
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The further inclusion of the NLC in the system disrupts or weakens even more the 
polymer network, as seen by a more marked decrease in the shear viscosity. This may 
be partially ascribed to the action of Tween® 80, as illustrated by the difference between 
the Gel+T+Et+L and Combo-NLC+Et+L Gel rheograms (Figure 6.2c). The surfactant-
polymer binding occurring mainly through a hydrogen-bonding interaction seems to be 
the mechanism that leads to the polymer aggregation (Figure 6.3a). This behaviour has 
already been reported for similar systems [23].  
Note, however, that the nanoparticles as a whole promoted a further decrease in 
viscosity (Figure 6.2c). Polymer/nanoparticle hydrophobic interactions as a result of the 
lipid nature of the latter, can be pointed out as the prevalent mechanism, combined to 
polymer/surfactant H-bonding at the particle surface [23]. Polymer-rich domains are thus 
created, perturbing the polymer network (see Figure 6.3b). This behavior contrasts to 
some reports [24-26] in which NLC are used as viscosity enhancers, probably due to the 
high concentrations employed and the increasing of the inter-particle adhesive forces. 
Temperature effects are described in Figure 6.2d. An increase in the temperature 
generally resulted in a decrease in the viscosity, being this effect more evident for non-
NLC hydrogels. The maximal viscosity present at ca. 25ºC for the formulations without 
NLC disappeared when the particles are present. It should be stressed, however, and 
from an application point of view, that the viscosity of the NLC hydrogels is adequate for 
use as a transdermal delivery system within the physiological temperature range. 
Chapter 6 – NLC characterization 
 
 165 
 
Figure 6.3 Schematic representation of the NLC (A) and surfactant (B) effects upon 
polymer gelling agent network. Note that the micelles and NLC structures are not drawn 
to scale. In (A), interaction between NLC and the carbomer produces both particle 
aggregation, visible as an increase in the mean particle size, and partial disruption of the 
polymer network, promoting a lower viscosity. In panel (B), a decrease in size is 
represented for each carbomer chain, resulting in less interchain entanglement and, 
again, lower viscosity. 
 
Figure 6.4 describes the influence of shear rate on shear stress, from which the yield 
stress, ie. the stress applied in order to make system start to flow could be extracted. 
The yield values for NLC hydrogels were substantially lower, compared with the non-
NLC hydrogels, which is clearly consistent with the trends reported above for viscosity. 
This again emphasizes the polymer compaction as a result of the interaction of the less 
hydrophilic components with the gelling agent. Also, the rheological analysis of 
hydrogels containing NLC shows a typical pseudoplastic behavior, which makes them 
convenient for transdermal purposes. 
 
A 
B 
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Figure 6.4 Dependence of shear stress on shear rate. The inflexion point of the 
curves corresponds to yield stress.  
 
These trends were verified through oscillatory (dynamic) rheology experiments (see 
Figure 6.5), where the addition of ethanol and limonene, has again reduced the 
interactions between the polymer and the solvent (water), as shown by the decline in the 
storage modulus (G’) curve. However, the system maintained the gel structure (solid 
character, G’>G’’) due to the presence of the gelling agent, which assured elasticity 
enough for the tested stresses range (G’=G’’ for higher shear stresses, see Figure 6.5), 
irrespective of the presence of the enhancers. In turn, the incorporation of NLC 
conducted to a sharper decrease in G’, and a loss of the elasticity for the lower stresses 
applied was visible.    
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Figure 6.5 Dependence of storage (G’) and loss (G’’) moduli on shear stress, 
determined at 25ºC. A) Gel; B) Gel+Et; C) Gel+Et+L; D) NLC+Et+L Gel; E) Combo-
NLC+Et+L Gel. All the experiments were carried out at 25 ºC, with exception of the 
optimized formulation (Combo-NLC+Et+L Gel), for which the temperature of 32 ºC was 
also considered.  
 
The dependence of loss tangent (Tan δ) on the applied stress, which is obtained by 
the  G’’/G’ ratio, corroborated the considerations described above, showing that lower 
values of shear stresses are needed to attain loss tangent values higher than 1, in the 
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hydrogels containing NLC (Figure 6.6). This indicates that the viscous component of the 
system predominates upon the elastic, and the system lost its gel structure earlier. 
 
Figure 6.6 Dependence of loss tangent (Tan δ) on the applied stress. 
 
The storage modulus was also sensitive to temperature (Figure 6.5e). The elasticity 
values, as well as the viscosity, dropped at 32ºC (reporting to the skin temperature), 
which may be associated to a better spreadability. 
Aditionally, the presence of the drugs in the optimized system (Combo-NLC+Et+L 
Gel in comparison with NLC+Et+L Gel), increased the shear stress for which G’=G’’ 
(Table 6.3).  
 
Table 6.3 Shear stress for which storage modulus (G’) equals loss modulus (G’’), as 
a function of the temperature, for hydrogels containing NLC.  
Temperature (ºC) 
NLC+Et+L Gel 
Shear stress (Pa) G’=G’’ 
Combo-NLC+Et+L Gel 
Shear stress (Pa) G’=G’’ 
25 15.54 43.34 
30 12.12 25.92 
32 14.46 27.31 
35 10.97 19.86 
40 16.42 25.31 
45 17.85 24.72 
50 17.57 24.43 
 
Analyzing now the effect of the temperature upon the optimized formulation with and 
without drugs (Figure 6.7), it can be inferred that for a fixed stress of 0.1 Pa, the system 
properties (complex viscosity, G’, and G’’), and thus its microstructure were generally not 
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affected by temperature. This indicates that hydrogels containing NLC keep their stability 
over the temperature range typical for a transdermal administration.  
 
 
Figure 6.7 Complex viscosity of (A) NLC+Et+L Gel and (B) Combo-NLC+Et+L Gel 
formulations as a function of the temperature and its correlation with G’ and G’’, for a 
shear stress of 0.1 Pa.  
 
6.3.4 Texture profile analysis 
 
Carbomer physical properties strongly affected the rheological behaviour of the 
formulations, which may influence adhesion on the application area and thus 
compromise drug release rates. Focusing now on a characterization directed to a 
pharmaceutical application and product performance, so as to complement the more 
fundamental approach carried out so far, mechanical properties of formulations are 
presented. Texture profile analysis (TPA) is an adequate and straightforward method for 
the mechanical characterization of semisolid drug dosage forms, and to assess the 
influence of the different components on hydrogel properties. Through TPA mode, 
parameters such as compressibility, hardness, adhesiveness, elasticity and 
cohesiveness can be extracted from the compression graphs. The results are presented 
in Table 6.4.  
Pertaining to gel hardness, which expresses the ease with which the gel is applicable 
on the skin, a slight decrease was observed when the enhancers, ethanol and limonene, 
were added. In turn, the subsequent addition of NLC caused an abrupt decline in this 
parameter. According to previous studies, the hardness values obtained in this work are 
acceptable for skin gel application [27-29]. This is due to a lower viscosity associated to 
a decrease in the degree of polymer entanglement, as extracted from the rheological 
results. The same trend was observed for compressibility and adhesiveness, which are 
correlated to the spreadability of the gel on the skin surface and bioadhesion, 
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respectively [29]. Again, the results reflect an easier application and a lower adhesion, 
although the latter is sufficient to keep the formulation in contact with the skin. This is 
compatible with an increase in the number of free carboxylic acid groups present on the 
polymer chains [30]. It should be stressed that the compressibility value must be low to 
extract the prepared gel from the container and to easily spread it on the skin [31]. For 
the elasticity value, which is defined as the rate at which the deformed sample returns to 
its original condition after the removal of the deforming force, a slight decrease after NLC 
incorporation was observed. It is described that lower quantitative values of elasticity 
obtained from TPA indicate a larger gel elasticity [30]. Thus, it can be inferred that the 
NLC contribute to an increase of hydrogel elasticity. Regarding cohesiveness, it provides 
information on the structural reformation following gel application, and usually, a high 
value is associated with a full structural recovery [29, 32]. The analysis of the present 
results indicated that the addition of enhancers and NLC to the reference hydrogel did 
not impact this parameter, and the values obtained are suitable for skin application.  
When the temperature was increased from 25 ºC to 32 ºC, the usual temperature at 
the skin surface, only compressibility and hardness seemed to be affected, with a 
decrease associated to that of the viscosity. This decrease again reflects a better 
performance when applying the hydrogel to the skin.  
 
Table 6.4 Mechanical properties of the Gel – Combo-NLC+Et+L Gel formulations 
extracted from the TPA mode. Results are indicated as a mean of six replicates ± 
standard deviation. 
Formulations 
Compressibility 
(g.sec) 
Hardness 
(g) 
Adhesiveness 
(g.sec) 
Elasticity 
Cohesiveness 
 
Gel 25ºC 13.±2 16.0±0.5 -12.±3 0.52±0.04 0.92±0.04 
Gel+Et 25ºC 10.±1 12.0±0.2 -11.±2 0.48±0.05 0.91±0.06 
Gel+Et+L 25ºC 11.±2 11.8±0.7 -9.±3 0.59±0.07 0.94±0.09 
NLC+Et+L Gel 
25ºC 
0.9±0.1 0.3±1.7 -3.0±0.9 0.25±0.02 0.9±0.2 
Combo-NLC+Et+L 
Gel 25ºC 
3.0±0.3 3.1±0.7 -3.±2 0.40±0.02 0.99±0.09 
Combo-NLC+Et+L 
Gel 32ºC 
1.8±0.3 0.2±0.2 -3.±1 0.30±0.02 0.9±0.1 
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6.3.5 Stability studies 
 
Analytical centrifugation 
 
The stability of Combo-NLC, Combo-NLC+Et+L and Combo-NLC+Et+L Gel 
formulations was assessed, in order to investigate the effect of the addition of each 
component on the sedimentation kinetics of the final formulation. A preliminary test was 
conducted for the three formulations at an acceleration of 2300 x g for 3 h 30 min. Figure 
6.8a illustrates the set of transmission profiles obtained for Combo-NLC. The 
transmission profiles are representative of the variation of particle concentration inside 
the sample (low transmission means high concentration, and conversely) [11]. According 
to this test, in the Combo-NLC dispersion a separation occurred since the first 
centrifugation cycle (indicated by the high transmission of the red profiles) being more 
evident as time elapses, as shown by the narrower distance between consecutive green 
profiles. Such behavior is indicative of the sedimentation profile of a suspension. The 
sediment formed exhibits a low height, which is in good agreement with the DLS 
findings, and are compatible with both a low polydispersity index and a low particle size.  
Figure 6.8b shows the kinetics of the evolution in the zones of clarification, displayed 
against the measuring time, and revealed the appearance of a creaming layer in the top 
of the cell. This indicates that the addition of the enhancers contributes to delay the 
separation process, and the character of the dispersion changes, becoming closer to an 
emulsion. Finally, the addition of the gelling agent, as depicted in Figure 6.8c clearly 
contributed to an increased stability, since there was no evidence of a separation 
process. For a better comparison between different systems, the dispersion stability can 
be quantitatively described by the instability index. This parameter is indicative of the 
overall demixing of each sample. Numbers close to 1 represent completely or almost 
completely demixed samples, numbers close to 0 indicate no or very slow demixing 
during the measurement. The analysis of this parameter (Figure 6.8d) also allows to 
order the formulations according to increasing stability as Combo-NLC<Combo-
NLC+Et+L<Combo-NLC+Et+L Gel.  
A second test with an extended time of centrifugation was performed, in order to 
further assess the two more stable formulations (Figure 6.9a, b and c). This test revealed 
that the gel kept its structure and integrity, even after 12 h of centrifugation at 2300 x g, 
since no high transmission zones were evident.  
Finally, the temperature effect from 15 °C until 30 °C with increments of 5 °C on the 
optimized gel formulation (Combo-NLC+Et+L Gel) was assessed (Figure 6.10). 
Comparing the instability index curves, only at 30 °C, some separation was observed. 
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Note that an increase in the temperature has generally resulted in a decrease in the 
viscosity, as extracted from rheological and mechanical results (sections 3.2 and 3.3) 
above reported. The results allow to conclude that when stored between 15 to 25ºC, the 
gel maintains its structure.   
  
 
Figure 6.8 Evolution of transmission profiles of the a) Combo-NLC, b) Combo-
NLC+Et+L, c) Combo-NLC+Et+L Gel formulations. The corresponding sequences of 
profiles are shown from red for the first profiles to green for the last ones. d) Instability 
indexes of Combo-NLC, Combo-NLC+Et+L, and Combo-NLC+Et+L Gel formulations, 
submitted to an acceleration of 2300 x g for 3 h 30 min.  
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Figure 6.9 Progression transmission profiles of (A) Combo-NLC+Et+L, and (B) 
Combo-NLC+Et+L Gel formulations submitted to an acceleration of 2300 x g for 12 h. 
(C) Instability indexes of the formulations previously referred. 
 
 Figure 6.10 (A) Instability indexes of the gel formulation (Combo-NLC+Et+L Gel) 
submitted to an acceleration of 2300 x g for 12h at temperatures of 15ºC, 20ºC, 25ºC 
and 30ºC, respectively. (B) Progression transmission profiles of the gel formulation 
(Combo-NLC+Et+L Gel) submitted to an acceleration of 2300 x g for 12 h at 30 ºC. At 
the end of the test, three distinct layers are evident: (1) creaming layer (2) stable layer, 
and (3) sediment layer. 
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Zeta potential 
 
The determination of zeta potential was performed to assess the influence of each 
enhancer and gelling agent in the system stability, so as to complement the previous 
transmission information (Table 6.5). NLC presented a negative zeta potential value, 
which might be attributed to the oleate molecules and polar groups of Tween® 80. The 
addition of ethanol and limonene tended to promote more negative zeta potential values, 
which stabilized the dispersion. The reason for this behavior may be explained by the 
slight increase in the pH when ethanol or limonene were added, which leads to an 
increase in the ionization of oleic acid. However, when Carbopol® Ultrez 10 NF hydrogel 
was added, zeta potential values became much more negative, as a result of the 
presence of carboxylate groups, leading to a more stable system. These results are in 
good agreement with LUMisizer analysis and rheological results. Note that the lowest 
zeta potential values are found for systems in which both carbopol and NLC are present, 
which is compatible with the model depicted in Figure 6.4(a). The drug loaded 
nanoparticles presented, in general, a slightly more negative or almost unchanged zeta 
potential relative to the unloaded nanoparticles (data not shown).  
 
Table 6.5 Influence of enhancers and hydrogel into zeta potential value of NLC.  
Formulations Zeta Potential (mV) pH 
Combo-NLC -29.2±0.6 6.2 
Combo-NLC+Et -35.±2 6.5 
Combo-NLC+L -38.±1 6.6 
Combo-NLC+Et+L -39.3±0.7 7.0 
Combo-NLC+Et+L Gel -68.±1 7.3 
Gel+Et+L -47.2±0.8 7.7 
 
6.3.6 Interaction with the skin  
 
As previously reported, it is generally accepted that the NLC act by promoting 
occlusion, as a consequence of a thin film formation with the stratum corneum (SC) [33, 
34]. On the other hand, the ethanolic solution of limonene promotes an alteration of the 
barrier properties of the SC [35]. To support these mechanisms, an in vitro occlusion test 
and ATR-FTIR measurements were performed.   
ATR-FTIR spectra of control (untreated skin) and newborn pig epidermis treated with 
Combo-NLC+Et+L Gel formulation after 48 h are shown in Figure 6.11. The spectra 
show a broad absorbance at 2100-3500 cm-1 due to O–H stretching vibrations, major 
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absorptions bands at 2920 and 2852 cm-1, due to asymmetric and symmetric C–H 
stretching, respectively, a strong band at 1642 cm-1 due to C=O stretching vibrations of 
amide I band, and one at 1535 cm-1 due to N-H bending vibrations of amide II. The ATR-
FTIR spectrum of the treated epidermis depicts a clearly lower intensity in the OH band, 
which is probably the result of an interaction with ethanol coupled with the NLC occlusion 
effect, suggesting a certain degree of lipid extraction, see panel (a). In the region of the 
C–H stretching, a decrease in the intensity of the bands may be ascribed to the 
interaction of the limonene with the ceramide tails. In panel (b), changes in the amide I 
and II region are also evident, which points to some interaction with the protein domain 
(see Section 4.3.5). 
 
 
Figure 6.11 ATR-FTIR spectra of untreated skin and skin treated with the Combo-
NLC dispersion, containing ethanol and limonene in the (A) regions of O–H and C–H 
stretching and in the (B) regions of amide I and II.  
 
In Figure 6.12 the results pertaining to the occlusion factor are depicted. Some 
occlusive effect from the nanoparticles is noticeable, especially in the first 6 hours. For 
longer periods, this effect becomes less pronounced, but remains essentially constant 
after 24 h. 
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Figure 6.12 Occlusion factor of Combo-NLC at different times after application. 
 
6.4 Conclusions 
 
A full characterization in terms of particle size, rheological and mechanical properties, 
and physicochemical stability is provided for a NLC formulation intended for transdermal 
administration. NLC particle size does not significantly vary with the composition of the 
formulation. The rheological characterization indicated that ethanol, limonene, and NLC 
led to a subsequent decrease in polymer entanglement that resulted in a loss of hydrogel 
viscosity. Changes in the polarity of the medium and dehydration effects concur for these 
observations. Mechanical properties elucidated by the texture profile analysis confirmed 
the rheological findings and indicated that the optimized formulation was suitable for skin 
application. The inclusion of enhancers and the incorporation of NLC into a hydrogel 
network promoted an increase in the physicochemical stability of the overall system. 
From a pharmaceutical and technological point of view, the results obtained allowed 
insight into important features that can modulate and impart formulation performance, 
particularly in the release and permeation behavior. This was confirmed by the 
interaction with the SC promoted by the final formulation. 
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Chapter 7 
 
Passive and active strategies for transdermal delivery using  
co-encapsulating nanostructured lipid carriers:  
in vitro vs. in vivo studies 
 
 
 
7.1 Introduction 
 
The work described in this chapter is the corollary of the different stages for the 
development of a final formulation, that is to be assayed in a pharmacokinetic study for 
the assessment of transdermal performance. 
Numerous passive and active methods or the combination of both have been used to 
enhance the drug skin permeation [1]. Within passive methods, the combined use of lipid 
nanoparticles and chemical enhancers has emerged as a promising strategy to improve 
drug permeation [2]. The active microneedle-mediated delivery of nanoparticles into the 
skin has been regarded as an appealing method to potentiate drug transport through the 
skin [3, 4].   
This chapter is designed in three distinct, but complementary parts. Firstly, the 
development of an appropriate NLC formulation, based on two different methods of 
production, solvent emulsification-evaporation and high pressure homogenization, for the 
coencapsulation of olanzapine and simvastatin is presented. Secondly, in vitro release 
studies with kinetic analysis and in vitro permeation are established. In vitro drug release 
fitted with different mathematical models elucidates the mechanisms involved in drug 
release, important to understand the in vivo performance of the dosage form. In vitro skin 
experiments range not only the assessment of the NLC and NLC combined with 
chemical enhancers formulations, but also the influence of NLC while aqueous 
dispersion or as semi-solid formulation using a hydrogel as transdermal vehicle. Thirdly, 
in vivo pharmacokinetic studies in rats are conducted in order to examine the ability of 
the aqueous NLC dispersion and hydrogel, both including chemical enhancers, as TDDS 
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to provide a steady-state plasma concentration of the drugs as well to correlate the in 
vitro and in vivo permeability data. Additionally, the potential of the combination of skin 
perforation with the application of the colloidal drug carrier system is evaluated. As an 
alternative route of administration, the pharmacokinetic profile of NLC subcutaneous 
injection is finally investigated. 
 
7.2 Materials and methods 
 
7.2.1 Chemicals 
 
Simvastatin was kindly provided by Labesfal (Santiago de Besteiros, Portugal). 
Olanzapine was purchased from Zhejiang Myjoy (Hangzhou, China). Simvastatin 
hydroxy acid ammonium salt and olanzapine-D3 were purchased from @rtmolecule 
(Poitiers, France). Glyceryl tripalmitate (tripalmitin, T8127), phosphate buffer saline pH 
7.4, polyvinyl alcohol 87–89% hydrolyzed (PVA, typical MW13.000-23.000), polysorbate 
80 (Tween® 80) and polyethylene glycol 400 (PEG 400) were purchased from Sigma. 
Oleic acid and limonene were acquired from Fluka. Carbopol® Ultrez 10 NF was kindly 
provided by Lubrizol (Quimidroga, Barcelona, Spain). The microneedle devices 
Dermaroller® MC905 and MC 915 (equipped with 192 stainless steel microneedles of 
500 μm, or 1500 μm length, respectively) were bought from Distrimed S.a.r.l. 
(Luxembourg). All chemicals used were of analytical grade, and solvents were of high-
performance liquid chromatography (HPLC) grade. 
 
7.2.2 Preparation of NLC by solvent emulsification/evaporation method 
 
The production of NLC by solvent emulsification-evaporation (SE/E) was based on a 
previously optimized method for the preparation of solid lipid nanoparticles [5]. Briefly, 
the solid and liquid lipids, tripalmitin and oleic acid, respectively, corresponding to a total 
amount of 250 mg, and 15 mg of both simvastatin and olanzapine (for detailed formulae 
and variations, see the Results and Discussion Section) were dissolved in 5 mL of 
dichloromethane and then added dropwise to 30 ml of 1% (w/V) PVA solution, under 
ultrasonication (40 W, 5 min; Branson, Sonifier 250). The obtained pre-dispersion was 
submitted to high shear homogenization (L5M-A, Silverson, UK), at 13,000 rpm for 7 
min. The dispersion was, finally, stirred at 200 rpm for 4 hours, in order to allow the 
solvent evaporation. The combined drug formulation will be referred as Combo-NLC 
SE/E.  
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7.2.3 Preparation of NLC by high pressure homogenization method 
 
The NLC were alternatively prepared by the hot high pressure homogenization (HPH) 
technique previously optimized [2], in which 750 mg of the lipid phase (tripalmitin:oleic 
acid, 50:50 weight ratio) melted at 80°C was pre-emulsified in 30 mL of a 3 % (w/V) 
polysorbate 80 solution at 80 ºC for 2 min, using an Ultra-Turrax X1020 (Ystral GmbH, 
Dottingen, Germany) set to 25000 rpm. The pre-emulsion was further subjected to hot 
HPH at 1000 bar for 2.5 min using an Emulsiflex®-C3 (Avestin Inc., Ottawa, Canada). 
The dispersion thus obtained was cooled at 4ºC to form the NLC.  
For drug encapsulation, 80 mg of OL and/or SV were added to the melted lipid 
phase, to produce NLC loaded with SV (SV-NLC HPH) or OL (OL-NLC HPH) or with 
both drugs (Combo-NLC HPH). 
 
7.2.4 Formulations for in vivo PK studies 
 
For the in vivo skin permeation studies, the optimized Combo-NLC formulation (see 
the Results and discussion section) was mixed with the permeation enhancers ethanol 
and limonene (as 70.4:24.6:5 wt%, respectively). This formulation was referred to as 
Combo-NLC+Et+L. An alternative gel formulation, referred to as Combo-NLC+Et+L Gel 
was prepared by adding 0.5% (w/w) carbomer (Carbopol® Ultrez 10 NF) and the gel-
inducer triethanolamine (final pH: 7.0-7.5) to the Combo-NLC+Et+L. 
In order to estimate basic pharmacokinetic (PK) parameters, drug solution for 
intravenous injections was prepared by dissolving simvastatin and olanzapine in PEG 
400 (2 mg/mL, for each drug). 
 
7.2.5 Particle size analysis 
 
The average particle diameter and polydispersity index (PI) were determined by 
dynamic light scattering at 25ºC, using a Delsa Nano C Submicron (Beckman Coulter, 
Krefeld, Germany) set at a 160º detection angle (backscattering). Samples were 
analysed three times and results were presented as mean ± standard deviation (SD), 
extracted from the Cumulants algorithm [6, 7]. 
 
7.2.6 Zeta potential 
 
Zeta potential (ZP) determinations were carried out in ultrapurified water (pH≈5.5) at 
25 ºC by electrophoretic light scattering, using a Delsa Nano C Submicron (Beckman 
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Coulter, Krefeld, Germany). ZP was calculated using the Helmholtz–Smoluchowsky 
equation.  
 
7.2.7 Entrapment efficiency and drug loading  
 
The entrapment efficiency of simvastatin and olanzapine in the NLC was determined 
indirectly, using Equations (2.3) and (2.4) in the case of NLC prepared by HPH and 
Equations (3.3) and (3.4) in the case of NLC prepared by SE/E.  
 
7.2.8 Thermal analysis  
 
Differential scanning calorimetry (DSC) analysis performed using a DSC-60 
differential scanning calorimeter (Shimadzu, Japan) was carried out to characterize the 
degree of crystallinity of the NLC and the drug lipid interactions. Pure compounds and 
lyophilized nanoparticles (2-3 mg) were placed in aluminum pans hermetically sealed. 
Empty pans were used as reference. Each sample was submitted to a heating cycle from 
25 to 210 °C, at the rate of 10 °C/min, with a nitrogen purge of 30 ml/min. The onset 
temperature (Ton), melting point (Tpeak), and enthalpy (∆H) were evaluated using the 
TA Software (Shimadzu, Japan).  
 
7.2.9 Attenuated total reflectance infrared  
 
In order to characterize the conformational changes of lipid molecules in the matrices 
and to analyse the influence of drug loaded in NLC, ATR infrared spectra of the particles 
were recorded using a FT-IR/FT-NIR spectrometer (Spectrum 400, Perkin-Elmer, 
Massachusetts, USA) with an ATR accessory fitted with a ZnSe crystal plate. Lyophilized 
samples were placed in the ATR device without previous treatment, and measured using 
16 scans for each spectrum, with a resolution of 4 cm-1 and a scan speed of 1 cm/s. 
Spectra were collected between 4000 and 650 cm-1.  
 
7.2.10 In vitro release studies  
 
In vitro release studies were performed using static Franz diffusion cells (PermeGear, 
Inc., PA, USA) as previously described in Section 4.2.11.  
The release pattern of SV and OL from the different nanoparticle formulations was 
also fitted to several mathematical models (see Results, Section 7.3.2).  
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7.2.11 In vitro permeation studies  
 
In vitro skin permeation studies were performed through static Franz diffusion cells, 
using human and newborn pig epidermis as skin models in the same conditions as in in 
vitro release studies. The skin was obtained according to the procedure described 
previously in Section 4.2.12 [2]. 
The cumulative amount of OL and SV penetrated as a function of time was 
calculated according to Equation (4.1). Note that SV cumulative amount is a result of the 
sum of SV (after stoichiometric conversion into SVA) and SVA contributions, since pH 
7.4 favors the conversion of pro-drug SV into the respective active metabolite SVA [9]. 
The steady-state flux (Jss) was obtained from the slope of the linear region of the curve, 
representing the amount of drug permeated per unit area versus time [10]. Based on the 
flux (Jss), the permeability coefficient (Kp) was estimated according to Equation (2.12) 
 
7.2.12 In vivo studies  
 
Animals  
 
Work with animals was conducted in compliance with EC Directive 2010/63/EU under 
agreement N° 86 051. Male Sprague-Dawley (SD) rats (n=36) from Janvier Laboratories 
(Le Genest-St-Isle, France), weighing between 270 and 330 g, were acclimatized in wire 
cages in a 12-h light-dark cycle with free access to food (A03, Safe; Villemoisson-sur-
Orge, France) and water for a minimum of 5 days before starting experiments.  
 
Implantation of femoral vein and artery catheters  
 
One day before pharmacokinetic (PK) experiments, the rats were anesthetized with 
isoflurane (Forene®, Abbot; Rungis, France) inhalation, by placing them into a hermetic 
enclosure, supplied with a 3.9 % air-isoflurane mixture at a flow rate of 500 ml/min 
(Anesthesia Unity, Univentor 400; Phymep, Paris, France). When animals were asleep, a 
mask was placed onto the muzzle, and the concentration of isoflurane was decreased to 
1.5 - 2% during the surgery. The animals were then placed in the dorsal position with the 
tail toward the experimenter. Polyethylene catheters constituted with the connection of a 
small-diameter catheter (inner diameter of 0.26 mm and outer diameter of 0.61 mm; 
Phymep, Paris, France) with a larger catheter (inner diameter of 0.58 mm and outer 
diameter of 0.96 mm; Harvard, Les Ulis, France) were implanted in the left femoral artery 
for blood sampling.  
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 Rats for IV PK studies were equipped with a second catheter in the left femoral vein 
for IV administration of drug solution. After surgery, rats were maintained under a heating 
lamp until the first signs of movement. They were then placed in individual cages with 
free access to food and water. Food was withdrawn 12 h before the PK experiments 
[11].  
 
Plasma pharmacokinetic studies  
 
Rats were divided in 6 groups (n = 6) for transdermal (4 groups), subcutaneous (1 
group) or intravenous (1 group) administrations. 
Transdermal administration: For transdermal administrations, four treatments were 
studied, based on a two-level, two-variable, 2k full factorial planning: (1) Transdermal 
Combo-NLC+Et+L formulation, (2) Transdermal Combo-NLC+Et+L formulation plus skin 
microneedle device pre-treatment, (3) Transdermal Combo-NLC+Et+L Gel formulation, 
and (4) Transdermal Combo-NLC+Et+L Gel formulation plus skin microneedle pre-
treatment. These groups were established taking the use of gel (x1) and skin 
microneedle pre-treatment (x2) as independent variables and pharmacokinetic 
parameters, such as, Cmax, tmax, AUC0-48h, Css and Jss as responses (R) or dependent 
variables. The mathematical model 
                                                                                                   (7.1)  
was applied for interpretation of the direct influence and interaction between 
variables, where β0 corresponds to the arithmetic mean of the response, β1 and β2 are 
the coefficients of the respective independent variables, and β12 the interaction term. 
Two coded values (-1) and (+1) were considered, corresponding, respectively, to the 
absence and presence of the independent variables.  
The rats were anesthetized by isoflurane inhalation as described in above and the 
upper back region was carefully shaved with an electric hair clipper. The integrity of the 
shaved skin was checked by measuring the transepidermal water loss using a 
vapometer (Delfin Technology, Kuopio, Finland). TEWL values lower than 10 g/cm2/h 
were considered as normal skin values [12]. A rubber ring (22 mm inner diameter and 
3.5 mm thickness) delimiting a diffusion area of 3.8 cm2 was then attached to the shaved 
skin with surgical glue (Vetbond®, 3M Co., St. Paul, MN, USA), in order to form a 
reservoir for the formulation applications. Subsequently, 800 μL of the transdermal 
formulations (corresponding to 1.45 mg of OL and SV) were applied, and the reservoir 
was tightly closed with Tegaderm film (3M Co., St. Paul, MN, USA), in order to prevent 
both formulation leakage and solvent evaporation. In the groups pretreated with 
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microneedles, the device was rolled in four different directions, ten times for each over 
the rat skin surface before sticking the rubber ring. 
 
 
Figure 7.1 Demaroller® pretreatment and formulation application to rats. 
 
Blood samples were collected from the femoral artery catheter at predetermined time 
points over 48 h after formulation application. Plasma was separated by centrifugation (3 
000 rpm, 10 min) and frozen at -80°C until analysis. 
 
Subcutaneous administration: Subcutaneous administration of Combo-NLC (5 mg 
of each drug per kg of body weight) was performed in the back region of the animals. 
Arterial blood samples were collected over 48 h postdosing via the left femoral artery 
catheter and handled as described above. 
Intravenous administration: The OL and SV solution for intravenous (IV) 
administration (1 mg drug per kg of body weight) was infused over 30 min via the left 
femoral vein, using a syringe pump (CMA 100 microdialysis pump; Phymep, Paris, 
France). Arterial blood samples were collected over 5 h, via the left femoral artery 
catheter and were handled as described above. 
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Transepidermal water loss measurements  
 
The rats were anesthesized with intraperitoneal injections of 60 mg/kg of 
pentobarbital. Subsequently, the back regions of the rats were shaved as described in 
7.2.12.3 and were divided in 3 areas. Two areas were treated with microneedle devices 
bearing 500 or 1500 μm-length microneedles, and the third one was used as control. 
TEWL measurements were performed before and 1 min, and every 15 min over 180 min, 
after skin treatment.  
 
LC-MS/MS analysis of SV, SVA and OL 
  
A validated liquid chromatography–tandem mass spectrometry (LC/MS/MS) method (see 
Appendix 2) was used to determine the concentration of simvastatin, simvastatin acid and 
olanzapine in the plasma samples, using mevastatin (MEV) and the deuterated olanzapine (OL-
D3) as internal standards (IS), respectively.  
Reversed-phase chromatography was performed on a Jupiter C18 column (5.0 μm, 50 
mm x 2.1 m; Phenomenex, Le Pecq Cedex, France). The mobile phase at a 0.2 mL/min flow 
rate was an ammonium formate (2 mM in water) and acetonitrile mixture, 25:75 (V/V). Injection 
volumes were of 20 μL for OL and 10 μL for SV and SVA quantitation. The LC-MS/MS system 
consisted of an Agilent 1100 separation module equipped with a binary pump, an autosampler 
thermostated at 4°C, and an API 3000, Sciex tandem mass spectrometer with an electrospray 
ionization (ESI) interface. The ESI source was operated in the positive-ion mode. Ions were 
analyzed by multiple-reaction monitoring (MRM), with transition ions m/z 313.2/256.1 for 
olanzapine, 441.2/325.3 for simvastatin, 459.5/343.3 for simvastatin acid, 316.2/256.1 for 
olanzapine-D3 and 413.2/311.2 for mevastatin. Calibration curves for OL, SV, and SVA 
concentrations ranged from 0.25 to 100 ng/mL. For calibration standards, controls, and samples, 
a two-step liquid-liquid extraction from plasma was carried out in order to extract sequentially 
analytes, i.e. first SV and SVA at  pH 4.5, which is a pH shown to minimize conversion of SV into 
SVA [13], and second OL at pH 10. Briefly, 200 μL of Titrisol buffer, pH 4, and 50 μL of OL-D3 
solution (20 pg/µL in water) were added to 100 μL plasma sample. After vortexing, 2 mL of 
diethyl ether were added. The mixture was vortexed for 1 min and then centrifuged at 3000 rpm 
for 10 min. The diethyl ether supernatant (containing mostly SV and SVA molecules) was then 
transferred to a glass tube and evaporated to dryness under a gentle stream of N2 gas at 45 ºC. 
Dry residues were re-dissolved in 70 μL of mobile phase and 50 μL of MEV solution (200 pg/μL 
in Titrisol buffer at pH 4). For OL extraction, 30 μL of NaOH 1.0 M were added to the aqueous 
phase (final pH: 10). After vortexing, 2 mL diethyl ether were added and the mixture was 
vortexed for 1 min and centrifuged at 3000 rpm for 10 min. The supernatant was transferred to a 
Chapter 7 – Passive and active strategies: in vitro vs. in vivo studies 
 
 189 
glass tube and evaporated as described above. Dry residues were finally re-dissolved with 120 
μL of mobile phase and transferred to the LC-MS/MS vials.  
The between-day variabilities for OL, SV, and SVA were characterized at the three 
levels of concentrations (n=6), with a precision and accuracy of less than 15%. 
All data were processed using Analyst Version 4.1.2 software. 
 
Pharmacokinetic analysis 
 
The clearance was determined through IV administration data, analyzed using a non-
compartmental model, through the WinNonLin software (version 5.3, Pharsight 
Corporation, Mountain View, California, USA) and taking into consideration the half-life 
elimination time (t1/2). The half-life of elimination from plasma was determined by linear 
regression of the terminal portion of the log (plasma concentration) versus time curves. 
The same procedure was applied to subcutaneous administration data. 
In the case of transdermal delivery, pharmacokinetic parameters, such as the 
maximal plasma drug concentration (Cmax) and the time to reach maximal plasma 
concentration (tmax), were inspected directly from each individual plasma concentration–
time profiles. The steady-state concentration of each drug was calculated by the average 
of the four last time points of concentration vs. time profile, in order to calculate the 
transdermal flux from the dispersion/hydrogel formulation at steady-state (   ) using 
equation 2.14 [14]                 , where A is the area of the applied formulation 
(3.80 cm2), Css is the steady-state plasma concentration (ng/mL) obtained from 
transdermal plasma profiles and Cl the total body clearance determined from the 
intravenous pharmacokinetic study. Data are expressed as the mean ± S.D. In the case 
of the calculation of the transdermal flux of SV, since it is rapidly converted into SVA post 
absorption, resulting in low SV concentration (see results), Jss was calculated using Css 
of SVA added to Css of SV previously converted into the corresponding stoichiometric 
SVA quantity. The same applies for the plasma concentration–time profiles. 
 
7.2.13 Confocal laser scanning microscopy  
 
In order to investigate the NLC skin distribution, 0.05% (w/w of lipids) Nile red-labeled 
Combo-NLC were formulated with ethanol, limonene with or without carbomer (NR-
Combo-NLC+Et+L and NR-Combo-NLC+Et+L Gel, respectively) as in 7.2.4 and were 
applied for 1 h 30 and 48 h on the back region of the rats, according to the procedure 
described in 7.2.12. For NR-Combo-NLC+Et+L Gel, the effect of Dermaroller® (D) was 
also assessed. After application, rats were sacrificed and the rubber rings removed. The 
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site of application of the formulation was wiped with wet gauze and an 8 mm full 
thickness biopsy taken. A piece of tissue (ca. 0.3 x 0.3 cm) of each biopsy was then cut 
out, embedded in optimal cutting temperature (OCT) compound and frozen at -20ºC. Ten 
transversal sections from the dermis to stratum corneum with a thickness of 50 μm were 
obtained using a cryostat (Leica (CM3050S, Wetslar, Germany) and stored at 4 ºC until 
confocal laser scanning microscopy (CLSM) imaging. A drop of glycerol was applied 
upon the slide containing the skin sections, which were then examined using a confocal 
FV-1000 station installed on an inverted IX-81 (Olympus, Tokyo, Japan) microscope. 
Images were obtained with an Olympus UplanSapo x20, 0.75 NA, objective lens (800 x 
800 pixels, 0.53 µm/pixel), with an exciting 543 nm laser wavelength and a 555-655 nm 
detection channel. Light images were obtained simultaneously. Untreated skin was used 
as control. 
 
7.3 Results and discussion  
 
7.3.1 Preparation and characterization of NLC  
 
The composition and production conditions of NLC prepared by solvent 
emulsification-evaporation were based on previous works, taking SV loaded solid lipid 
nanoparticles as template, therefore tripalmitin as oil phase [5]. However, for the 
preparation of the OL-loaded NLC, due to the low OL solubility in tripalmitin (<12 mg/g) 
[2], fixed amounts of tripalmitin were replaced with oleic acid (Table 7.1). 
 
Table 7.1 Optimization of the OL loaded NLC composition prepared by SE/E. Key: 
EE - entrapment efficiency; DL - drug loading; PI - polydispersity index. The results are 
expressed as mean ± SD (n=3). 
Formulations 
OL amount and Oleic 
Acid:Tripalmitin ratio 
Mean particle 
size (nm) 
PI 
Zeta potential 
(mV) 
%EE %DL 
NLC (25:75) 227.±6 0.152 -35.7±0.4 - - 
OL5mg-NLC (25:75) 226.±6 0.130 -33.9±0.3 76.5±0.2 1.561±0.004 
OL10mg-NLC (25:75) 229±10 0.193 -32.5±0.9 77.61±0.03 3.104±0.001 
OL15mg-NLC (25:75) 226.±7 0.190 -27.3±0.6 79.5±0.2 4.80±0.01 
NLC (35:65) 224.±4 0.121 -36.4±0.1 - - 
OL15mg-NLC (35:65) 226.±4 0.151 -31.8±0.5 84.2±0.2 5.05±0.01 
NLC (50:50) 231.±4 0.103 -35.9±0.8 - - 
OL15mg-NLC (50:50) 226.±4 0.094 -34±3 91.±1 5.48±0.08 
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The OL entrapment efficiency (EE) increased with the oleic acid content (Table 7.1). 
The ratio 50:50 oleic acid:tripalmitin (OL15mg-NLC) was selected for the Combo-NLC 
formulation, since it allowed EE higher than 90% and low polydispersity index. For 
Combo-NLC, the same amount of OL and SV (15 mg each for SE/E and 80 mg in the 
case of HPH) was used. Physicochemical properties of Combo-NLC prepared by SE/E 
and HPH methods are presented in Table 7.2. 
 
Table 7.2 Physicochemical properties of the optimized Combo-NLC formulation 
prepared according to SE/E and HPH methods. The results are expressed as mean ± 
SD (3≤n≤6).   
Formulation 
code 
Mean particle 
size (nm) 
PI 
Zeta potential 
(mV) 
% EE % DL 
Combo-NLC 
SE/E 
223.±4 0.122 -32.±3 
SV 98.0±0.8 
OL 92.8±0.9 
SV 5.88±0.05 
OL 5.57±0.05 
Combo-NLC 
HPH
(a)
 
149±18 0.271 -36.3 ±1.6 
SV 99.72±0.05 
OL 97.0±0.5 
SV 10.637±0.005 
OL 10.34±0.05 
(a) Ref. [2] 
 
Compared with the SE/E method, the Combo-NLC prepared by HPH displayed a 
lower mean particle size, a higher polydispersity, but similar zeta potential, which confers 
physical stability to NLC suspensions [15]. In addition, HPH led to an almost two-fold 
higher drug loading, associated to an entrapment efficiency exceeding 95% for both 
drugs. 
Using the HPH method, the Combo-NLC presented an average particle size between 
OL-NLC and SV-NLC (Table 7.3), and a polydispersity index below 0.3. Zeta potential 
values were all below -30 mV, which warrantied NLC physical stability. With an 
entrapment efficiency higher than 95% for both drugs, NLC were found to be efficient 
carriers for co-encapsulation. The high EE obtained were confirmed by the DSC results 
(Figure 7.2). The thermograms of NLC did not display the melting transition peak of SV 
and OL, irrespective of the method of production, indicating that the drug is dissolved 
within the lipid matrix, without the presence of crystals in the external phase. Concerning 
the crystallinity degree of the NLC lipids, whatever the preparation method, NLC 
matrices presented a higher degree of disorder due to the presence of oleic acid, since a 
shift of the tripalmitin melting point towards lower temperatures was observed (Table 
7.4). A less structured matrix seemed to be associated to the NLC prepared by SE/E, 
compared with NLC prepared by HPH, as evidenced by the broadness of the peak 
transitions and by the slight decrease in the enthalpy observed. In the case of NLC 
Chapter 7 – Passive and active strategies: in vitro vs. in vivo studies 
 
 
192 
prepared by HPH, the incorporation of the drugs also generally led to a decrease in the 
crystallinity of the lipid matrix, particularly when both drugs were entrapped (Table 7.4). 
 
Table 7.3 Physicochemical properties of the optimized NLC prepared through the hot 
high pressure homogenization (HPH) technique: mean particle size, polydispersity index 
(PI), zeta potential, entrapment efficiency (EE) and drug loading (DL). The results are 
expressed as mean ± SD (3≤n≤6).  
 Formulation Code 
Physicochemical 
property 
NLC 
HPH 
OL-NLC HPH SV-NLC 
HPH 
Combo-NLC 
HPH
(a)
 
Particle size (nm) 152.±9 181±22 131±23 149±18 
PI 0.278 0.199 0.212 0.271 
Zeta potential (mV) -37.±5 -36.±9 -36.±6 -36.3 ±1.6 
%EE (OL) - 96.±2 - 97.0±0.5 
%EE (SV) - - 99.5±0.3 99.72±0.05 
%DL (OL) - 10.2±0.2 - 10.34±0.05 
%DL (SV) -  10.62±0.03 10.637±0.005 
(a) Ref. [2] 
 
 
 
Figure 7.2 DSC thermograms of the pure compounds (drugs and tripalmitin) and of 
NLC prepared by SE/E or HPH.   
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Table 7.4 DSC melting characteristics of pure compounds and NLC formulations. 
Pure compounds/ 
NLC formulations 
Ton (ºC) Tpeak (ºC) 
Enthalpy of 
fusion (J/g) 
Olanzapine 193.93 195.86 -116.73 
Simvastatin 139.93 141.28 -76.83 
Tripalmitin 61.08 64.08 -171.35 
NLC SE-E 52.02 58.83 -35.33 
Combo-NLC SE-E 52.60 59.49 -41.17 
NLC HPH 55.82 59.62 -58.14 
Combo-NLC HPH 57.07 60.27 -33.54 
OL-NLC HPH 56.54 59.60 -45.08 
SV-NLC HPH 57.59 59.86 -36.61 
 
The IR spectrum analysis from 1200 to 1400 cm−1 focused on the conformation of the 
CH2 groups from the acyl chains (tripalmitin and oleic acid) (Figure 7.3A). Spectra of 
NLC prepared by HPH presented several regular bands, while spectra of NLC prepared 
by SE/E showed a significant convolution. The regular bands in the NLC prepared by 
HPH were ascribed to a tendency for a full-trans arrangement of the methylene groups, 
and the mutual coupling vibrations of the long chains of tripalmitin and oleic acid [16]. 
This order of the acyl chains was somewhat lost in the lipid matrix of the NLC prepared 
by SE/E, resulting in broader peaks, which suggests a less ordered structure or an 
amorphous state of the lipid matrix. These results correlated well with the DSC analysis 
(Table 3). In the spectra of NLC prepared by SE/E (Figure 7.3B), a broad peak was also 
present at around 3320 cm-1, probably corresponding to the stretching of the PVA 
hydroxyl groups. Additionally, there was some evidence of the presence of olanzapine at 
the surface of the NLC prepared by HPH, as illustrated by the C=C stretching around 
1587 cm-1 (Figure 7.3C), which could be ascribed to the high drug load. 
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Figure 7.3 FTIR spectra of NLC prepared by SE/E or HPH: (A) 1400-1200 cm-1, (B) 
4000-650 cm-1 and (C) 2000-1400 cm-1, the latter including OL and SV as pure 
compounds.   
 
7.3.2 Release profiles from Combo-NLC dispersions 
 
Figure 7.4 displays the release profiles of NLC formulations prepared by SE/E or 
HPH. It can be observed that olanzapine was released to a higher extent than 
simvastatin, irrespective of the method of preparation. This was ascribed to their 
differential solubility in tripalmitin and oleic acid, which, in turn, led to different drug 
distribution within NLC. Simvastatin exhibited a higher solubility in the solid lipid 
tripalmitin, leading to a higher control over the release. Conversely, olanzapine being 
more soluble in the liquid lipid oleic acid, the degree of retention was lower. NLC 
prepared by HPH tended to release drugs more slowly than the ones prepared by SE/E, 
which was ascribed to the less structured matrix of the latter (see DSC and FTIR 
analysis). The use of different emulsifiers, PVA in SE/E and Tween® 80 in HPH, may 
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also influence results. Release profiles obtained with Combo-NLC prepared with HPH 
were, however, comparable to those obtained with single-drug loaded NLC. 
 
Figure 7.4 In vitro release profiles of the NLC prepared through the SE/E and HPH 
methods. (mean ± SEM, 3≤n≤ 6). a The mean OL percentage release (48 h) is 
statistically higher than the respective SV in both methods, for a p<0.05. b The mean OL 
SE/E percentage release (48 h) is statistically higher than the respective OL HPH, for a 
p<0.05.     
 
Table 7.5 compiles the parameter values for different mathematical models used for 
regression of the release data. For the first-order and Weibull functions, one additional 
parameter, c1, was introduced taking into account the predicted asymptotic value for 
release, which may differ from 100% [17]. It can be concluded that the Weibull function 
provided, in general, the best regression function, followed by the Korsmeyer-Peppas 
and first order models, of similar performance. Focusing on the Weibull model, it should 
be noted that the shape parameter (c3) characterizes the curves as exponential (c3=1), 
sigmoidal (c3>1), i.e. S-shaped with an upward curvature followed by a turning point, or 
parabolic (c3<1), with a higher initial slope and after that consistent with the exponential 
[18]. According to the results obtained, c3 is systematically lower than 1 for OL HPH 
formulations, and slightly above unity for SV HPH formulations. However, low values of 
c2, indicated that the formally first-order release approached in fact a zero order. In 
addition, with c3 values above 1, the sigmoid shape of the Weibull function indicated that 
a complex mechanism governed the release process [19]. This seems to indicate that 
OL NLC formulations tended more rapidly to a steady state, corresponding to the drug 
with the highest release rate (Figure 7.5A) and B)). In the case of NLC prepared by 
SE/E, an exponential shape characterised the OL release profiles, and the SV release 
profiles were close to the ones found for the OL HPH profiles. 
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Figure 7.5 Representation of the least squares regression of the release profiles: (A) 
and (B) Weibull model; (C) and (D) Korsmeyer-Peppas model.   
 
In the first order model the c1 parameter corresponds to the asymptotic value 
predicted for each profile, and this value was higher for the OL-loaded NLC than for the 
SV-loaded NLC. The corresponding release rates were also larger, as extracted from the 
c2 values. For Combo-NLC prepared by HPH, the SV profile followed very closely a zero-
order release.   
The value of the c2 parameter in the Korsmeyer-Peppas model is important for the 
characterization of the drug transport mechanism. Thus, c2 values close to 0.5 
correspond to a Fickian diffusion process and values between 0.5 and 1.0 to an 
anomalous (non-Fickian) transport. With c2 value of 1.0, a zero-order model applies. 
Note that for the estimation of this exponent, only the first 60% of the release are 
considered [20]. Transposing this classification to the results obtained, it is seen that the 
OL HPH formulations display a diffusionally controlled release (c2~0.5), while the SV 
HPH are characterized by a zero-order release (c2~1) [20]. For OL and SV SE/E 
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formulations, an anomalous transport is reported (0.5<c2<1.0), where diffusion is coupled 
with other mechanisms (Table 7.5 C) and D)).  
 
7.3.3 In vitro permeation studies  
 
NLC prepared by HPH promoted a higher permeation rate than NLC SE/E (Table 
7.6). This can be attributed to the higher drug loading in HPH, in spite of the higher 
release rate observed in the SE/E formulations. On the other hand, differences between 
methods are less marked in the Kp values. This can be ascribed to the use of a majorant 
for C0, Equation (2.12), based on the total drug content of the NLC, which is higher for 
the HPH method. Also, OL permeated in a higher degree than SV, as evidenced by the 
Q24 and Q48 parameters, which is compatible with the respective release rate.  
 
Table 7.6 In vitro permeation parameters (human skin) of OL and SV released by 
Combo NLC prepared by SE/E or HPH. mean ± SEM (3≤n≤6).  
 
Taking into consideration the higher drug loading, the better permeation rate, and 
other advantages, such as the scale up feasibility, the avoidance of organic solvents and 
the shorter production process, NLC prepared by HPH were chosen to proceed into the 
in vitro/in vivo studies.  
The effect of the permeation enhancers (ethanol and limonene) and of the vehicle 
viscosity on the permeation of the drugs formulated as NLC was subsequently 
investigated (see Table 7.7, which also gathers some previously obtained data, [2]). Due 
to the large number of experiments, the readily available newborn pig skin was used in 
place of human skin, since it gave similar results (see Combo-NLC data, Table 7.7). The 
addition of ethanol to the Combo-NLC dispersion medium increased the permeation rate, 
compared to the respective aqueous medium (Table 7.6). The skin-permeation-
enhancing effect of ethanol is well-known [21]. Ethanol is reported to act by a dual 
mechanism: acting as a co-solvent, increasing permeant partitioning into and solubility 
within the stratum corneum, and acting as a permeation enhancer by extracting large 
amounts of stratum corneum lipids [21, 22]. Olanzapine tended to permeate to a higher 
Combo-NLC 
Preparation Method 
Drugs 
Jss 
(μg/cm2/h) 
Kp (cm/h) 
(x 10-3) 
Q24 
(μg/cm2) 
Q48 
(μg/cm2) 
SE/E 
OL 0.09±0.03 0.17±0.05 0.9±0.4 2.5±0.4 
SV 0.19±0.01 0.38±0.02 1.7±0.3 6.4±0.5 
HPH 
OL 0.43±0.08 0.16±0.03 4.4±0.2 15.7±0.9 
SV 0.33±0.07 0.12±0.03 2.7±0.4 7.4±0.1 
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extent when alone than when in association with simvastatin (Table 7.7), while the 
opposite behaviour was observed for simvastatin. The addition of limonene, also a well-
known permeation enhancer [23], at a previously optimized concentration [2] further 
increased permeation rates. Increasing the vehicle viscosity with carbomer had a 
negative effect on permeation rates. This behaviour has already been reported, and was 
attributed to the effect of the gel viscosity on the diffusion coefficient in the vehicle [24]. 
Q24, Q48 and Kp corroborated this trend. In what follows, liquid and gel formulations 
including ethanol and limonene were used for the PK studies in rats.  
 
Table 7.7 In vitro OL and SV permeation parameters for NLC prepared by the HPH 
method, in the presence of permeation enhancers, ethanol (Et) and/or limonene (L), 
(mean±SEM, 3≤n≤6).  
 (a) Ref. [2] 
 
7.3.4 In vivo pharmacokinetic studies in rats  
 
Transdermal administration 
 
In order to evaluate the efficiency of Combo-NLC with permeation enhancers, either 
in the liquid dispersion (Combo-NLC+Et+L) or in the carbomer hydrogel (Combo-
NLC+Et+L Gel), together with the effect of skin microneedle pretreatment in vivo 
pharmacokinetic studies were performed in rats (Figure 7.6). The 500 μm or 1500 μm-
length microneedles gave similar increase in TEWL values, compared to control skin, in 
agreement with previous studies [25, 26]. Accordingly, the 500-µm-length microneedles 
were used for the in vivo PK studies.  
 
Skin 
origin 
Formulation 
Jss 
(μg/cm
2
/h) 
Kp (cm/h) 
(x 10
-3
) 
Q24 
(μg/cm
2
) 
Q48 
(μg/ cm
2
) 
OL SV OL SV OL SV OL SV 
Human 
OL-NLC + Et 2.5±0.3 - 1.3±0.2 - 25.±4 - 83.±8 - 
SV-NLC + Et - 0.59±0.04 - 0.32±0.02 - 9.±2 - 26.±2 
Combo-NLC 
+ Et 
1.9±0.7 0.8±0.1 1.0±0.4 0.43±0.07 12.±5 7.±3 55±17 21.±3 
Newborn
pig 
Combo-NLC 
+ Et
(a)
 
1.9±0.4 0.74±0.08 1.2±0.2 0.42±0.05 29.±7 13.±3 79±18 31.±5 
Combo-
NLC+Et+L
(a)
 
15.±2 7.0±0.8 10.±1 3.9±0.5 261±51 82±19 534±33 249±36 
Combo-
NLC+Et+L 
Gel
(a)
 
7.5±0.3 3.6±0.3 4.8±0.2 2.1±0.2 145.±6 48.±5 314±10 133±12 
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Figure 7.6 Dependence on time of TEWL determined on rat skin in vivo, with and 
without the application of Dermaroller® with microneedles length of 500 μm and 1500 μm. 
Results are expressed as mean ± SEM (n=3).   
 
The application of the formulation had no visible impact on skin integrity, as 
observations showed after formulation removal. 
The mean plasma concentration-time profiles for OL and SV after transdermal 
administration are depicted in Figure 7.7 and PK and permeation parameters are 
summarized in Table 7.8.  
 
 
 
Figure 7.7 Plasma concentration-time curves of (a) OL and (b) SV after application 
of NLC plus permeation enhancers in the liquid dispersion (Combo-NLC+Et+L) or the gel 
(Combo-NLC+Et+L Gel) vehicle, with and without Dermaroller® (D) skin pretreatment, 
mean±SEM (n=6).   
 
Chapter 7 – Passive and active strategies: in vitro vs. in vivo studies 
 
 201 
Table 7.8 Pharmacokinetic parameters of OL and SV after skin application of 
Combo-NLC formulations, in a liquid or gel permeation enhancer-containing vehicle. 
Results are expressed as mean±SD (n=6).  
 
Without microneedle skin 
pretreatment 
With microneedle skin 
pretreatment 
Formulation 
Combo-
NLC+Et+L 
Combo-
NLC+Et+L Gel 
Combo-
NLC+Et+L 
Combo-
NLC+Et+L Gel 
OL PK and 
skin 
permeation 
parameters 
Cmax (ng/mL) 10.1±5.2
a
 5.7±1.5 11.6±7.2 8.2±1.7
b
 
tmax (h) 5.0±1.6
c
 6.0±0.0 2.3±1.0 4.5±1.6
b,d
 
AUC0-48 (ng h/mL) 214.9±99.1 171.8±66.1 220.3±172.2 229.0±52.8 
Css (ng/mL) 3.9±2.0 3.2±1.4 3.3±3.1 4.3±1.2 
Jss (μg/cm
2
/
 
h) 1.7±0.8 1.4±0.6 1.4±1.2 1.9±0.5 
SV PK and 
skin 
permeation 
parameters 
Cmax (ng/mL) 7.2±5.2 3.2±1.4 8.9±4.2 8.8±5.5
b
 
tmax (h) 3.0±0.0 6.0±0.0 2.5±0.8 5.7±2.6
d
 
AUC0-48 (ng h/mL) 70.0±41.2 78.0±32.5 105.8±56.8 182.3±108.6
b
 
Css (ng/mL) 0.7±0.3 1.4±0.8 1.4±1.5 2.5±1.3
b
 
Jss (μg/cm
2
/
 
h) 0.3±0.1 0.5±0.3 0.7±0.7 0.9±0.5 
Key: a Combo-NLC+Et+L > Combo-NLC+Et+L Gel,  
b Combo-NLC+Et+L Gel+D > Combo-NLC+Et+L Gel,  
cCombo-NLC+Et+L > Combo-NLC+Et+L+D, 
d NLC+D > Gel+D, for p<0.05. 
  
In general, plasma concentration reached a maximum 2 to 6 hours post skin 
application and then decreased to reach a plateau at around 10 h which was maintained 
for 48 h (Figure 7.7). The Cmax and Jss values for OL were higher than for SV, a result 
that is in agreement with the in vitro skin permeation studies conducted using newborn 
pig skin (Table 7.7). Microneedle pre-treatment generally resulted in earlier tmax and 
higher Cmax. With the gel vehicle, the mean Cmax values were approximately twice lower 
than with the liquid vehicle, and the tmax was delayed (Table 7.8). This trend is confirmed 
by the 22 full factorial planning (Table 7.9). A negative sign associated to β1 indeed 
corresponded to a decrease in the PK parameters (e.g., Cmax and AUC0-48h for OL, and 
Cmax for SV) when the gel is applied. In the case of OL, Css and Jss were similar whatever 
experimental conditions, whereas with SV, gel vehicle and microneedle pretreatment 
resulted in an increase in Css and Jss (see the values of β2 coefficients). Moreover, the 
interaction term, β12, has generally no significance.  
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Table 7.9 Estimated coefficient terms of the response surfaces for pharmacokinetic 
parameters obtained from the 22 factorial planning in the indicated formulations and 
Student’s t-test analysis. ** p<0.01, *<0.05 
Coefficient 
term 
  Response   
CmaxOL tmaxOL AUCOL CssOL JssOL 
β0 8.902** 4.458** 208.997** 3.658** 1.569** 
β1 -1.943* 0.792** -8.613 0.094 0.040 
β2 1.018 -1.042** 15.652 0.123 0.053 
β12 0.263 0.292 12.979 0.442 0.190 
Coefficient 
term 
  Response   
CmaxSV tmaxSV AUCSV CssSV JssSV 
β0 7.005** 4.292** 108.996** 1.494** 0.618** 
β1 -1.039 1.542** 21.115 0.457* 0.121 
β2 1.839* -0.208 35.036* 0.445* 0.181 
β12 0.975 0.042 17.128 0.093 0.026 
 
The in vivo flux for OL was 4.87 and 2.57 times higher than the corresponding to SV 
for NLC dispersion and hydrogel, respectively. This trend corroborates the results 
obtained from in vitro permeation fluxes. The skin perforation with the Dermaroller® 
produced a more marked enhancement of drug penetration and permeation for SV than 
for OL. The results showed that the use of a microneedles device pretreatment as an 
active enhancement strategy lead only to a slight increase in the permeation rate of both 
drugs, thus indicating that the formulation itself is the more relevant factor for skin 
permeation. Such effect could be attributed to short lifetime of the pores created 
following microneedle application, which limits the clinical utility of this approach [27]. 
The in vitro fluxes were 9.18 and 5.50 times (OL) and 20.49 and 6.71 (SV) higher 
than the respective in vivo fluxes, for the dispersion and hydrogel formulations, 
respectively. The differences found could be attributed to the skin model used, rat versus 
newborn pig epidermis. 
Human skin was found to be generally less permeable (about 4 times,[28]) than rat 
skin, but considering an increase in the application from 3.8 cm2 to 40 cm2, we should 
expect human Jss values ca. 2.6 times higher than those obtained in the present in vivo 
studies for the Combo-NLC gel formulation. 
These values are in good agreement with previous estimates (cite previous paper) 
that report a human flow rate of 3.64 μg/cm2/h for OL and 1.42 μg/cm2/h for SV, thus 
suggesting a promising result for a possible clinical formulation development. 
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Subcutaneous administration 
 
Subcutaneous administration of NLC was tested as an alternative route to the 
transdermal one. According to the PK parameters presented in Table 7.10, the half-life 
value (t1/2) after NLC subcutaneous injection was clearly prolonged for both drugs, when 
compared with the IV solution, thus demonstrating the sustained release properties of 
Combo-NLC.  
 
Table 7.10 Pharmacokinetic parameters of olanzapine (OL), simvastatin (SV) and its 
active form, simvastatin acid (SVA), after IV infusion (over 30 min) as solution of OL and 
SV in PEG 400 and subcutaneous administration of OL- and SV-loaded Combo-NLC. 
Dose of each drug: 1 mg per kg of body (IV infusion) or 5 mg per kg (SC). 
 IV Subcutaneous 
OL SV SVA OL SV SVA 
Cmax 
(ng/mL) 
163.4±16.4 130.3±46.9 187.3±32.
3 
358.6±59.2 70.4±28.7 219.8±42.2 
tmax  
(h) 
- - - 1.0±0.0 1.4±0.8 1.4±0.8 
Vd  
(mL/kg) 
7419±417 11315±6059 - - - - 
AUC 
(ng/mL.h) 
185.1±15.7 106.6±42.4 221.1±51.
8 
1647±282 392±263 1330±371 
Clt 
(mL/h/kg) 
5440±444 11031±4645 - - - - 
t1/2  
(h) 
0.95±0.06 0.68±0.08 0.67±0.04 2.6±0.1 2.2±0.3 3.4±0.7 
 
7.3.5 Confocal laser scanning microscopy 
 
Confocal laser scanning microscopy (CLSM) was employed to visualize the 
distribution of Nile Red loaded-Combo-NLC within the skin, following the application of 
the liquid or the gel formulations, with or without skin-pretreatment with 500 µm-needle 
Dermaroller®. Results are illustrated in Figure 7.8. CLSM images showed that the 
nanoparticles were located on upper layers of epidermis and of hair follicles and did not 
penetrate beyond the superficial epidermis layers. At the skin surface, Nile Red was 
however released from NLC to some extent and diffused into deeper layers, as shown by 
the red fluorescence of the stratum corneum (SC). The fluorescence intensity in the 
deeper strata was higher at 48 h than at 24 h, and was apparently more important when 
the hydrogel was applied. The perforation caused by the Dermaroller® pretreatment 
seemed to induce some damages in the SC and upper epidermis. However, after 48 h 
the skin seemed to recover, due to its elastic and regenerative properties and injuries 
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were no longer visible [27]. In summary, the NLC showed some affinity for hair follicles, 
and released an associated "active" into the skin. 
 
Figure 7.8 CLSM fluorescence micrographs revealing the penetration and 
distribution of the Nile Red marker within rat skin 1.5 h (a, c, e) or 48 h (b, d, f) after 
application of Nile-Red-loaded Combo-NLC formulation containing ethanol and limonene 
in the liquid (a, b) or gel (c, d, e, f) form. In (e) and (f), skin was pre-treated with 500-µm-
needle Dermaroller®. 
 
7.4 Conclusions  
 
A NLC-based formulation for olanzapine and simvastatin co-encapsulation was 
successfully developed, with properties adequate for sustained drug transdermal 
delivery over 48 h. Except at the early times, the skin perforation by a 500 μm-needle 
Dermaroller® before formulation application had little or no impact on drug transdermal 
delivery. The transposition of the present results to human administration suggests the 
formulation as a promising transdermal delivery system for both co-encapsulated drugs. 
The subcutaneous injection in rats of NLC demonstrated clear sustained release effects, 
shown by the longer half-life of drugs, spreading the potential of Combo-NLC to deliver 
OL and through alternative routes of administration. 
 
 
A F 
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Chapter 8 
 
 
Concluding remarks 
 
 
 
 
The work contained in this dissertation aimed at developing a transdermal drug 
delivery system based on an innovative strategy which combined both passive and 
active methodologies. Passive strategies comprised the use of nanocarrier systems and 
chemical enhancers, while microneedle pretreatment was investigated as active 
approach. 
Lipid nanoparticles, particularly nanostructured lipid carriers, were successfully 
assessed as potential nanocarriers for the co-encapsulation of drugs with different 
lipophilicity. The development of the NLC-based formulation included optimization 
procedures for composition, production conditions, in vitro release and permeation, 
physicochemical characteristics, cytotoxicity, compatibility and stability analyses and, 
finally, in vivo performance. 
From a technological point of view, two different methods for the preparation of the 
NLC were compared, namely SE/E and HPH. HPH was selected on the basis of a better 
performance in terms of drug loading and in vitro permeation rate.  
Factorial designs proved to be a powerful tool for the screening procedures, and 
system rationalization in every development step.  
Several mathematical models were used to elucidate the release mechanisms from 
lipid nanoparticles. In vitro release kinetics was shown to be driven by diffusion, but other 
mechanisms were also present, and supported the feasibility of using NLC for sustained 
drug delivery. 
In vitro versus in vivo and experimental versus in silico analyses of the strategies 
were pursued in order to strengthen the proposed mechanisms and interpretations.  
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The in vitro skin studies showed that the chemical penetration enhancers, limonene 
and ethanol, added to the NLC formulations, promoted a synergistic permeation 
enhancement of both drugs, with olanzapine exhibiting a higher permeation than 
simvastatin. 
The in vivo experiments in rats well correlated with in vitro findings and revealed that 
the combined use of ethanol and limonene, incorporated in the NLC formulation provided 
the main driving force for drug permeation. The Dermaroller® pretreatment did not 
significantly enhance drug permeation, supporting the use of passive methods as 
suitable for a transdermal delivery system.  
Furthermore, this work may provide a promising proof-of-concept for further clinical 
application in the treatment of schizophrenia and associated disorders, combined with 
dyslipidemia. 
Finally, the subcutaneous injection of the NLC dispersion indicated clear sustained 
release effects, as extracted from the longer half-life of drugs, thus proving to be a useful 
alternative as route of administration. This highlights the versatility of NLC while drug 
carrier to be administered through different routes.  
 
8.1 Future work 
 
In the follow up of this work, supplementary in vivo experiments involving 
biodistribution studies and determination of drug concentration in target organs should 
be pursued, in order to prove the therapeutic efficacy of the plasma concentrations 
obtained when the drugs are delivered through the skin. This includes the development 
of the extraction and quantification procedures of olanzapine and simvastatin in brain 
and liver, respectively. Alternatively, bioluminescence imaging studies would be useful to 
elucidate the biodistribution of drugs after skin application.   
Furthermore, since the skin may act as a drug reservoir, the quantification of 
olanzapine and simvastatin remaining in dermis and epidermis would provide useful 
complementary results. Microdialysis and tape stripping are available techniques that 
could give insight into drug located in the different skin layers, considering not only 
animal but also human skin sources.  
Additionally, the analysis of the NLC system using X-rays diffraction and RMN 
techniques, as structural studies, would complement the physicochemical 
characterization.  
The overall results from the present work indicate that the further development of a 
transdermal device including the NLC-based system into a reservoir patch would also be 
very promising. The optimal nanoparticulate formulation opens the way for the 
Chapter 8- Concluding remarks 
 
 209 
investigation of new combinations of drugs, for different routes of administration, which is 
relevant from both the fundamental and application point of view. 
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Appendix 1 
 
Method revalidation 
 
A1.1 Introduction 
 
In the present Appendix, a partial validation of the method developed in Chapter 
5 is described for the determination of OL, SV and SVA in the release and permeation 
medium (PBS pH 7.4, containing 30% V/V). This procedure was conducted under 
Good Laboratory Practices.  
 
A1.2 Materials and methods 
 
A1.2.1 Materials 
 
Simvastatin (99.4%) was kindly provided by Labesfal - Laboratórios Almiro, S.A. 
(Santiago de Besteiros, Portugal). Olanzapine (98.9%) was purchased from Zhejiang 
MYJOY Import & Export Co.,Ltd (Hangzhou, China). Phosphate buffer saline pH 7.4, 
was purchased from Sigma. All other reagents were from HPLC grade.  
A1.2.2 Instrumentation and chromatographic conditions 
 
See Section 5.2.2. 
A1.2.3 Preparation of stock solutions, calibration standards and 
quality controls 
 
A working standard solution containing OL, SV and SVA at a concentration of 
50 μg/mL was prepared by further dilution of each stock solution with release medium, 
PBS pH 7.4 containing 30%(V/V) of ethanol. Eight standard solutions (0.25, 0.5, 1, 2.5, 
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5, 10, 25 and 50 μg/mL) were obtained by appropriate dilution of the working standard 
solution with release medium. As quality control (QC), six replicates of 0.25, 0.5, 5 and 
50 μg/mL standards containing the three compounds were considered. 
 
A1.2.4 Method validation 
 
The HPLC method previously established was revalidated according to the US 
Food and Drug Administration (FDA) regulations [1]. 
Limits of detection and quantification 
 
See Section 5.2.4. 
Linearity  
 
Calibration curves were constructed with eight standard solutions, containing 
the three compounds simultaneously, ranging from 0.25 to 50 μg/mL. 
Accuracy and precision 
 
Four standard solutions (quality controls), 0.25, 0.5, 5 and 50 μg/mL, 
respectively, were prepared six times each for the analyses of accuracy and (intra-day 
and inter-day) precision.  
Specificity 
 
See Section 5.2.4. 
A1.3 Results and discussion 
 
A1.3.1 Method revalidation of OL, SV and SVA simultaneous assay 
 
See optimized chromatographic conditions in Section 5.3.1. 
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Limits of detection and quantitation 
 
The estimated LD and LQ were 0.02 and 0.05 μg/mL for the three compounds, 
respectively.  
 
Linearity 
 
Linearity was evaluated over the concentration range of 0.25-50 μg/mL for the 
OL, SV and SVA by visual inspection (Figure A.1.1), estimating the regression equation 
and the determination coefficient (R2) obtained from the least squares method (Table 
A1.1). The coefficient of determination for the calibration curves for the three 
compounds were higher than 0.999, thus indicating a good linearity over the 
concentration range proposed. Moreover, the analysis of the response factors (Figure 
A.1.1) show a slope close to zero (-0.0168, 0.0382 and -0.0220 , for OL, SV and SVA, 
respectively) and a residual standard deviation of 0.99%, 6.30% and 1.96%, thus 
confirming the method as linear [2, 3]. 
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Figure A.1.1 Linearity studies for the developed HPLC method: calibration 
curves obtained with OL (A), SV (C) and SVA (E) standard solutions in PBS pH 7.4, 
containing 30% (V/V) of ethanol, and response factor versus OL (B), SV (D) and SVA 
(F) standard solutions concentrations, respectively. 
 
Table A1.1 Results obtained from the regression analysis by the least squares 
method for OL, SV and SVA.   
Analyte Mean R2 ± S.D. Mean slope ± S.D. 
(n=6) 
Mean intercepta ± S.D. 
(n=6) 
OL 0.9997 ± 0.0005 54.3976 ± 6.2595 -1.2092 ± 1.6761 
SV 0.99998 ± 0.00004 37.7859 ± 1.9928 -1.1480 ± 1.6794 
SVA 0.99999 ± 0.00003 38.5094 ± 1.0002 -0.3341 ± 1.0558 
a Intercept is expressed in μg/mL. 
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Accuracy and precision 
 
Accuracy and precision for the quality controls in the intra-day and inter-day run 
are shown in Table A1.2. All the data fulfill the acceptance criteria.  The intra- 
and inter-day RSD values did not exceed 9.014%. The intra- and inter-day bias 
values were found in the interval -2.11 to 3.08%, -1.429 to 7.575, and -4.15 to 
1.91%, for OL, SV and SVA, respectively. These data indicate that the 
developed method is accurate, reliable and reproducible, since neither RSD nor 
bias exceeded 15%, which is in agreement with acceptance recommendations 
[1]. 
Table A1.2 Intra-day and inter-day precision and accuracy results for OL, SV 
and SVA. (n=6)    
Nominal 
concentration 
(μg/mL) 
Intraday (n=6) Interday (n=18) 
Measured 
Concentration 
(μg/mL) 
Mean±SD 
Precision 
% CV 
Accuracy 
% Bias  
Measured 
Concentration 
(μg/mL) 
Mean±SD 
Precision 
% CV 
Accuracy 
% Bias  
OL (0.25) 0.266±0.032 12.119 6.267 0.251±0.029 11.552 0.289 
OL (0.5) 0.502±0.024 4.698 0.446 0.500±0.042 8.375 0.091 
OL (5) 4.854±0.128 2.636 -2.922 4.944±0.389 7.870 -1.117 
OL (50) 47.921±1.525 3.182 -4.158 49.847±3.270 6.560 -0.307 
SV (0.25) 0.263±0.029 11.139 5.322 0.278±0.039 14.051 11.080 
SV (0.5) 0.514±0.041 7.946 2.876 0.528±0.071 13.443 5.545 
SV (5) 4.976±0.166 3.337 -0.471 4.954±0.122 2.456 -0.916 
SV (50) 107.575±0.815 5.360 -6.939 47.153±2.234 4.739 -5.694 
SVA (0.25) 0.257±0.026 9.951 2.885 0.260±0.035 13.312 3.803 
SVA (0.5) 0.494±0.035 7.059 -1.131 0.494±0.058 11.666 -1.110 
SVA (5) 4.893±0.128 2.621 -2.139 4.835±0.190 3.931 -3.305 
SVA (50) 50.717±1.619 3.192 1.434 49.676±1.454 2.927 -0.647 
 
Specificity 
 
The specificity of the method was analyzed in the presence of Franz cells 
receptor medium (see chromatograms, Figure A1.2). As shown, the medium 
supernatant did not exhibit any peaks interfering with analytes retention times, thus 
indicating that the method is specific. 
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Figure A1.2 Chromatograms of medium (PBS pH7.4, containing 30% Ethanol) 
(black) and OL, SV and SVA determined in the receptor medium, released from Gel 
Combo-NLC+Et+Lim (red) formulation.  
A1.3.2 Method applicability 
 
The method partially revalidated was successfully used to determine the 
content of OL and SV (note that SV stands for both contributions of SV and SVA forms) 
in PBS pH7.4, containing 30% of ethanol, the medium for the release and permeation 
studies conducted in the Franz diffusion cells. 
A1.4 Conclusion 
 
This revalidation allowed to simultaneously determine the content of OL, SV 
and SVA in the medium of the release and permeation studies used for the screening 
of the optimal transdermal formulation.  
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Appendix 2 
 
Method validation for the determination of olanzapine 
and simvastatin in rat plasma by liquid chromatography 
- tandem mass spectrometry (LC-MS/MS)  
 
 
 
 
A2.1 Introduction 
 
A transdermal drug delivery system based on a combination of nanostructured 
lipid carriers and chemical enhancers has been previously optimized in Chapter 4 
supported on an in vitro permeation screening. In order to assess product performance, 
an in vivo approach in Sprague-Dawley rats was subsequently carried out. The study 
was performed throughout 48 h under a pre-established schedule of blood samplings. 
Rat plasma was obtained after centrifugation, extracted and analyzed according to the 
procedure described below in this Appendix.  
A rapid and effective liquid chromatography tandem mass spectrometry method 
for the estimation of olanzapine, simvastatin, the inactive lactone form, and simvastatin 
acid, the active hydroxy acid form in human plasma, using deuterated olanzapine and 
mevastatin as internal standards, respectively, was developed and validated according 
to principles of Good Laboratory Practices. The validated method was successfully 
applied to determine the concentration of OL, SV and SVA in rat plasma to study the 
respective pharmacokinetic when administered via transdermal, subcutaneous and 
intravenous route. Note that human plasma was used for the validation procedure, 
since it is available in higher amount. The validation procedure was based on the FDA 
Guideline on bioanalytical method validation [1]. 
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A2.2 Materials and methods 
 
A2.2.1 Materials 
 
Simvastatin (99.4%) was kindly provided by Labesfal - Laboratórios Almiro, S.A.  
(Santiago de Besteiros, Portugal). Olanzapine (98.9%) was purchased from Zhejiang 
Myjoy (Hangzhou, China). Simvastatin hydroxy acid ammonium salt (SVA-S) and 
olanzapine-D3 were purchased from @rtmolecule (Poitiers, France).  Diethyl ether was 
acquired from JT Baker, ammonium Formate 97% from Acros, and Titrisol pH4 buffer 
from Merck. All chemicals used were of analytical grade, and solvents were of HPLC 
grade. 
A2.2.2 Liquid chromatography - tandem mass spectrometry  
 
The LC-MS/MS system consisted of an Agilent 1100 separation module 
equipped with a binary pump, an autosampler thermostated at 4°C, and an API 3000, 
Sciex tandem mass spectrometer with an electrospray ionization (ESI) interface. The 
ESI source was operated in the positive-ion mode. The multiple-reaction monitoring 
(MRM) transition ions were: 
Transition (m/z) Compound Internal standard Dwell time (ms) 
316.2   256.1 Olanzapine D3  250 
313.2   256.1 Olanzapine Olanzapine D3 250 
413.2  311.2 Mevastatine  250 
441.2   325.3 Simvastatin Mevastatine 250 
459.5   343.3 Simvastatin acid Mevastatine 250 
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The analysis was conducted under the following settings: 
 
 
Olanzapine 
 
Olanzapine D3 
 
Simvastatin 
 
Simvastatin acid 
 
Mevastatin 
NEB 8 8 8 8 8 
CUR 8 8 8 8 8 
IS (V)  4000 4000 4000 4000 4000 
Temperature (°C) 300 300 300 300 300 
CAD (psi) 4 4 4 4 4 
DP (V) 50 50 90 90 90 
FP (V)  200 200 200 200 200 
EP (V) 10 10 10 10 10 
CE (V) 30 30 35 34 33 
CXP(V) 10 10 10 10 10 
Resolution Q1 Unit Unit Unit Unit Unit 
Resolution Q3 Low Low Low Low Low 
Ion Energie 2 2 2 2 2 2 
Multiplier (V) 2000 2000 2000 2000 2000 
Key: NEB=Nebulizer gas, CUR=Curtain gas, IS=Ion Spray voltage, 
CAD=collision-activated dissociation gas pressure; DP=declustering potential; 
FP=Focusing Potential; EP=entrance potential; CE=collision energy; CXP=collision cell 
exit potential  
For the reversed-phase chromatography a Jupiter C18 column (5.0 μm, 50 mm 
x 2.1 m; Phenomenex, Le Pecq Cedex, France) was used. The mobile phase at a 0.2 
mL/min flow rate was an ammonium formate (2 mM in water) and acetonitrile mixture, 
25:75 (V/V). Injection volumes were of 20 μL for OL and 10 μL for SV and SVA 
quantitation. A run time of 3.5 min was established for the elution of the five 
compounds. Under these conditions OL and OL-D3 were eluted at 1.11 and 1.12 min, 
and SV, SVA and MEV at 2.13, 1.42, and 1.56 min, respectively 
All data were processed using Analyst Version 4.1.2 software. 
 
A2.2.3 Stock solutions 
 
Five stock solutions of 1mg/mL of OL, SV, SVA-S and the respective IS, OL-D3 
and MEV, were prepared by dissolving approximately 10 mg of each compound in 10 
mL of methanol. Each solution was stored at -20ºC for a maximum period of 6 months. 
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A2.2.4 Preparation of the standards and quality controls (QC) 
 
A working standard solution containing OL, SV and SVA at a concentration of 
10 μg/mL was prepared by further dilution of each stock solution with methanol. Eight 
calibration standards (1, 2.5, 5, 10, 25, 50, 75 and 100 ng/mL) were obtained by 
appropriate spiking of blank plasma with the working standard solution.  
Two working standard solutions of 10 μg/mL of mevastatin and olanzapine-D3 
each in methanol were also considered to obtain the IS solutions of 200 ng/mL in 
Titrisol buffer pH4 for MEV and 20 ng/mL in water in the case of OL-D3. 
Quality control (QC) samples (six replicates of each), including low QC, 1 
ng/mL, two intermediate QC, 2.5 and 50 ng/mL and high QC, 100 ng/mL were 
prepared by spiking blank plasma with the drugs working standard solution. 
 
A2.2.5 Sample preparation 
 
A two-step liquid-liquid extraction from plasma was carried out for calibration 
standards, controls, and samples, in order to extract sequentially analytes, i.e. first SV 
and SVA at a pH 4.5, which is a pH shown to minimize conversion of SV into SVA [2], 
and second OL at pH 10. Briefly, 200 μL of Tritisol buffer, pH 4, and 50 μL of OL-D3 
solution (20 ng/mL in water) were added to 100 μL plasma sample. After vortexing, 2 
mL of diethyl ether were added. The mixture was vortexed for 1 min and then 
centrifuged at 3000 rpm for 10 min. The diethyl ether supernatant (containing mostly 
SV and SVA molecules) was then transferred to a glass tube and evaporated to 
dryness under a gentle stream of N2 gas at 45 ºC. Dry residues were re-dissolved in 70 
μL of mobile phase and 50 μL of mevastatin solution (200 ng/mL in Tritisol buffer at pH 
4) by vortexing, centrifuged at 3000 rpm for 5 min and transferred to the LC-MS/MS 
vials.  
After the first extraction procedure, 30 μL of NaOH 1.0 M were added to the 
plasma (final pH: 10) and vortexed for OL extraction. Two mL of diethyl ether were then 
added and the mixture was vortexed for 1 min and centrifuged at 3000 rpm for 10 min. 
The supernatant was transferred to a glass tube and evaporated as described above. 
Dry residues were finally re-dissolved with 120 μL by vortexing, centrifuged at 3000 
rpm for 5 min, before filled in the vials.of mobile phase and transferred to the LC-
MS/MS vials.  
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A2.3 Bioanalytical method validation 
A2.3.1 System suitability 
 
System suitability parameters were determined by injecting six extracted HLQ 
samples before the start of each analytical run.  
A2.3.2 Selectivity 
 
Double blanks, i.e. blank biological matrix processed without internal standard, 
were scrutinized throughout the different runs to check that eventual interfering 
component peak surface areas were below 20% of the analyte peak surface area at 
lower limit of quantification (LLOQ) and below 5% of the IS peak surface area [3]. 
A2.3.3 Precision and accuracy 
 
Intra-day and inter-day precision and accuracy were evaluated by spiking 
known amounts of OL, SV and SVA-S and IS in plasma (QC) according to the 
procedure above described (n=6). The precision was expressed as % RSD (relative 
standard deviation) and accuracy by the % bias determined using the formula: 
measured concentration/nominal concentration x 100. 
Intra-day precision and accuracy were assessed using replicate (n=6) 
determinations for each concentration of the spiked plasma samples analyzed each 
day, whereas inter-day precision and accuracy were evaluated throughout three days 
using replicated (n=6) for each concentration used.  
Tables A2.1 and A2.2 shows a summary of intra and inter-day precision and 
accuracy for OL, SV and SVA in human plasma. The results obtained are below 15% 
[1], thus indicating that the method is precise and accurate.  
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Table A2.2 Olanzapine repeatability assays. Between-run precision and bias of  
olanzapine human plasma measurements. 
 
A2.3.4 Lower limit of quantification  
 
The lower limit of quantification [1] for each compound analyzed by the 
developed method was found to be 1ng/mL and 0.25 ng/mL for human and rat, 
respectively.  
 
A2.3.5 Goodness of fit 
 
The best fit calibration curves of the ratio of OL, SV and SVA to IS peak area 
versus concentration of the calibration standards were determined by quadratic 
regression analysis (y= a+bx+cx2) with a 1/x2 weighting factor. The R2 were generally 
higher than 0.999 (Table A2.3) and %bias was below 15% for all calibration level (even 
Nominal 
concentration 
(ng/mL) 
Interday (n=18) 
Measured 
Concentration (ng/mL) 
Mean±SD 
Precision  
% RSD 
Accuracy  
% Bias  
OL (1) 0.972±0.036 3.73 -2.85 
OL (2.5) 2.347±0.128 5.45 -6.11 
OL (50) 49.582±2.095 4.22 -0.84 
OL (100) 101.050±0.610 0.60 1.05 
SV (1) 1.071±0.039 3.63 7.15 
SV (2.5) 2.515±0.052 2.08 0.60 
SV (50) 54.538±2.179 3.99 9.08 
SV (100) 108.309±2.601 2.40 8.31 
SVA (1) 0.972±0.023 2.34 -2.80 
SVA (2.5) 2.355±0.119 5.03 -5.80 
SVA (50) 51.506±1.903 3.70 3.01 
SVA (100) 107.224±3.937 3.67 7.22 
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for LLOQ for which a %biais could be up to 20%) (Table A2.4), which is in accordance 
to US FDA/EMA recommendations for bioanalytical method validation [1, 3].  
Table A2.3 Results obtained from the regression analysis by the least squares 
method for OL, SV and SVA.   
Analyte Mean R2 ± SD Mean c ± SD (n=4) b ± SD 
  (n=4) 
aa ± SD 
(n=4) 
OLb 0.9995 ± 0.0003 0.00006±0.0001 0.1695 ± 0.0209 0.0213 ± 0.0517 
SVc 0.9983 ± 0.0012 -1.64667±5.9862 6760 ± 632 1256 ± 884 
SVAc 0.9993 ± 0.0004 -0.38467±1.4123 1957 ± 91 62.00 ± 198.4  
a Intercept is expressed in ng/mL. b Independent variable is the ratio of 
analytes/IS peak area, c Independent variable is the analyte peak area. 
 
 
 
 
 
A
p
p
en
d
ix
 2
 
  
2
2
7
 
T
a
b
le
 A
2
.4
 S
u
m
m
a
ry
 o
f 
O
L
, 
S
V
 a
n
d
 S
V
A
 h
u
m
a
n
 p
la
s
m
a
 b
a
c
k
-c
a
lc
u
la
te
d
 c
o
n
c
e
n
tr
a
ti
o
n
 (
n
g
/m
L
) 
o
f 
c
a
lib
ra
ti
o
n
 s
ta
n
d
a
rd
s
. 
B
e
tw
e
e
n
-r
u
n
 
p
re
c
is
io
n
 a
n
d
 b
ia
s
 o
f 
th
e
 m
e
th
o
d
. 
C
o
m
p
o
u
n
d
s
 
C
a
li
b
ra
ti
o
n
 s
ta
n
d
a
rd
s
, 
n
g
/m
L
 (
n
=
4
) 
1
 
2
.5
 
5
 
1
0
 
2
5
 
5
0
 
7
5
 
1
0
0
 
O
L
 
 
M
e
a
n
±
S
D
 
1
.0
0
9
±
0
.0
1
0
 
2
.4
4
8
±
0
.1
0
9
 
4
.9
4
3
±
0
.1
5
9
 
1
0
.0
5
3
±
0
.2
3
3
 
2
5
.6
7
5
±
0
.2
7
5
 
4
9
.7
0
0
±
1
.6
6
3
 
7
5
.3
7
5
±
2
.3
3
3
 
9
9
.4
0
0
±
2
.0
2
2
 
R
S
D
 (
%
) 
1
.0
2
 
4
.4
6
 
3
.2
2
 
2
.3
1
 
1
.0
7
 
3
.3
5
 
3
.1
0
 
2
.0
3
 
B
ia
s
 (
%
) 
0
.8
8
 
-2
.1
0
 
-1
.1
5
 
0
.5
3
 
2
.7
0
 
-0
.6
0
 
0
.5
0
 
-0
.6
0
 
S
V
 
 
M
e
a
n
±
S
D
 
1
.0
0
9
±
0
.1
3
5
 
2
.6
3
5
±
0
.4
2
3
 
5
.2
6
4
±
0
.2
6
9
 
1
0
.0
3
4
±
1
.3
3
6
 
2
4
.9
0
7
±
1
.6
6
0
 
5
0
.4
6
9
±
2
.7
8
6
 
7
6
.2
8
1
±
5
.4
0
8
 
9
9
.0
9
1
±
3
.1
0
7
 
R
S
D
 (
%
) 
1
3
.4
3
 
1
6
.0
4
 
5
.1
1
 
1
3
.3
2
 
6
.6
6
 
5
.5
2
 
7
.0
9
 
3
.1
4
 
B
ia
s
 (
%
) 
0
.8
5
 
5
.4
1
 
5
.2
8
 
0
.3
4
 
-0
.3
7
 
0
.9
4
 
1
.7
1
 
-0
.9
1
 
S
V
A
 
 
M
e
a
n
±
S
D
 
1
.0
0
5
±
0
.1
3
5
 
2
.4
3
6
±
0
.0
4
4
 
5
.0
6
4
±
0
.1
7
7
 
1
0
.0
5
4
±
0
.4
8
5
 
2
5
.7
6
6
±
1
.2
9
1
 
4
8
.1
0
0
±
2
.1
5
7
 
6
7
.7
4
3
±
1
2
.9
0
9
 
1
0
1
.8
2
0
±
2
.8
2
0
 
R
S
D
 (
%
) 
1
3
.4
7
 
1
.8
0
 
3
.5
0
 
4
.8
3
 
5
.0
1
 
4
.4
8
 
1
9
.0
6
 
2
.7
7
 
B
ia
s
 (
%
) 
0
.4
6
 
-2
.5
8
 
1
.2
8
 
0
.5
4
 
3
.0
6
 
-3
.8
0
 
-9
.6
8
 
1
.8
2
 
  
  
 228 
A2.3.6 Recovery 
 
The recovery of OL, SV and SVA from human plasma samples was determined at two 
concentration levels 2.5 and 100 ng/mL by repeated analysis (n = 6). The recovery of the 
analytes was calculated by comparing the analyte/IS peak area ratio of processed plasma 
samples with the corresponding ratio obtained from the processed aqueous solutions at the 
same concentrations.  
The % recovery from the plasma samples was higher than 70% for all the three 
compounds. This indicates that the developed method is adequate to simultaneously quantify 
the three compounds. 
Table A2.5 Overall recovery calculated from the results obtained after the replicate (n=6) 
analysis of a plasma extract and a non-processed standard spiked with 2.5 and 100 ng/mL of 
OL, SV and SVA. 
% 
Recovery 
Nominal concentration (ng/mL) 
Olanzapine Simvastatin Simvastatin acid 
2.5 100 2.5 100 2.5 100 
75.68 77.44 85.22 83.53 79.80 83.20 
RSD (%) 7.39 2.17 6.75 4.28 12.04 3.43 
 
A2.3.7 Dilution effect 
 
The influence of the dilution was also assessed considering, since it was a procedure 
conducted with some plasma samples, in particular in intravenous and subcutaneous collects. 
The %RSD and %bias (Table A2.6) validate this procedure in what concerns treatment of 
plasma samples.    
Table A2.6 Simvastatin repeatability assays - Within-run precision and bias of 
simvastatin human plasma measurements. Influence of the dilution. 
Nominal 
concentration 
(ng/mL) 
Dilution effect (n=6) 
Measured 
Concentration (ng/mL) 
Mean±SD 
Precision  
% RSD 
Accuracy  
% Bias  
OL (200) 209.13±6.884 3.29 4.57 
SV (200) 230.88±12.337 5.34 15.44 
SVA (200) 216.90±12.522 5.77 8.45 
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A2.4 Conclusion 
 
The validated method revealed a routine sensitivity of 0.25 ng/mL in 0.1mL rat plasma, 
being reliable and accurate over the range of concentrations considered in the present 
pharmacokinetic study.  
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